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Immunity against tuberculosis 
Currently no effective vaccines exist against the three deadliest infectious diseases on earth: 
tuberculosis, HIV/AIDS and malaria [1]. Tuberculosis (TB) - in humans and other 
species - is caused by bacteria of the Mycobacterium tuberculosis complex (MTBC): a 
highly genetically conserved group of mycobacteria including M. tuberculosis, M. 
africanum and M. bovis, that has evolved from an estimated 3 million years old common 
progenitor [2]. The origin of M. tuberculosis (Mtb), the main causative agent of human TB, 
can in all probability be traced back at least 70 000 years to early human populations in 
Africa, and Mtb’s distinct seven lineages correspond to the migration patterns of humans 
across the globe [3]. TB became epidemic in medieval Europe, in which period the 
disease had many names including ‘consumption’ or ‘the white plague’ [4]. No other 
pathogen in the history of man has resulted in so many deaths [4]: in the past 200 years 
around one billion people have died from TB. Only in the late 19 t h  century Mtb was 
identified by Robert Koch as the pathogen causing human TB. The discovery of the first 
antibiotics against TB dates back to the 1940s [4]. Currently, one-third of the world 
population is latently infected with Mtb [5]. In latent infection non- or slowly replicating 
Mtb bacilli are present, yet the infection is contained in a subclinical state [6]. The 
lifetime risk of developing active TB disease is 3 - 10%; this risk increases to 5 - 10% 
per year in HIV-infected individuals [6]. Though in the western world TB incidence has 
dropped spectacularly, in developing countries TB has become one of the major health 
problems. This has partly been driven by high HIV prevalence, and TB is the leading 
cause of death in HIV-infected patients [5]. The increased prevalence of type-II diabetes 
mellitus in developing countries further adds to the TB epidemic [7]. In 2013 1.5 million 
people died from TB disease, and middle- or low-income countries accounted for 95% of 
these TB-deaths [5]. 
During its co-evolution with the human host, Mtb has evolved as a master manipulator of 
the immune system. Following inhalation of Mtb-loaded aerosols, the bacterium is 
phagocytosed by professional phagocytic cells in the airways. Mtb is however 
remarkably capable of persisting in these innate phagocytic cells, employing various 
strategies that enable it to survive in the hostile cellular compartments within the 
infected host cell (reviewed in [8]). Mtb also inhibits the migration of infected dendritic 
cells (DCs) from the infected site to the draining pulmonary lymph nodes (LN) by 10-14 
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days, thereby delaying the initiation of the adaptive immune response compared to other 
pathogens, as assessed in murine TB infection models [6;9]. This time-window likely 
enables establishment of infection before onset of specific immunity. Within the draining 
lymph nodes, naive T-cells are primed and induced towards differentiation into a variety 
of pro-inflammatory or regulatory CD4+ and CD8+ T-cell subsets [8].  
Both CD4+ T helper (Th)-1 (IFNγ+)-cells as well as CD8+ T-cells are essential in protection 
against TB [10]. Th1 IFNγ- and TNFα-producing T-cells activate macrophage effector 
mechanisms, whereas CD8+ T-cells produce cytolytic molecules as well as pro-
inflammatory cytokines [11]. IFNγ+IL2+TNFα+ polyfunctional CD4+ T-cells could be 
important mediators of protection against TB, since polyfunctional T-cells produce 
higher levels of cytokines compared to single-cytokine producing T-cells, and their 
simultaneous production might also allow for synergistic activity of these cytokines [12]. 
Indeed, in a murine model of vaccination against Leishmania major, an intracellular 
pathogen, the frequency of IFNγ+IL2+TNFα+ polyfunctional CD4+ T-cells correlated with 
vaccine-induced protective immunity; and similar data were reported for BCG in that same 
study [12]. One approach in the quest for immune correlates of protection has been to 
compare immunity in individuals with latent, controlled infection versus individuals with 
active TB. However, reports on mono- vs. triple-cytokine producing T-cells in latent versus 
active TB in adults have been conflicting [13;14]. Since polyfunctional T-cells are present 
in active TB they appear not to be the hoped for surrogate marker of protection against 
active TB [11;14]. 
Other T-helper subsets include Th17-cells, Th22, Th9-cells, and follicular helper T-cells 
[8]. Th17 cells produce IL17, a cytokine that is vital in the recruitment and activation of 
neutrophils, but its excessive production can lead to hyper-inflammation and tissue 
damage [11]. CD1-restricted T-cells, MAIT cells and HLA-E restricted CD8+ T-cells are 
alternative T-cell subsets that recognize antigens through non-classical MHC-1b 
presentation, that may contribute directly in the combat towards Mtb [15-17]. 
 
 
M. tuberculosis-induced regulatory T-cells 
As opposed to pro-inflammatory cells, regulatory T-cells (Treg cells; Tregs) inhibit pro-
inflammatory responses and are vital for maintaining immune homeostasis, inhibiting auto-
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immunity, and preventing excessive tissue destruction that results from persistent 
immune activation during infection [18]. However, regulatory mechanisms can also be 
exploited by Mtb for its own benefit, as demonstrated in murine TB-models: Tregs were 
induced in the LN by Mtb-infected DCs, and further delayed the priming of pro-
inflammatory CD4+ and CD8+ T-cells, thereby even further delaying the migration of 
these cells to the lung [19]. The early establishment of successful Mtb infection therefore 
is favoured by a myriad of mechanisms, including suppression of immunity by Tregs. 
A hallmark of Mtb infection is granuloma formation: early during the immune response 
innate cells control and sequester the infectious lesion, followed after two weeks by T-
cells migrating into the granuloma periphery, further sequestrating the infected tissue [6]. 
Also during chronic infection, the granuloma represents a dynamic environment with in- 
and efflux of immune cells and a spatial distribution of pro- and anti-inflammatory immune 
cells [20;21]. Although as mentioned above, Tregs may have a beneficial effect in 
limiting pulmonary tissue destruction during inflammation, this comes at the potential risk 
of pathogen persistence [18]. 
Chapter 2 further introduces and reviews the role of Tregs in acute and chronic 
human infectious diseases, including Mtb, the induction of Tregs by tolerogenic antigen-
presenting cells, other mechanisms of Treg induction and expansion, and their modes of 
suppressing  immunity. 
 
 
Terminally differentiated T-cells in chronic Mtb infection 
During chronic infection, pro-inflammatory T-cells are essential to maintain control of 
Mtb, and this requires continued effector T-cell function and proliferation of T-cells [22]. 
However, in chronic viral infections and tumours many studies have shown how continued 
antigen exposure ultimately drives T-cells into functional exhaustion, a state also called 
terminal differentiation or the chronic (infection) phenotype [23]. These T-cells are 
marked by the expression of inhibitory receptors and are impaired in their 
proliferative capacity [23]. Persistent Mtb infection could thus potentially exhaust the T-
cell response in a similar way. 
Expression of PD-1 has been associated with exhaustion of T-cell function in many human 
chronic viral infections [24-26], but interestingly, in murine TB proliferating and cytokine-
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producing T-cells were marked by PD-1 expression [27;28]. In contrast, murine T-cells 
with impaired proliferative and/or cytokine-expressing capability expressed the inhibitory 
marker KLRG1 [27-29]. Also the protective efficacy against TB-challenge of Mtb-antigen 
specific KLRG1+ T-cells was decreased, compared to PD-1+ T-cells, in a murine adoptive 
transfer model [27]. These markers have not been compared yet in the various stages of 
human TB infection, and it is unknown whether these markers demarcate antigen 




BCG-vaccination against tuberculosis 
Mycobacterium bovis bacillus Calmette-Guérin (M. bovis BCG), the only available and 
licensed TB-vaccine, was developed already in 1921. BCG was derived from 
Mycobacterium bovis, a bacterium of the Mycobacterium tuberculosis complex that causes 
TB in cattle and wildlife; and attenuated through years of continuous in vitro passage by 
Albert Calmette and Camille Guérin [30]. Estimates are that BCG has been administered 
at least 3 billion times since its introduction in 1921, which is more than any other 
vaccine. It is part of the WHO Expanded Programme on Immunization (EPI) and as such 
routinely administered at birth in nearly all (developing) countries with high TB-
prevalence. M. bovis BCG-vaccination protects infants from disseminated forms of TB, but 
it provides insufficient and inconsistent protection against pulmonary TB in adults [31].  
Although new vaccines against TB are being developed and evaluated, aiming to either 
replace BCG or boost its effect, no new effective vaccine is available yet [31]. A recent 
phase 2B trial in infants in South Africa demonstrated no efficacy in terms of protection 
against developing TB disease of the TB-vaccine candidate MVA85A, when given as a 
booster following previous BCG-vaccination, compared to BCG alone, even though T-cell 
responses were induced [32].  
TB-vaccine efficacy would have to include protection against the development of active 
pulmonary TB in the adult population, since this is the transmissible form of the disease; it 
has been estimated that a vaccine effective against active pulmonary TB in the adult 
population would have an enormous impact on the TB-epidemic [33]. A major conundrum 
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in TB-vaccinology is what exactly constitutes protective immunity against TB and how this 
can be achieved by vaccination. Most successful vaccines against human pathogens have 
been those for which the induction of humoral immunity sufficed [34]. The 
predominantly intracellular lifestyle of Mtb, however, clearly necessitates more than 
antibodies, as is the case for HIV and malaria [35]. However, there is no clear leading 
example for vaccine design against these three deadly infectious diseases. Basic 
research into which exact mechanisms of vaccine-induced (cellular) immune responses are 
essential to induce protection, are needed to guide vaccine design [31]. A further 
complicating factor is the lack of any true correlate of protection, such that vaccine trials 
currently require long follow up to reach clinical endpoints [36]. New surrogate endpoints 
of protection may be identified through researching vaccine-induced cellular profiles and 
mechanisms of protection. The availability of such correlates would accelerate the 
evaluation of TB-vaccine candidates in smaller cohorts through increased statistical power 
[36;37]. 
The effect of BCG-vaccination in protecting infants from disseminated forms of TB 
may be partly due to epigenetic modifications in innate immune cells such as trained 
immunity [38], and this could also explain the ‘non-specific effect’ of BCG-vaccination 
in protecting infants against other unrelated infectious diseases [39]. Further, specific 
cytokine-expressing CD4+ and CD8+ T-cells are induced by BCG-vaccination in infants 
and adults [40-47]. IFNγ+IL2+TNFα+ polyfunctional  CD4+ T-cells have been demonstrated  
in infant BCG-vaccination [48], yet conflicting reports exist on whether adult BCG-
vaccination induces polyfunctional T-cells [49;50]. A large follow up study in BCG-
vaccinated infants revealed that there was no association between the induction of 
polyfunctional CD4+ T-cells and protection against TB [51]. Thus, it is not clear whether 
BCG-vaccination induces polyfunctional CD4+ T-cells in adults, and whether these cells 
are involved in mediating vaccine-induced protective immunity in adults against 
pulmonary TB. 
Several other, and non-mutually exclusive hypotheses exist concerning the incomplete 
protection mediated by BCG-vaccination in adults. Systematic reviews have indicated 
that the protective efficacy of BCG wanes over time [52;53], and this could partly be 
explained by the relative inability of BCG to induce stable long-term central memory 
T-cells [54;55]. Further, the immune response to BCG-vaccination in adults may be 
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hampered by blocking BCG replication through pre-existing immune responses against 
non-tuberculous mycobacteria (NTM) that are present in the environment (especially in 
tropical regions, and this would explain the ‘latitude effect’ in protective efficacy) [56]. 
Also, BCG’s protective efficacy could have diminished through the loss of protective 
antigens by in vitro passaging [57], and indeed it has been shown that BCG-vaccination 
fails to induce immune responses to e.g. DosR regulon proteins, likely because these are 
not expressed following intradermal vaccination [58]. In addition, the response to BCG-
vaccination could be modulated by helminth or NTM co-infection [31]. 
M. bovis BCG may itself induce regulatory responses in humans; IL10-producing CD4+ 
Tregs have indeed been demonstrated in BCG-vaccinated newborns and adults [59;60]. 
CD8+ Tregs were demonstrated in mycobacteria-infected lymph nodes, and could be 
isolated from in vitro live BCG-activated PBMCs from blood donors, that had in vitro 
reactivity to Mtb-PPD [61]. However, CD8+ Tregs are less studied - and often even 
overlooked - compared to CD4+ Tregs, especially in infectious diseases and vaccination 
[18], and no paired analysis of BCG-activated CD4+ vs. CD8+ Tregs exists. Thus, there are 
virtually no data to estimate the relative impact of CD4+ vs. CD8+ Tregs on BCG-vaccine 
immunogenicity or protective efficacy. In addition, much is still unknown regarding how 
CD8+ Tregs mediate suppression of Th1 T-cells [18]. 
Recent studies in murine TB-vaccine models discovered a relation between expression of 
KLRG1 or PD-1 and vaccine-induced immunity against TB: in these models KLRG1 
expression marked terminally differentiated T-cells that had decreased cytokine 
polyfunctionality and proliferative capability compared to PD-1-expressing T-cells, and 
KLRG1 expression was associated with impaired protection against TB-challenge [62;63]. 
However, the induction of KLRG1 expression on human T-cells in response to 
mycobacteria in particular has not been investigated yet. M. bovis BCG can be 
isolated as a live bacterium from the vaccine lesion months after vaccination, 
demonstrating antigen persistence, but it remains unknown whether prolonged antigen 
exposure could drive inhibitory marker expression by T-cells.  
Thus, several possible explanations have been formulated to account for the incomplete 
protection against TB mediated by BCG-vaccination in the adult population, and better 
research into BCG-vaccine immunogenicity in adults is needed to understand immune 
responses and immune response diversity induced by this almost a century old vaccine. 
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Basic research into which exact mechanisms of vaccine-induced (cellular) immune 
responses are essential for protection will also help guiding future vaccine design 
[31], and new surrogate endpoints of protection may be identified in parallel. 
 
 
Outline of this thesis 
There is no effective vaccine against pulmonary TB in adults. The only currently available 
TB-vaccine, M. bovis BCG, reduces the risk of severe TB in infants, but provides highly 
variable and only limited protection against pulmonary TB in adults. This thesis aims to 
characterize the M. bovis BCG-reactive human T-cell response, in order to identify 
cellular responses that may account for the suboptimal and poorly understood protective 
efficacy of BCG-vaccination. Firstly, through assessment of the induction of CD4+ and 
CD8+ regulatory T-cells by BCG in human adults. Secondly, in view of the inconsistent 
results on (vaccine-induced) cytokine-producing T-cell subsets in protected vs. non-
protected cohorts, by investigating primary BCG-vaccine induced T-cell responses, 
including both pro-inflammatory and regulatory cellular subsets. Thirdly, by assessing 
specific induction of inhibitory markers, especially KLRG1, expressed on human T-cells 
following BCG-vaccination in adults, and whether expression of such inhibitory markers 
would correlate with impaired immune control in patients with active TB disease compared 
to individuals with latent (controlled) Mtb infection. 
Chapter 2 summarizes and discusses current evidence for the impact of regulatory T-cells 
on protective immunity  in  human  infectious  diseases  and  following  vaccination. The 
chapter highlights mycobacteria, including M. tuberculosis, M. bovis BCG, M. leprae and 
non-tuberculous mycobacteria (NTM) as manipulators of the human immune system.  
Chapter 3 presents a comparative analysis of the suppressive phenotypes and functions of 
BCG-activated CD4+ compared to CD8+ T-cells. PBMCs were isolated from human donors 
who responded in vitro to M. tuberculosis PPD and restimulated with BCG. Considering 
the partly different antigen presentation pathways targeted by live vs. killed BCG bacteria 
in activating CD8+ vs. CD4+ T-cells we compared live vs. heatkilled BCG in inducing the 
suppressive phenotype and function of BCG-activated CD4+ vs. CD8+ T-cells.  
CD39 (E-NTPDase1), an ectoenzyme hydrolysing pericellular ATP to AMP, is a relatively 
new marker of CD4+ T-cells with a regulatory phenotype and activity. CD39 has been 
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found to be expressed on T-cells circulating in patients with active TB and is also induced 
on T-cells following vaccination with novel candidate TB-vaccines. The role of CD39 or 
its expression by BCG-activated CD8+ Treg cells, however, had not been investigated. 
Chapter 4 investigates the expression of CD39 and its involvement in mediating 
suppression by in vitro live BCG-activated CD8+ Treg cells. 
The above studies describe in vitro BCG-activation of Treg subsets. However, to follow 
induction of T-cell subsets by BCG-vaccination, we prospectively studied the pro-
inflammatory and regulatory T-cell response induced by primary BCG-vaccination of 
healthy adult volunteers (Chapter 5). Identification of immune responses was further 
complemented by assessing local vaccine-induced skin reactivity (by ‘classical’ 
inflammation markers), serum CRP, and IFN -expression/-production assays. 
Finally, in Chapter 6 the expression of markers with a role in T-cell inhibition was 
studied: the expression of KLRG1, PD-1 and CTLA-4 on T-cells was determined 
following BCG-vaccination, the proliferative capacity of KLRG1- vs. PD-1-expressing T-
cells was compared; and the expression of these markers in active TB disease, latent Mtb 
infection, and following TB-treatment was evaluated. 
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Abstract 
Regulatory T-cells (Tregs) act at the interface of host and pathogen interactions in human 
infectious diseases. Tregs are induced by a wide range of pathogens, but distinct effects of 
Tregs have been demonstrated for different pathogens and in different stages of infection. 
Moreover, Tregs that are induced by a specific pathogen may non-specifically suppress 
immunity against other microbes and parasites. Thus, Treg effects need to be assessed not only 
in homologous but also in heterologous infections and vaccinations. Though Tregs protect the 
human host against excessive inflammation, they probably also increase the risk of pathogen 
persistence and chronic disease, and the possibility of disease reactivation later in life. 
Mycobacterium leprae and Mycobacterium tuberculosis, causing leprosy and tuberculosis, 
respectively, are among the most ancient microbes known to mankind, and are master 
manipulators of the immune system toward tolerance and pathogen persistence. The majority 
of mycobacterial infections occur in settings co-endemic for viral, parasitic, and (other) 
bacterial co-infections. In this paper, we discuss recent insights in the activation and 
activity of Tregs in human infectious diseases, with emphasis on early, late, and non-
specific effects in disease, co-infections, and vaccination. We highlight mycobacterial 
infections as important models of modulation of host responses and vaccine-induced 
immunity by Tregs. 
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Introduction 
A myriad of innate and adaptive immune regulatory cells is induced upon infection, 
including cells of different lineages: regulatory-like macrophages, dendritic cells (DCs), 
NKT-cells, T-cells, B-cells, neutrophils, and mesenchymal stem cells. During the last 
decade, many reports have described the role of regulatory T-cells (Tregs) in infectious 
diseases and following vaccination. In infectious diseases, Tregs play a dual role: they 
benefit the host by limiting immune-mediated pathology and also facilitate chronic 
pathogen persistence by reducing effector immunity and clearance of infection [1]. During 
acute infection, the beneficial role of Tregs seems to predominate, by regulating leukocyte 
in- and efflux into lymph nodes (LN) and infected sites, suppression of proliferation of 
infected cells, and favoring memory formation by increasing the time window of antigen 
availability. 
Regulatory T-cells can be induced either in an antigen- and T-cell receptor (TCR)-
dependent or in an antigen- and TCR-independent manner [2;3]. Specificity for self- or 
pathogen-derived antigens (or dual-specificity) was originally used to divide Treg 
populations into ‘natural’ resp. ‘adaptive’ Tregs, but it was recently recommended to 
denote Treg populations by place of induction: ‘thymus derived’ or ‘peripherally derived’, 
or when the origin is unclear ‘Foxp3+ Treg cell’ [4]. Designations of human Tregs are, 
however, complicated by the fact that, unlike murine Tregs, unique markers are lacking. In 
addition, non-Treg populations can express ‘Treg markers’ such as Foxp3 and CD25 upon 
activation; therefore, human Tregs are preferably defined by multiple regulatory markers 
and/or by demonstrating suppressive activity [5]. Human CD8+ Tregs have been studied 
much less than CD4+ Tregs [5], even though they were among the first described 
‘suppressor cells’, especially in mycobacterial infections [6;7]. The relative lack in studies 
on human CD8+ Tregs is possibly the result of technical difficulties in isolating and 
assessing functions of CD8+ T-cells [8]. Notwithstanding, CD8+ Tregs are re-emerging as 
important players in general, including in human infectious disease and following 
vaccination [5]. 
Once activated, Tregs can suppress pro-inflammatory cells through several mechanisms 
that are adaptable to the local environment [9]. These mechanisms can mostly be divided 
into inhibitory cytokine production (either membrane-bound or by their release in the 
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pericellular environment), suppression by cytolysis, metabolic disruption of pro-
inflammatory cells, modulation of antigen-presenting cells (APCs), and the activity of 
certain Treg membrane expressed molecules (see below) [10]. These mechanisms indeed 
support the concept that antigen-specifically induced Tregs can cross-suppress also other 
cells irrespective of the presence of their cognate antigen or specificity, e.g., through the 
secretion of cytokines [5]. This ‘bystander’ or heterologous suppression can compromise 
immunity toward unrelated pathogens, as has been described for co-infection by helminths 
in diseases such as malaria and tuberculosis (TB) [11]. Helminth co-infections can also 
impair the immunogenicity of vaccines such as (oral) cholera vaccination and (intradermal) 
BCG (Mycobacterium bovis bacillus Calmette-Guérin) and tetanus vaccination [12]. 
Several Treg-expressed molecular markers have now been implicated directly in mediating 
suppression, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which 
modulates APCs via its ligands CD80 and CD86. Tregs were shown to use trans-
endocytosis of CD80 and CD86, followed by their intracellular degradation, thereby 
relatively depleting the APC’s expression of essential co-stimulatory receptors for T-cell 
CD28 ligation [13]. In addition, the ectoenzyme CD39 (E-NTPDase1), which is a relatively 
recently discovered Treg marker, exerts its suppressive effects through breakdown of 
adenosine triphosphate (ATP) [14].  
In this paper, we will discuss the induction of Tregs (both specific and non-specific) by 
various pathogens as well as the functional implications of CD4+ and CD8+ Tregs in acute 
vs. chronic infectious diseases. We will discuss the role of Tregs in co-infections and 
highlight in particular infections with M. leprae and M. tuberculosis (Mtb), which are 
master manipulators of the human innate and adaptive immune response through the 
induction of regulatory circuits. We will discuss how the balance of pro- vs. anti-
inflammatory responses could ultimately regulate pathogen persistence, and impact on the 
development of active vs. latent or reactivation of disease. We will also discuss the impact 
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Mechanisms of Treg induction by pathogens 
As a first line of host-defense against infection, the activation of innate immune cells 
through pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), lectin 
receptors, retinoic acid-inducible gene (RIG) receptors, scavenger, and phagocytic 
receptors, activates these cells to phagocytose and process the pathogen, after which they 
migrate to the draining lymph node (DLN) and present antigen to prime naive T-cells. 
These cells then can differentiate into various classes of T-helper cells (Th), cytotoxic T-
cells, or Tregs. Further activation and differentiation signals are provided to the T-cells 
upon migration into the infected tissue; these signals originate from other T-cells, activated 
tissue-resident APCs, or even directly from the pathogen (see below). Tissue-resident, 
circulating, and migrating APCs comprised heterogeneous populations, and the activation 
of APCs can lead to the induction of pro-inflammatory or regulatory, homeostatic T-cell 
responses [15]: for example, pro-inflammatory human type-1 macrophages promote Th1-
immunity and are characterized by IL-23 production and secretion of IL-12 after IFNγ 
stimulation, whereas type-2 macrophages poorly express co-stimulatory molecules, produce 
IL-10, and induce Tregs [16;17]. 
Modulation of macrophages and DCs toward tolerogenic subsets has been described for 
various pathogens: after in vitro treatment of human DCs with Japanese encephalitis  virus 
or Mtb, DCs upregulated the inhibitory receptor PD-L1, which induced the expansion of 
Tregs through PD-1 ligation [18-20]. These effects were mediated by the Mtb-derived 
protein Acr (HspX Rv2031c), which is expressed during latency: Acr induced expression of 
PD-L1, TIM3, IDO, and IL-10 by murine DCs and promoted the induction of 
CD4+CD25+Foxp3+ T-cells [21]. Furthermore, APCs can be modulated through alterations 
in (pericellular) purinergic pathways: extracellular ATP, a pro-inflammatory danger signal, 
which activates the killing of Mtb in macrophages, is rapidly hydrolyzed to AMP by CD39, 
which is expressed by various regulatory cells [14]. The degradation of ATP to AMP in the 
microenvironment was accompanied by a switch in macrophage gene expression from type 
1 toward type 2, and Mtb infection actively upregulated expression of the adenosine A2A 
receptor on macrophages [22]. This receptor has been described as a major 
immunosuppressive immune cell adenosine receptor acting through elevation of cAMP 
[23], and its expression on macrophages was central to M2-like polarization after Mtb 
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infection [22]. Other cell types acting as APCs were demonstrated to contribute to Treg 
induction: both hepatitis C virus (HCV)-infected hepatocytes and H. pylori-infected gastric 
epithelial cells directly induced Tregs through production of TGF-β [24;25]. 
Regulatory T-cells can also be induced directly through pathogen-derived components. This 
has been demonstrated in several murine studies: zwitterionic capsular polysaccharides 
from S. pneumoniae-induced CD8+CD28− Tregs that were CD122LOCTLA-4+CD39+, 
synthesized IL-10 and TGF-β, and exhibited suppressive activity. This induction was 
independent of APCs and involved direct crosslinking of the TCR [26]. In another murine 
study, proteins secreted by H. polygyrus induced Foxp3+ T-cells through ligation of the 
TGF-β-receptor [27]. The herpes virus entry mediator HVEM, a binding site for viral 
glycoprotein HSVgD, is upregulated on murine CD4+Foxp3+ Tregs after HSV-1 infection, 
and activation of this receptor led to preferential expansion of Tregs [28]. In the human 
situation, CD4+CD25+ Tregs exhibited extended survival and increased suppressive 
capacity after binding HIVgp120 [29]. 
The preferential expression of TLRs, such as TLR2, on Tregs as compared to 
‘conventional’ T-cells has been reviewed by Sutmuller and colleagues [2]. A large variety 
of TLR2 ligands have been described in bacteria, including Mtb [30]. Mtb-induced TLR-
signaling in APCs leads to inhibition of the MHC-II transactivator-gene CIITA, thereby 
decreasing expression of MHC-II and antigen presentation [30]. During chronic Mtb 
infection, prolonged TLR2 signaling (e.g., through the 19kD lipoprotein) can lead to 
suppressive cytokine production [31] and recruitment of CD4+ Tregs to the lung [32]. A 
role for TLR-mediated Treg induction has also been described in murine malaria: murine 
Plasmodium-activated DCs induced Tregs through TLR9, and TLR9(−/−) mice had impaired 
activation of Tregs, associated with a partial resistance to lethal infection [33]. Other factors 
in the local environment vital for the expansion and function of Tregs include changes in 
metabolism [34], endothelial cytokine (IL-33) production and cytokine balance (IL-23 : IL-
33 ratio) [35], and metabolite products from commensal microbiota [36;37]. Thus, specific 
pathogen components can skew toward Treg phenotype or function. The significance of 
these Tregs for the disease process, concomitant diseases, and vaccinations will be 
discussed further below. 
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The impact of Tregs in infectious diseases 
 
Viral infections: acute vs. chronic infectious disease 
Regulatory T-cells have been found after retrovirus-, RNA virus-, and DNA virus infection 
in mice and humans [reviewed in Ref. [3]; figure 1A]. Various CD4+ and CD8+ Treg 
subsets have been identified [38], but mostly in chronic viral infection. Yet, in hepatitis A 
virus infection - an acute inflammatory disease, usually followed by pathogen clearance - 
hepatitis A virus bound to its cellular receptor (HAVCR1), which is expressed on Tregs, 
which resulted in inhibited Treg function and inflammation [39]. By contrast, in acute 
dengue fever, Treg function and the suppression of vasoactive cytokine release were similar 
in acutely infected and recovered patients, such that in this case, the disproportionate 
activation of pro-inflammatory cells and cytokines often found in dengue fever was not 
explained by acute phase Treg malfunction [40]. Thus, blockade of Tregs in acute viral 
infection could assist in pathogen clearance, at the cost of temporary hyper-inflammation, 
but not all (pathological) hyper-inflammation is associated with Treg hypo-functionality. 
On the other side, Tregs could also benefit the host during acute infection: first, Treg 
depletion in murine herpes simplex infection increased LN levels of IFN-α and -γ, but 
infection-site-associated IFNγ was decreased, and the arrival of DCs, NK cells, and T-cells 
at the infected lesion was delayed [41], pointing to a role for Tregs in promoting LN in- and 
efflux of pro-inflammatory cells [42]. Second, Tregs may suppress infected cell 
proliferation at the mucosal point-of-entry to a level where infection cannot be established, 
which was suggested as a protective mechanism in early HIV infection [43;44]. Third, 
Tregs were vital in allowing memory formation through promoting antigen persistence, as 
was recently demonstrated in a murine West Nile virus infection model [45]. 
The role of human Tregs  in chronic viral infection has been more extensively delineated. A 
meta-analysis of 12 studies demonstrated increased CD4+ Treg frequencies in chronic 
hepatitis B virus (HBV) infection compared to both acute infection and healthy controls, 
revealing a strong association of Tregs with disease progression, viral load, absence of 
therapy response, and risk of hepatocellular carcinoma [46]. In chronic HCV infection, the 
contribution of Tregs to low inflammatory CD4+ and CD8+ T-cell responses has been 
described [47;48]. Tregs were recruited to the liver through the Treg-attracting chemokines 
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CCL17 and CCL22 [49], thereby promoting pathogen persistence. It has been argued, 
however, that Tregs may also be functional in limiting HCV-induced liver damage [48]. 
In chronic HIV infection, CD4+ Tregs were relatively increased in the mucosa and in the 
circulation compared to healthy controls, but the Treg-mediated effects on anti-HIV 
immune responses remain a matter of debate [50]. CD4+ Tregs decreased HIV replication in 
T-cells in vitro through CD39-mediated ectonucleotide shifts and by transfer of cAMP 
through gap junctions formed with conventional T-cells [43]. Tregs inhibited spreading of 
virus from DCs to T-cells through interfering with the immunological synapse [51]. In 
another study, blocking of CD39 by monoclonal antibodies (mAbs) restored cytokine 
production by HIV-gag-stimulated CD8+ T-cells [52]. Indeed, the relative frequency of 
CD4+CD39+ Tregs positively correlated with HIV viral loads and disease progression in 
infected individuals [53]. These different effects of Tregs could be explained by 
differentiating between acute and chronic infection, as argued in Ref. [ 50]: control of 
viral replication by CD4+(CD39+) Tregs may be important early after infection with a 
limited number of infected cells (relatively high Treg : T-effector ratio), yet during chronic 
infection Tregs may not be able to suppress proliferation of all infected cells, and potentially 
become more detrimental due to dampening anti-HIV responses. This points to the need for 
more detailed analyses of Treg functions in acute vs. chronic (hyper-) inflammation. 
 
 
Bacterial infections: reservoirs for Treg induction  
Early vs. late effects of Tregs in bacterial infection were elegantly described in a mouse 
model of Salmonella (Salmonella enterica serotype Typhimurium): Tregs suppressed early 
protective immunity, thereby allowing for establishment of infection, yet clearance of 
infection at later time points corresponded with a decrease in Treg suppressive capacity 
[54]. After acute infection, Treg-mediated failure to completely eradicate Salmonella may 
thus lead to a carrier state of persistent asymptomatic infection, resulting in a reservoir for 
shedding of pathogens into the environment and further infection (reviewed in Ref. [55]). 
A carrier state of Streptococcus pneumonia in the nasopharynx was associated with 
increased TGF-β levels from nasal washes in humans, and TGF-β was shown to lead to 
Treg expansion in in vitro murine experiments [56]. In Helicobacter pylori infection, a 
carrier state can last for life; and several studies have described the ability of Helicobacter 
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pylori to induce Tregs. These Tregs were found in the circulation as well as in the gastric 
mucosa of both infected children and adults, and though Tregs initially can limit 
inflammation and therefore probably gastric ulceration, pathogen persistence could, on the 
other hand, lead to chronic inflammation and tumor  induction [57] (reviewed in Ref. [58]).  
Increasing attention has been drawn to the interplay of the immune system with non-
pathogenic commensal microbiota in the intestine. Tregs can be induced by commensal 
microbiota, as has been demonstrated in multiple murine studies: butyrate, a metabolite 
from commensals, potently induced Tregs in the intestine [36;37], possibly through 
butyrate-mediated enhanced histone H3 acetylation in the FOXP3 promoter [37]. 
Polysaccharide A (PSA) from B. fragilis induced conversion of T-cells into Tregs, and 
cured experimental colitis [59]. The CNRZ327-component from Lactobacillus delbrueckii 
induced regulatory responses in colonic tissue, but importantly also in cecal LNs and the 
spleen, pointing to systemic distribution of these microbiota-induced Tregs [60]. 
Raising mice in germ-free conditions decreased the number of Tregs in the gut, but the 
number of cutaneous Tregs was increased, possibly through loss of inhibition by pro-
inflammatory cells [61]. In any case, data on activation of Tregs by skin commensals is also 
emerging [61], and these Tregs induced by skin microbiota may modulate systemic 
inflammatory responses [61]. As recently reviewed [62], increasing evidence reveals 
resident microbiota in the lungs. Though relatively low in bacterial biomass compared to 
the microbiota of the skin and the intestinal mucosa, these microorganisms are present in 
healthy lungs as they are at other mucosal surfaces, and probably differ in composition 
between healthy individuals and individuals with (pulmonary) disease [62]. 
Clearly, mucosal surfaces are the primary sites both for pathogenic and commensal 
microbiota; and induction of Tregs - within the myriad of innate and adaptive cells - has 
been described for both. Further research should elucidate local and systemic effects of 
Tregs induced at barrier sites in human studies, and whether systemic effects of Tregs 
induced by (non-pathogenic) commensals are to be expected (figure 1A). 
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Figure 1. Main effects of Tregs as described for various pathogens. 
A: Various Treg-mediated effects have been described for the various classes of pathogens; early vs. late, and 
heterologous suppression, are described in several taxonomies. Prominent features are noted, as well as prominent 
Treg markers for the various pathogens. Circles ‘CD4/CD8’ depict the scale in reports of either CD4+ or CD8+ 
Tregs in literature for the various classes. B: Treg effects on TB-vaccine immunogenicity are displayed in a similar 
fashion. BCG immunogenicity may be decreased by or inversely related to BCG-induced Tregs, or may be 
suppressed by heterogenic Tregs. Treg induction has also been described in various TB-vaccine candidate trials. 
BCG = Mycobacterium bovis bacillus Calmette-Guérin; CCL4 = CC chemokine ligand 4; CTLA-4 = cytotoxic T-
lymphocyte-associated antigen 4; LAG-3 = lymphocyte activation gene-3; LN = lymph node; LTBI = latent 
tuberculosis infection; MDR-TB = multi-drug-resistant tuberculosis; NTM = non-tuberculous mycobacteria; TB = 
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Parasitic infections: suppression across boundaries 
Murine Leishmaniasis models have been pivotal in demonstrating Tregs at the site of 
(parasitic) infection: antigen-specific CD4+CD25+ Tregs were present at the site of chronic 
Leishmania major infection [63] and retention at the infection site was dependent on 
expression of CD103 by CD4+CD25+ Tregs [64]. In this model, the impact of Tregs on 
establishment of chronic infection and reactivation of disease was elegantly demonstrated: 
after pathogen clearance, Leishmania super-infection led to reactivation of disease and 
increased Treg numbers at the primary site. Also, adoptive transfer of Tregs from infected 
mice into chronically infected mice caused reactivation of disease [65]. Mechanisms of 
suppression included IL-10 production by Tregs as well as other mechanisms [66]. In 
another study, Foxp3-negative cells were the major producers of IL-10, and anti-IL-10R 
mAb treatment decreased parasite burden to a greater extent compared to anti-CD25-mAb 
treatment [67]. In humans, functionally suppressive CD4+CD25+ Tregs have been isolated 
from cutaneous leishmaniasis (skin) lesions [68]; and FOXP3 mRNA levels in skin lesions 
were increased in chronic compared to acute Leishmania major infection [69]. Also in 
Leishmania guyanensis-induced skin lesions, FOXP3 mRNA levels were significantly 
higher in chronic compared to acute patients, though in both cases Tregs isolated from these 
lesions displayed suppressive activity in vitro [70]. Importantly, IL-10 and FOXP3 mRNA 
expression in Leishmania guyanensis-infected skin lesions were associated with 
unresponsiveness to treatment [71]. 
Several studies have reported increased Treg frequencies in Plasmodium falciparum-
infected individuals compared to asymptomatic or uninfected controls [72]; furthermore in 
patients with clinically severe malaria, the frequency of CD4+CD25+Foxp3+CD127LO Treg 
cells correlated with levels of parasitemia and total parasite biomass [73]. Tregs were 
associated with risk of malaria disease: reduced expression of CTLA-4 and FOXP3 was 
found in Fulani, an ethnic group in Burkina Faso relatively resistant to P. falciparum 
compared to Mossi (a different ethnic group from the same region) [74]. Proliferative 
PBMC responses to malaria antigens from Mossi were increased following CD25+-
depletion, but those from Fulani were not [74]. In Kenyan  adults with natural  immunity to 
malaria, CD4+CD25HI T-cell frequency at enrollment was associated with the risk of 
developing clinical malaria during follow up [75]. 
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Many helminth parasitic infections steer immunity toward Th2 and T-regulatory responses 
[12]; and murine data indicate that immune suppression is achieved through cross-mucosal 
induction of regulatory cytokines, regulatory DCs, macrophages, and CD4+ and CD8+ 
Tregs [76]. In a recent study of murine Trichuris muris infection, Th2 cell proliferation was 
enhanced by early Treg depletion post-infection and by Treg depletion after establishment 
of infection [77]. However, the ultimate effect of Tregs on pathogen persistence was clearly 
time dependent: both early and late Treg depletion enhanced Th2 responses and reduced 
Th1 responses, but while early Treg depletion resulted in enhanced clearance of infection, 
later, during infection, Treg depletion resulted in enhanced worm burden [77].  
Importantly, in geohelminth-infected children in vitro depletion of CD4+Foxp3+CD25HI T-
cells increased not only antigen-specific proliferative responses but also IFNγ production in 
response to Plasmodium-infected red blood cells [11]. The in vivo effect of helminth co-
infection on immunity against Plasmodium varies between studies, but helminth co-
infection may be associated with protection against cerebral malaria, a state of severe 
hyper-inflammation [12]. Latent tuberculosis infection (LTBI) individuals with hookworm 
[78] and filarial co-infection [79] had decreased Th1 and Th17 responses and increased 
Treg frequencies compared to parasite-uninfected LTBI individuals. Whether deworming 
has clinical impact on the course of TB disease is not clear: in TB patients with helminth 
co-infection, albendazole treatment decreased IL-10 levels, but there was no clinical 
improvement in TB after 2 months [80]. Since (helminth-induced) Tregs are capable of 
exerting non-specific suppressive responses, research in malaria and TB (diseases where 
strong Th2 and Th1 responses are vital, respectively) will hopefully clarify the effect of 
Tregs across the boundaries of disease (figure 1A), especially in settings where co-infection 
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Tregs in leprosy and tuberculosis 
 
Tregs in leprosy, an ancient disease 
Leprosy, caused by M. leprae, is an ancient, chronic, disabling, but curable disease 
affecting the skin, the peripheral nerves, the eyes, and mucosa of the respiratory tract [81]. 
The clinical spectrum of the disease ranges from tuberculoid (TT) and borderline 
tuberculoid (BT) to borderline lepromatous (BL) and lepromatous leprosy (LL), where 
TT/BT is immunologically characterized by a strong Th1 response accompanied by limited 
growth of the bacillus (paucibacillary leprosy), whereas BL/LL is classically characterized 
by a predominant Treg/Th2 response, high antibody titers, absent granuloma formation, and 
thus poor containment of infection and clinical deterioration [82]. 
Though the exact mechanisms ruling this spectrum have not been elucidated, it is clear that 
Tregs play a part, and demonstration of the suppressive activity of CD4+ and CD8+ Tregs 
isolated from the skin and circulation of LL patients were among the first reports on 
‘human T-suppressor cells’ [6;7]. In the circulation of leprosy patients, both CD4+Foxp3+  
and CD8+Foxp3+ T-cells were almost twofold increased compared to healthy contacts [83]. 
Within the spectrum of disease, increased percentages of CD4+Foxp3+CD25+ and 
CD8+Foxp3+CD25+ T-cells have been demonstrated in the circulation of LL patients 
compared to BT patients or healthy contacts [82;84]. Also in lepromatous lesions, Foxp3+ 
T-cells were increasingly expressed in LL compared to TT/BT patients [82;84]. 
Suppression of the Th1 response by Tregs was demonstrated by enhanced in vitro IFNγ 
production through depletion of CD25+ cells in a subset of LL patients [82]. Both 
CD4+CD25+ derived IL-10 production and regulation through TGF-β have been described 
[85;86]. 
A possible mechanism of Treg induction by M. leprae-infected DCs is the expression of the 
mycobacterial cell wall component PGL-1, that by association with the complement 
component C3 can steer toward Treg differentiation [87]. Type-2 anti-inflammatory 
(CD163+) macrophages are important Treg inducers [17], possibly due to the action of ROS 
[88]; indeed, a regulatory phenotype was described in monocytes stimulated with M. leprae 
[89]. Recently, CD68+CD163+ cells were demonstrated in LL skin lesions with increased 
frequencies compared to BT/TT lesions [82]. Intracellular pathways leading to enhanced 
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Foxp3 expression in CD4+ T-cells have been described in association with progression of 
disease toward BL/LL, in addition to low Foxp3 ubiquitination (marked for intracellular 
degradation) [86]. In T-cells isolated from LL patients, Foxp3 interacted with histone 
deacetylases and bound directly to the promotor regions of CD25 and CTLA-4 [90]. The 
importance of this transcriptional regulation by Foxp3 within the immunological spectrum 
of disease is further supported by the fact that not only Treg frequencies are increased in LL 
compared to BT patients but also the intensity of expression (mean fluorescence intensity) 
of Foxp3 as determined by flow cytometry [83]. 
Thus, Tregs are clearly involved in the impairment of mycobacterial control. However, this 
does not necessarily equate to increased suppression of Th1 over Th2 responses toward the 
LL pole spectrum: gene expression profiling of PBMCs isolated from TT, LL, and 
borderline leprosy patients revealed decreased expression of both Th1 and Th2 genes in LL 
patients, but enhanced expression of CTLA-4 and TGFB1 [91]. The authors further found 
overexpression of CBL-B, an E3 ubiquitin-ligase that after encounter with antigen is crucial 
in modulating T-cells toward activation vs. anergy, dependent on the presence or absence of 
co-stimulatory signals [92]. Cbl-b, TGF-β, and CTLA-4 expression were molecularly 
related, as demonstrated by the dependency of Cbl-b expression on TGF-β and the 
decreased expression of Cbl-b after treatment with CTLA-4 siRNA [91]. Within the 
paradigm of a generalized suppressed peripheral T-cell response associated with LL 
development, Tregs could thus play an important role in inducing and maintaining low 
cellular immune responsiveness (figure 1A), although their impact on humoral (mostly but 
not exclusively Th2-related) responses remains less clear. Further work would be needed to 
clarify causal relationships, e.g., if Tregs are a cause or consequence of bacterial burden in 
LL disease [93]. 
 
 
Tuberculosis: early and late effects of Tregs 
Pathogen-specific Tregs were induced by Mtb as demonstrated in a murine Mtb aerosol 
infection model, and these Tregs delayed priming of CD4+ and CD8+ T-cells in the 
pulmonary LNs, thereby delaying migration of these cells to the lung [94]. Tregs were 
demonstrated in the lung, including in granulomas [95], and were shown to prevent 
pathogen clearance [96]. Interestingly, in contrast to Listeria monocytogenes, pathogen-
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specific Treg expansion could be found in LNs only after Mtb infection [97]. Thus, Mtb-
induced Tregs contribute to the delayed onset of adaptive immunity that is observed in TB 
compared to other diseases and which allows establishment of infection [98;99]. The 
impact of Tregs on establishment of infection was further demonstrated in a murine study, 
where depletion of CD25+ cells early after Mtb infection - but not during chronic infection -
decreased bacterial load and granuloma formation [100]. However, it might also be that 
(pre-existing) Tregs have a beneficial role very early in infection, but also these data are 
only derived from animal experiments. In macaques, Tregs and IFNγ-producing effector T-
cells expanded early after pulmonary TB infection, yet in vivo depletion of both IFNγ-
producing- and regulatory T-cells led to decreased resistance against granuloma 
progression [101]. Analogous to the possibly beneficial role for Tregs in regulating LN in- 
and efflux during early murine HSV infection [41;42], it is conceivable that the presence of 
a very low level of (possibly pre-existing) Tregs before or in a very early state after Mtb 
infection might thus accommodate priming and subsequent emergence of a pro-
inflammatory immune response. Clearly, further research will be needed to specify the 
impact of Tregs in various organs [102], early in (human) Mtb infection, and to 
differentiate their impact in early vs. chronic infection (figure 1A). 
Regulatory T-cells are also present in human Mtb infection as has been demonstrated 
extensively: Tregs could be isolated both from the circulation and from the site of infection 
in TB patients. In the circulation of TB patients, an increase in FOXP3 mRNA expression 
was found compared with healthy controls [103], and also an increase in CD4+ T-cell 
frequencies with regulatory phenotypes was demonstrated (defined as CD4+CD25+/HI 
[103;104], CD4+Foxp3+CD25HI [105;106], or CD4+CD25HICD39+ [105]). Tregs could be 
isolated from various Mtb-infected sites, including bronco-alveolar lavage (BAL) fluid, 
ascites, pericardial fluid, and pleural fluid; and FOXP3 mRNA expression levels and 
CD4+CD25HI T-cell frequencies were increased stronger locally than systemically (in the 
circulation) [103;107]. In a study comparing TB cases with infected and uninfected TB 
contacts (defined by positive tuberculin-skin test (TST) and ELISpot results), PBMCs from 
uninfected contacts had lower FOXP3 mRNA expression levels compared to TB cases, but 
higher FOXP3 expression levels compared to infected TB contacts; which according to the 
authors could signify migration of Tregs to the lungs during early infection, with a 
reappearance in the circulation during latent (established) infection [108]. Also 
Chapter 2    
 
- 40 - 
 
CD8+Foxp3+CD25+ Tregs were demonstrated in the circulation and BAL fluid of TB 
patients [107]; and CD8+LAG-3+CCL4+ Tregs (lymphocyte activation gene-3 (LAG-3); CC 
chemokine ligand 4 (CCL4)) were shown by histological staining of infected LNs from TB 
patients [109]. Furthermore, after stimulation with HLA-E restricted Mtb-derived peptides 
CD8+ Tregs could be isolated from PBMCs of in vitro mycobacterial purified protein 
derivative (PPD)-reactive donors [110;111]. 
Elevated frequencies of circulating Tregs in TB patients declined during successful 
chemotherapy [106], in contrast, in patients with emerging MDR-TB circulating Treg 
frequencies remained persistently high [106]. Other data on Tregs in MDR vs. normally 
resistant (NR)-TB are scarce and conflicting: similar frequencies of circulating 
CD4+Foxp3+ Tregs were found in MDR-TB patients compared to (NR-)TB patients [112]; 
however, in another study comparing MDR-TB, NR-TB, and non-tuberculous 
mycobacteria (NTM) infections, increased ex vivo frequencies of Tregs were found in 
MDR-TB but also in NTM infections compared to NR-TB. This may reflect chronicity of 
infection in MDR-TB and NTM infection, which is often treated suboptimally; however, 
the contrast reported by the authors between elevated serum IL-10 levels in MDR-TB 
patients vs. elevated serum TGF-β levels in NTM-infected patients could also suggest 
different subsets of Tregs or different suppressive effector pathways to be involved in 
MDR-TB vs. NTM [113]. 
 
 
Tuberculosis: Tregs differentiate active from latent disease 
CD4+Foxp3+CD25+ Tregs are increased in frequency in active TB compared to LTBI 
[107;114], both in the circulation and in BAL fluid [107] (figure 1A). A report on 
CD4+CD25+CD134+ T-cells in TB demonstrated differentiation between active and latent 
TB solely through the presence or absence of the CD39-molecule on this subset [115]. 
Stasis of mycobacterial growth in macrophages, both monocyte-derived and alveolar, was 
suppressed by CD4+ Tregs [107]. Depletion of CD4+Foxp3+CD25HI T-cells increased IFNγ 
responses to the mycobacterial antigen heparin-binding hemagglutinin (HBHA) of patients 
with active TB in vitro, to the level observed in LTBI individuals [116]. Treg frequency in 
the circulation of smear-positive TB patients was increased compared to smear-negative 
Regulatory T-cells in infectious diseases and vaccination 
 
- 41 - 
 
patients; however, this did not correlate with radiologic determination of extent of disease 
[112]. 
Pro-inflammatory signatures of CD8+ T-cells differentiated between latent infection and 
active TB disease [117], and also in vitro an association was found between burden of 
infection of cells and lysis by cytotoxic CD8+ T-cells [118]. The frequency of CD8+  T-cells 
producing IL-10 or TGF-β was increased in active TB patients compared to latently  
infected or control subjects [119]. In this study, CD8+, CD8+IFNγ+, and CD8+IL-17+ T-cell 
numbers were similar between groups, and were - interestingly - not dependent on sputum 
bacillary load, while sputum bacillary load was positively associated with specific 
regulatory cytokine expression in CD8+ T-cells, and negatively associated with CD8+ 
granzyme-B expression [119]. However, in another study, the frequency of 
CD8+Foxp3+CD25+ Tregs did not differ between active vs. latent TB, or between cells 
isolated from the circulation vs. cells isolated from BAL fluid [107]. The differences 
between these reports may be explicated by differences in regulatory markers that were 
studied, or by methods that were used: in the former study, cells were stimulated with Mtb 
specific antigen for 96 hours, while in the latter study, cells were PPD-stimulated for 12 
hours. CD8+ Tregs are relatively understudied compared to CD4+ Tregs in mycobacterial 
infection [5], and this clearly points to the need for more (uniform) research into these 
possibly important regulators and/or markers of activity of disease. Of note, CD8+ Tregs 
were found at the disease site in mice, and progression of disease correlated with 
accumulation of IL-10-secreting CD8+ T-cells in granulomas [120]. 
Instead of being a steady state of infection, latent TB comprises a dynamic spectrum with 
supposedly increasing rates of subclinical Mtb replication and inflammation extending 
eventually to active TB. Serial IGRA testing has been proposed as an indicator of human 
host resistance in latent TB. Using serial testing, a consistently negative test in TB-exposed 
individuals would likely indicate strong resistance to infection, a consistently positive test 
(recent) active infection, and (repeated) test conversions (positive to negative, possibly 
followed by conversion, etc.) changing dynamics of infection and control of bacterial load. 
In a comparison of T-cell subsets between IGRA-consistently positive and consistently 
negative TB-case contacts, CD4+Foxp3+ and CD4+CTLA-4+ Tregs were increased in TB-
case contacts with consistently positive IGRA tests, possibly indicating Treg interference 
with host resistance in the development of active infection [121]. 
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Tuberculosis: Tregs in extra-pulmonary disease 
A minority of TB cases present with extra-pulmonary disease or extra-pulmonary 
involvement following pulmonary infection, and it is assumed that this represents failure of 
the immune system to contain infection [122]. Multiple studies indicate involvement of 
Tregs in dissemination of disease (figure 1A). An increase in FOXP3 mRNA expression 
has been described in PBMCs from patients with extra-pulmonary TB (disseminated and 
lymphatic TB) compared to pulmonary TB [103]. In a comparison of TB pleural effusion 
and miliary TB, representing in this case containment vs. dissemination of disease, elevated 
FOXP3 mRNA expression levels and frequencies of CD4+Foxp3+CD25+ T-cells were 
found in cells isolated from miliary disease sites [123]. Another study confirmed an 
increase in CD4+ Treg frequencies in patients previously treated for extra-pulmonary TB 
compared to pulmonary TB, but reported an analogous increase in CD4+ activation markers 
[124]. In TB pleurisy, CD4+Foxp3+CD25HI Treg frequencies were increased in pleural fluid 
compared to the circulation [125;126], and Tregs suppressed IFNγ expression in CD4+ and 
CD8+ T-cells [126]. Pleural CD39+ Tregs inhibited generation of Th17 cells, which could 
be reversed in vitro by antagonizing TGF-β through the addition of latency-associated 
peptide (LAP) [127]. Mtb infection of the pleurae favored Treg migration into the pleural 
exudate when compared to other causes of pleurisy: tuberculous pleural fluid, but not 
effusions from other bacterial origin, or transudates, had high concentrations of the 
chemoattractant CCL22, which is chemotactic for Treg migration in vitro, and an increase 
in CD4+CD25HI T-cell frequency compared to the circulation [125]. Intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on pleural 
mesothelial cells regulated migration of leukocytes from the circulation into the pleural 
fluid; however, these molecules also seemed to favor (non-antigen-specific) expansion of 
Tregs [128]. 
In TB lymphadenitis in children, CD4+Foxp3+ T-cells were demonstrated in the LNs, and 
quantitative mRNA analysis demonstrated induction of TGFβ and IL13, but not of IFNγ, 
TNFα, or IL-17 [129]. Data on frequency and function of Tregs in other forms of TB 
disease, such as bone TB, urogenital TB, or TB of the central nervous system (CNS) are 
scarce. It is, however, conceivable that the interplay of Tregs and Mtb may differ in 
infections at immune-privileged sites, such as the CNS or the eye. The assessment of anti-
inflammatory mechanisms could be highly relevant in regard to CNS-immune 
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reconstitution syndromes, given their often disastrous outcomes [130]. Several studies have 
associated plasma biomarkers and CD4+ T-cell activation with the development of HIV-
associated immune reconstitution inflammatory syndromes (IRIS), but did not find an 
association with (CD4+) Treg frequencies, both in the development of cryptococcal-IRIS 
disease [131] and TB-IRIS disease [131;132]. TB-IRIS may either be ‘unmasking’ (of an 
occult infection) or ‘paradoxical’ (worsening of a known infection during retroviral 
treatment) hyper-inflammation: decreased serum IL-10 levels were found in paradoxical 
compared to unmasking syndromes [133]. Interestingly, this might represent Treg function, 
not Treg phenotype: a study in patients developing symptoms of Mycobacterium avium and 
intracellulare complex-infection, following commencement of retroviral treatment, 
reported a significant expansion of CD4+Foxp3+CD25+CD127LO Tregs, but reduced 




Tuberculosis: Tregs in the clinic 
Tregs may interfere with clinical diagnosis of TB (figure 1A). Classically, diagnosing TB 
has relied for decades on the TST, testing cell-mediated immunity against intradermally 
injected Mtb-derived tuberculin PPD. Skin anergy is defined as the absence of dermal 
reactivity in otherwise confirmed Mtb infection. In vitro PPD stimulation of cells isolated 
from PPD-reactive TB patients induced both IL-10- and IFNγ-production; however, cells 
from anergic TB patients produced only IL-10 but not IFNγ [135]. Reduced levels of IFNγ 
and IL-2, and increased levels of IL-10 in anergic compared to PPD-reactive TB patients 
were confirmed in another study. This anergy was found only after in vitro stimulation with 
PPD- but not unrelated antigens, indicating an antigen-specific anergic reaction [136]. 
Suppression of IL-2- and TNFα-production was accompanied by CD8+ T-cell expansion 
and high levels of IL-10 in anergic TB patients, and CD8+ T-cell depletion and blocking of 
IL-10 reversed this suppression [137]. 
A direct effect of Treg-mediated suppression on interferon-γ release assays (IGRAs), such 
as the in-tube QuantiFERON Test, has so far not been established. Nevertheless, several 
studies have described ‘rescue’ of mycobacterial-specific IFNγ production by Treg 
depletion in Mtb-infected individuals [104;105;114;138]. Interestingly, depletion of CD25+ 
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T-cells increased IFNγ production by PBMCs in Mtb-infected individuals, but did not 
increase the production of IL-17A [114]. Yet, pleural CD39+ Tregs (CD4+ 
CD25+CD39+CD127−) inhibited Th17 differentiation [127], and an inverse correlation 
between production of IL-17A and CD39-expressing Tregs has been described after 
vaccination [139;140]. CD39 expression on Tregs may thus be more closely linked to 
suppression of IL-17 production compared to cells expressing CD25, but this needs further 
clarification. Also the extent of TB infection as determined by chest X-ray (CXR) scoring 
was associated with T-cell modulation: in a study dividing patients by severity of disease 
by CXR, double-negative (DN, CD4−CD8−) TCRγδ T-cells from patients with severe 
disease displayed a modulatory profile with high IL-10 production, in contrast to patients 
with less severe disease, where TCRγδ DN T-cells displayed a pro-inflammatory cytokine 
profile with high IFNγ [141]. 
During TB therapy, circulating CD4+ Treg frequencies declined as mentioned; however, 
this was only noted following chemotherapy for pulmonary TB (figure 1A) [106;142;143]. 
In contrast, an increase was noted during extra-pulmonary TB treatment [143;144]. 
Differences between forms of disease possibly represent differences in 
compartmentalization of Tregs, or heterogeneous kinetics of Treg contraction following 
decrease of bacterial burden. TB patients in which MDR-TB emerged during therapy had 
persistent circulating Treg frequencies [106], which could be analogous to a phenomenon 
observed during IFNα therapy for chronic HBV infection: therapy non-responders were 
characterized by an increase in CD4+CD25+ T-cells and IL-10-producing cells [145]. Thus, 
circulating Treg frequencies might be used as parameter of therapy response in specific 
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Tregs in vaccination against tuberculosis 
Even in early life, immunoregulatory mechanisms, including Tregs, may dampen vaccine-
induced immunity [146]. We describe here how immunogenicity of TB-vaccines may be 
influenced by Tregs, induced by the vaccination itself, by closely related pathogens, or 
induced by unrelated pathogens (figure 1B). M. bovis BCG, the only available vaccine 
against TB, is a live bacterial vaccine aimed at inducing effective T-cell responses, yet 
BCG itself also induces Tregs [5]. This ability to induce Tregs could limit its ability to 
induce optimal protective immunity against TB; it is, however, conceivable that future 
medicine may be able to tailor BCG-induced Tregs to regulate hyperinflammation. 
 
 
Tregs induced by vaccination: M. bovis bacillus Calmette-Guérin 
Bacillus Calmette-Guérin, the only licensed vaccine against TB since 1921, was derived 
from virulent M. bovis by years of continuous in vitro passage. Estimates are that BCG has 
been given >3 billion times since its introduction, and it is part of the WHO Expanded 
Programme on Immunization (EPI). BCG was used in one of the first experiments 
establishing the idea of ‘suppressor cells’ interfering with control of infection: transfer of 
thymocytes from BCG-immunized rats suppressed immune responses in naive recipient rats 
against new BCG infection [147]. Though BCG-vaccination induces CD4+ and CD8+ 
effector T-cell responses in newborns [148;149] and protects them from disseminated forms 
of disease, it does not induce consistent protection against pulmonary TB, especially in 
adults [150]. We have previously hypothesized that one explanation for this lack of 
protection is the induction of Tregs by the vaccine among various other hypotheses [5]. In a 
large cohort of 5675 South-African infants who had been vaccinated at birth, stimulation of 
whole blood with mycobacterial antigens at 10 weeks of age resulted in production of IFNγ 
or IL-10, but not both [151]. CD4+CD25+ Treg cells were demonstrated in another study in 
BCG-vaccinated infants, and depletion of these Treg cells resulted in lower IL-10 levels in 
PPD-stimulated cell cultures [152]. IL-10-producing CD4+ T-cells have been demonstrated 
in previously BCG-vaccinated adult donors, and in vitro suppression of target cell 
proliferation could be reversed by a blocking αIL-10-antibody [153]. 
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CD8+ Tregs are generally less studied compared to CD4+ Tregs, especially in infectious 
diseases [5]. We have previously studied the presence, phenotype, and suppressive activity 
of CD8+ Treg cells among live BCG-stimulated PBMCs of in vitro PPD-responsive donors. 
Surprisingly, we found a significantly higher expression of regulatory markers on live (but 
not killed) BCG-activated CD8+ T-cells compared to CD4+ T-cells, and there was 
significant enrichment of CD8+ Treg cells within the BCG-activated CD25+ T-cell 
compartment [154]. Also, suppressive activity was dominantly present in live BCG-
activated CD8+, but not in live BCG-activated CD4+ T-cells [154]. CD8+ Treg cells isolated 
from live BCG-stimulated PBMCs were enriched for expression of LAG-3 and CCL4, co-
expressed CD25 and Foxp3, and inhibited Th1 cell proliferation [109]. Inhibition was 
partly mediated by secretion of CCL4, which reduced Ca2+-influx early after TCR 
triggering [109]. We have additionally described expression of CD39 on live BCG-
activated CD8+ Treg cells, and a direct involvement of CD39 in mediating suppression by 
CD8+ Tregs, as both the chemical CD39 antagonist ARL 67156 and a blocking αCD39-
antibody were able to partly inhibit the suppressive activity of CD8+CD39+ Tregs [155]. Of 
note, CD8+ Tregs could only be demonstrated in donors primed in vivo with mycobacteria, 
indicating a memory recall response following in vitro BCG-stimulation. Taken together, 
our work identified at least two different mechanisms by which BCG-activated CD8+ Tregs 
could inhibit Th1 responses, via CCL4 and via CD39. Despite the above findings and 
despite the fact that CD8 was originally identified as a marker of Treg cells, then coined T-
suppressor cells, pathogen-activated CD8+ Tregs still remain significantly understudied 
compared to CD4+ Tregs. It is important to note here that in vitro stimulation with live 
BCG preferentially activated CD8+ Tregs [154], while stimulation with killed BCG (or 
PPD) seems to activate different populations. 
 
 
Tregs induced by new TB-candidate vaccines  
Regulatory T-cell induction has been demonstrated in several TB-vaccine candidate trials. 
After M72/AS01-vaccination of South-African healthy adults, Tregs expanded concurrently 
with cytokine-producing pro-inflammatory CD4+ T-cells [156]. Circulating CD4+CD25+ 
Foxp3+ T-cells were demonstrated after vaccination with another TB-vaccine candidate, 
modified vaccinia Ankara-85A (MVA85A). Interestingly, CD4+CD25+Foxp3+ T-cells were 
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increased in recipients with low antigen 85A-specific IFNγ-responses compared to high 
IFNγ-responders [157]. Also, the frequency of CD4+CD25+CD39+ T-cells was inversely 
related to IL-17A production in vitro [139]. IL2RA mRNA expression on the day of 
vaccination and CTLA-4 expression 2 days after vaccination inversely correlated with the 
magnitude of the IFNγ ELISpot response induced by MVA85A-vaccination in healthy 
British adults, pointing to a possible role for Tregs very early or even before vaccination 
[157]. In African infants vaccinated with MVA85A, an early and strong innate response 
was associated with enhanced IFNγ ELISpot responses; thus, the authors concluded that 
Treg modulation of vaccine responses could differ between populations, and that more 
research is needed to explain these differences and the impact on vaccine efficacy [158]. 
Assessment should, however, include possible dissimilarities between long-term effects of 
Tregs and early after vaccination. 
 
 
Other Tregs can modulate TB-vaccine-induced responses 
Regulatory T-cells induced by other microbes can likely alter immunogenicity of TB 
vaccines. Exposure to environmental mycobacteria may decrease TB-vaccine efficacy 
through cross-reaction of antigens [94]. Pre-existing immune responses can either ‘block’ 
or ‘mask’ the BCG-induced immune response, possibly explaining the decreased vaccine 
efficacy of BCG in developing countries, where there is a higher prevalence of 
environmental mycobacteria [159]. Another potential explanation for decreased vaccine 
efficacy is induction of Tregs by environmental mycobacteria [160]. Priming mice with M. 
chelonae before BCG-vaccination increased Foxp3 expression on BCG-specific 
CD4+CD25+ T-cells compared to non-sensitized mice, and CD4+CD25+ T-cells of 
sensitized mice decreased immune responses in vitro [161]. Adoptive transfer of 
CD4+CD25+ T-cells into naive mice suppressed IL-2 production in the lungs, and enhanced 
IL-10 after BCG-vaccination [161]. Suppression after murine sensitization was reversed by 
a blocking αCD25-mAb during challenge, indicating active involvement of cross-reactive 
Tregs during vaccination [162]. 
Modulation of DC TLRs by helminth molecules leads to increased Th2 and Treg responses, 
which possibly decreases vaccine efficacy in developing countries, where also the majority 
of the one billion helminth-infected people live [12]. Tregs induced by helminths in 
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mucosa-associated lymphoid tissue (MALT) may migrate to other sites, exerting non-
specific suppressive effects and preventing clearance of Mtb at distant sites as well [163]. 
Although the frequency of CD4+Foxp3+CD25HI T-cells was similar in helminth-infected 
and non-infected Indonesian children, BCG-specific (and as mentioned, also Plasmodium 
falciparum-specific) proliferative responses were increased after depletion of CD4+CD25HI 
T-cells in helminth-infected children only, pointing to differences in suppressive capacity 
induced by helminth infection [11]. Deworming increased BCG immunogenicity in vivo 




Modulating the modulators: future prospects for Tregs in TB-vaccination 
The ability of BCG to induce Tregs may in the future be exploited to benefit the human 
host in the contexts of auto-immune and/or hyper-inflammation-related diseases. This has 
been noted in a murine model of Parkinson’s disease, where protection against nerve 
damage was induced by BCG-vaccination through Tregs [165]. Also in experimental auto-
immune encephalomyelitis, myelin oligodendrocyte glycoprotein-specific IFNγ-producing 
CD4+ T-cells, and both specific and non-specific CD4+IL-17+ T-cells in the CNS, were 
suppressed by cerebral BCG infection [166]. Other murine studies have demonstrated 
BCG-induced suppression of asthma responses and dampening of colitis [167;168]. Further 
research will hopefully elucidate if and how these findings can be translated to the human 
situation. 
Interestingly, mucosal vaccination of macaques with a vaccine consisting of inactivated 
simian immunodeficiency virus (SIV) and a live bacterial adjuvant (BCG or Lactobacillus) 
generated HLA-E restricted, non-cytolytic CD8+ Tregs [169]. After challenge with SIV 
infection, these CD8+ Tregs suppressed proliferation of infected CD4+ T-cells, thereby 
protecting almost all vaccinated macaques for up to 4 years after vaccination [169]. As 
mentioned, in acute viral infection, Tregs could have a beneficial role to play, such as in 
acute SIV/HIV infection where Tregs decrease proliferation of infected cells at mucosal 
surfaces [44]. 
In a TB-vaccination context, however, it may be crucial to avoid excessive Treg induction 
by the vaccine. Analogous to the reduced burden of TB observed in mice following 
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treatment with chemical compounds inhibiting Treg and Th2 induction prior to infection 
[170], a similar approach was tested in murine BCG-vaccination: chemical inhibition of 
Treg induction increased BCG-mediated protection against pulmonary TB in mice and 
favored central-memory T-cell induction (long-lived vaccine responses) [171]. Blocking 
the IL-10-receptor with an αIL-10-receptor antibody increased BCG-induced Th1, Th17, 
innate lymphoid IFNγ, and IL-17 responses in mice, leading to enhanced protection against 
TB [172]. An additional, important role for IL-22 producing NK cells through lysing of 
CD4+ Tregs was described, and addition of IL-22 also increased Th1 vaccine-induced 
responses [173]. In contrast, only  moderate efficacy of treatment with a blocking αCD25-
antibody on BCG-vaccine efficacy was described [174]. It is possible that blocking CD25 
results in partial Treg depletion while other Treg subsets could survive during such 
treatment. However, CD25 is expressed also by activated T-helper cells such that CD25-
depletion may additionally also deplete essential effector cells of protective immunity. 
Regardless, even after selective deletion of all Foxp3+ cells, homeostatic expansion may 
occur from a small subset of remaining Tregs [175]. Since various Treg marker-expressing 
subsets exist, this points to the importance of assessing the dynamics and fluidity of various 
subsets within the Treg compartment, in order to improve vaccine design by effective 
modulation of Treg activity and function. Compounds inhibiting Treg induction or blocking 
‘upstream’ signaling through the IL-10-receptor could improve vaccine efficacy. Other 
options would include the addition of adjuvant antagonists of chemokine receptors 
expressed by Tregs, as described for a CCR4 antagonist that blocked CD4+ Tregs and 
increased in vitro responses to MVA85A and recombinant HBV surface antigen 
vaccination [176], or the inclusion of TLR-agonists combined with agents selectively 
blocking TLR-induced anti-inflammatory signaling pathways in DCs [177]. Future studies 
may integrate these findings to increase TB-vaccine-induced protective immunity through 
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Concluding remarks and future directions 
For many pathogens, induction, expansion, recruitment, or inhibition of Tregs has been 
demonstrated. Mycobacterium leprae and Mycobacterium tuberculosis are master 
manipulators of human immunity and are able to establish chronic infection among others 
by activating immune regulation. The effects of Tregs impact on clinical symptoms and 
performance of immunodiagnostic assays, differ in acute vs. chronic diseases and can 
suppress protective immunity and vaccine immunogenicity. Importantly, this can partly be 
the result of cross-suppression from Tregs induced by unrelated pathogens, possibly even 
by non-pathogenic microbes. This is particularly important in endemic settings, e.g., 
settings endemic for both helminths, TB, malaria, and HIV. 
Through precisely (and timely) targeted Treg manipulation, vaccine-induced protective 
immunity may be enhanced. Most data are necessarily derived from murine studies, and 
need to be translated to the human situation. This should also offer opportunities for new 
immunotherapeutic vaccines for the treatment of inflammatory disorders, e.g., auto-immune 
diseases, and for the design of vaccines aimed at interfering with acute (viral) infection. 
Through manipulating the manipulators, increased immunity against infectious diseases 
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Abstract 
Mycobacterium bovis bacillus Calmette-Guérin (M. bovis BCG), the only currently 
available vaccine against tuberculosis, has been reported to induce regulatory T-cells in 
humans. The activity of regulatory T-cells may not only dampen immunogenicity and 
protective efficacy of tuberculosis vaccines, but also hamper diagnosis of infection of 
tuberculosis, when using immune (e.g. IFNγ-release) assays. Still, in settings of infectious 
diseases and vaccination, most studies have focused on CD4+ regulatory T-cells, and not 
CD8+ regulatory T-cells. Here, we present a comparative analysis of the suppressive 
phenotype and function of CD4+ versus CD8+ T-cells after in vitro live BCG activation of 
human cells. Moreover, as BCG is administered as a (partly) live vaccine, we also 
compared the ability of live versus heatkilled BCG in activating CD4+ and CD8+ regulatory 
T-cell responses. BCG-activated CD8+ T-cells consistently expressed higher levels of 
regulatory T-cell markers, and after live BCG activation, density and (co-)expression of 
markers were significantly higher, compared to CD4+ T-cells. Furthermore, selection on 
CD25-expression after live BCG activation enriched for CD8+ T-cells, and selection on co-
expression of markers further increased CD8+ enrichment. Ultimately, only T-cells 
activated by live BCG were functionally suppressive and this suppressive activity resided 
predominantly in the CD8+ T-cell compartment. These data highlight the important 
contribution of live BCG-activated CD8+ Treg cells to immune regulation and emphasize 
their possible negative impact on immunity and protection against tuberculosis, following 
BCG-vaccination. 
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Introduction 
Tuberculosis (TB), one of the major global health challenges, accounted for 1.3 million 
deaths in 2012. It is estimated that one-third of the world population is (latently) infected 
with Mycobacterium tuberculosis (Mtb) [1]. Containment of the disease is dependent on 
innate and adaptive immune responses, and though CD4+ Th1 (IFNγ)-responses are 
considered quintessential, definition of immunological correlates of protection remains 
unresolved.  
Active TB disease has been associated with decreases in Mtb-specific IL17A-producing 
CD4+ T-cells [2] and in multifunctional (IFNγ+IL2+TNFα+) CD4+ T-cells [3]. Conversely, 
CD4+ T-cells single-positive for TNFα were identified as a strong classifier of active 
disease versus latent infection [4]. For Mtb-specific CD8+ T-cells, a reduction in dual 
IFNγ+IL2+-secreting cells in active vs. latent TB [LTBI] [5], as well as changes in memory 
phenotype [5;6], have been reported. CD8+ T-cells preferentially recognized heavily 
infected cells in vitro [7]; and higher Mtb-specific CD8+ responses correlated with clinical 
parameters of bacterial load (defined as smear-positive vs. smear-negative TB) [6].  
Mtb-specific immune responses and mycobacterial growth inhibition can be suppressed by 
circulating, alveolar and pleural CD4+ regulatory T-cells (Treg cells) in humans [8-10]. 
Recently, also suppression of T-cell cytokine production and proliferation by myeloid-
derived suppressor cells in TB-patients were described [11]. Although CD8+ regulatory T-
cells have been reported in TB [9] and leprosy [12,13], they remain generally understudied 
compared to CD4+ Treg cells [14]. CD4+ T-cells producing IL-10 were shown to hamper 
clinical diagnosis based on dermal reactivity to mycobacterial purified protein derivative 
(PPD) in anergic TB-patients [15]. In PBMCs isolated from patients with active TB, 
depletion of CD4+CD25+ or CD4+CD25+CD39+ T-cells increased Mtb-specific IFNγ 
production [8,16]. Healthy, previously BCG-vaccinated volunteers, who were vaccinated 
with MVA-85A (modified vaccinia virus Ankara expressing antigen 85A), and who 
exhibited relatively low responses in antigen 85A-specific IFNγ ELISPOTs, had increased 
frequencies of circulating CD4+CD25+Foxp3+ cells, compared to high IFN -responders 
[17]. Also, MVA85A-induced production of IL17A was affected by Treg responses 
[18,19]. IFNγ- and IL17-responses were enhanced by addition of ARL67156 [19], a 
chemical inhibitor of CD39 [20], suggesting a population of CD39+ cells that actively 
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dampened cytokine production. Thus, (CD4+) Treg cells can negatively influence immunity 
and immune dependent protection, both in natural infection and in vaccination settings.  
The only currently available vaccine against TB, Mycobacterium bovis bacillus Calmette-
Guérin (M. bovis BCG), induces CD4+ and CD8+ T-cell responses in newborns [21-23] and 
protects them from disseminated forms of disease; but it does not induce consistent 
protection against pulmonary TB, especially in adults [24]. One explanation for this lack of 
protection is the induction of regulatory T-cells by the vaccine [14;25], amongst other 
hypotheses [26;27]. CD4+CD25+ Treg cells have been found after BCG-vaccination of 
newborns [28] and adults [29], and CD4+CD25+-depleted T-cell cultures resulted in lower 
PPD-stimulated IL-10 levels [28]. We previously demonstrated the presence and strong 
suppressive activity of CD8+ Treg cells among live BCG-stimulated PBMCs of in vitro 
PPD-responsive donors, which were enriched for the markers lymphocyte activation gene-3 
(LAG-3) [30] and CD39 [31]. Suppressive activity of CD8+ Treg cells could be reversed by 
blocking CC chemokine ligand 4 (CCL-4) [30], membrane-bound TGFβ (mTGFβ) [32] and 
CD39 [31]. Still, knowledge about CD8+ regulatory T-cells is generally limited compared 
to CD4+ Treg cells. 
Furthermore, though multiple mycobacterial-activated Treg subsets, either CD4+ or CD8+, 
have been demonstrated in humans, no comparative studies have been performed assessing 
suppressive capacity of Mycobacterium-induced CD4+ vs. CD8+ T-cells. In this study, we 
compared the suppressive phenotype and function of human BCG-activated CD4+ and 
CD8+ T-cells. We demonstrate significantly higher expression of regulatory markers on live 
BCG-activated CD8+ T-cells, compared to CD4+ T-cells, and enrichment for CD8+ Treg 
cells within the BCG-activated CD25+ T-cell compartment. Finally, suppressive Treg 
activity was dominantly present in live BCG-activated CD8+, but not in live BCG-activated 
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Materials and Methods 
 
Ethics statement. All donors had signed consent for scientific use of blood products. Blood 
products were collected anonymously, which, according to institutional ethical policy, does 
not require a separate review by the Ethical Committee. 
 
Blood samples. Anonymous buffy coats were collected from healthy adult blood bank 
donors (Sanquin, Leiden). PBMCs were isolated by density centrifugation and 
cryopreserved in fetal calf serum-supplemented medium according to Standard Operating 
Procedure [33]. Cells were counted using the CASY cell counter (Roche, Woerden, the 
Netherlands). Donors were selected on recognition of mycobacterial PPD by assessing 
IFNγ production in vitro. PBMCs were stimulated with 5 μg/ml PPD (Statens Serum 
Institute, Copenhagen, Denmark) for 6 days and supernatants were tested in IFNγ-ELISA 
(U-CyTech, Utrecht, the Netherlands). Positivity was defined as IFNγ production ≥ 150 
pg/ml.  
 
Cell cultures and BCG infection. PBMCs were thawed (64% median viable cell yield) 
and stimulated with Bacillus Calmette-Guerin (Pasteur). BCG was grown in 7H9 plus 
ADC, frozen in 25% glycerol and stored at -800C. Before use, bacteria were thawed and 
washed in PBS/0.05% Tween 80 (Sigma-Aldrich, Zwijndrecht, the Netherlands). Infections 
were done at a multiplicity of infection (MOI) of 1.5. For heatkilled BCG-stimulated cell 
cultures, bacteria were inactivated at 800C for 30 minutes. PBMCs were cultured for six 
days in Iscove's modified Dulbecco's medium (Life Technologies-Invitrogen, Bleiswijk, the 
Netherlands) supplemented with 10% pooled human serum. Sera were pretested in 
standardized protocols; only sera were pooled that had no inhibitory activity in standard 
mixed allogeneic lymphocyte cultures. IL-2 (25U/ml; Proleukin; Novartis Pharmaceuticals 
UK Ltd., Horsham, UK) was added after 6 days of culture. CD4+ and CD8+ T-cells were 
enriched by positive selection using magnetic beads (MACS, Miltenyi Biotec, Teterow, 
Germany). Purity of sorts was ≥ 97% as assessed by flowcytometry.  
Restimulation of CD4+ cell lines was done in 24 well plates (2 x 105 cells/w) with 
αCD3/CD28 beads (Dynabeads Human T-activator, Life Technologies-Invitrogen) and IL2 
(25 U/ml). Pooled, irradiated (30 Gy) PBMCs were added as feeders (1 x 106 cells/w). 
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CD8+ cell lines were restimulated in 96 well roundbottom plates (1 x 104 cells/w) with 
αCD3/CD28 beads, IL2 (50 U/ml), IL7, IL15 (both 5 ng/ml, Peprotech, Rocky Hill, NJ, 
USA) and pooled, irradiated (30 Gy) PBMCs added as feeders (5 x 104 cells/w). Cells were 
maintained in IL2 (100 U/ml). 
 
FACS analysis. PBMCs were incubated overnight with αCD3/28 beads, for the last 16 
hours Brefeldin A (3 μg/ml, Sigma-Aldrich) was added. The following antibodies were 
used for surface staining: CD8-HorizonV500 (clone RPA-T8), CD3-PeCy5 (clone UCHT-
1), CD4-PerCPCy5.5 (clone RPA-T4) (all BD Biosciences, Eerembodegem, Belgium), and 
CD39-PE (clone A1; Biolegend, London, U.K.). For intracellular staining we used the 
FIX&PERM® Cell Permeabilization Kit from An Der Grub BioResearch GMBH 
(Susteren, The Netherlands) and the following antibodies: CCL4-FITC (clone 24006; R&D 
Systems, Abingdon, UK), Foxp3-Alexa Fluor 700 (clone PCH101; eBioscience, Hatfield, 
UK), CD25-allophycocyanin-H7 (clone M-A251; BD Biosciences) and LAG-3-atto 647N 
(clone 17B4; ENZO Life Sciences, Antwerp, Belgium). Samples were acquired on a BD 
LSRFortessa using FACSDiva software (version 6.2, BD Biosciences) using compensated 
parameters.  
Analysis was performed using FlowJo software (version 9.5.3, Treestar, Ashland, OR, 
USA). The detailed gating strategy is demonstrated in figure 1A. Cut-off for positive 
populations of interest was defined by comparison to samples of cell lines not stimulated 
with BCG (Supplementary figure S1) and were similar for CD4+ and CD8+ T-cell 
populations, as shown in figure 1A. Also, to assess differences in intrinsic frequency and 
density (MFI) of Treg-cell marker expression on CD4+ vs. CD8+ T-cells, positive Treg 
marker populations on CD4+ and CD8+ T-cells were compared in samples not stimulated 
with BCG. 
 
Suppression assays. Cell lines were tested for their capacity to inhibit proliferation of a 
Th1 responder clone (Rp15 1-1) in response to its cognate M. tuberculosis hsp65 p3–13 
peptide presented by HLA-DR3 positive, irradiated (20 Gy) PBMCs. Proliferation was 
measured after three days of co-culture by addition of (3H)thymidine (0.5 μCi/well) and 
incorporation was assessed after 18 hours. Background proliferation was assessed by 
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adding T-cells without the peptide. Validation of this co-culture assay has been reported 
previously [30-32;34]. 
Proliferation was divided by Th1 reporter clone proliferation in the absence of Treg cells to 
obtain relative proliferation and enable analysis across experiments. Values represent 
means from triplicate wells, that were subsequently averaged for repeated experiments per 
donor. Demonstrated values represent pooled data from different donors. Raw data can be 
provided per request. 
 
Statistical analyses. Wilcoxon signed-rank tests were performed using GraphPad Prism 
(version 6, GraphPad Software, San Diego, CA, USA) and SPSS statistical software 
(version 20, SPSS IBM, Armonk, NY, USA). 
 
Laboratory. Studies were conducted in a laboratory guided by exploratory research 





Heatkilled vs. live BCG-activated expression of Treg-cell markers on CD4+ and CD8+ 
T-cells 
PBMCs were isolated from healthy human donors that had been selected based on their in 
vitro response to mycobacterial PPD as described before [30;31;35]. The PBMCs were 
stimulated with heatkilled or live BCG, and CD4+ and CD8+ T-cells were analysed for 
regulatory T-cell marker expression after six days. Figure 1A depicts the full gating 
strategy, and an example of the synchronized gating on a positive population for CD4+ and 
CD8+ T-cells, in compliance with MIATA guidelines [36]. Background expression of Treg-
cell markers was compared between CD4+ and CD8+ populations of samples that were not 
stimulated with BCG (Supplementary figure S1); only the background expression of CCL4 
on CD8+ T-cells was significantly higher compared to CD4+ T-cells (median 11% vs. 2%; p 
< 0.01; Wilcoxon signed-rank test) [36]. Heatkilled, as well as live BCG stimulation, 
activated expression of regulatory T-cell markers on CD4+ and CD8+ T-cells of in vitro 
PPD-responsive donors, including CD25, Foxp3, LAG-3 and CD39 (figure 1B). 
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Figure 1. Heatkilled vs. live BCG-activated expression of Treg-cell markers on CD4+ and CD8+ T-cells. 
A: Gating strategy: cells were gated on single cells, live lymphocytes, CD3+ and CD4+CD8- vs. CD4-CD8+. 
Demonstrated is the synchronized gating on the positive population of interest for CD4+CD8- and CD8+CD4- T-
cells; here the CD25-positive population. B: Heatkilled and live BCG activate CD25+Foxp3+ and LAG-3+CD39+ 
T-cells. Expression of regulatory T-cell markers on CD4+ and CD8+ T-cells of in vitro PPD-responders was 
analysed by flowcytometry six days after heatkilled or live BCG stimulation. For each donor gating was compared 
to samples not stimulated with BCG (demonstrated in Supplementary figure S1). Data are representative of seven 
responders.    
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Treg-cell marker frequency and density are increased on live BCG-activated CD8+ vs. 
CD4+ T-cells  
Heatkilled and live BCG activated a  higher percentage of total CD8+ T-cells, compared to 
CD4+ T-cells, that expressed CD25, Foxp3, CD39, LAG-3 or CCL4, depicted in figure 2A 
as frequency of (CD8+ or CD4+) parent. Live BCG-activated CD8+ T-cells exhibited 
significantly increased Treg-cell marker frequencies compared to live BCG-activated CD4+ 
T-cells (*p < 0.05; Wilcoxon signed-rank test).  
To determine cellular densities of expression of Treg-cell markers, mean fluorescence 
intensities (MFIs) of positive populations were compared for BCG-activated expression of 
CD25, Foxp3 and CD39. MFIs of CD25 and CD39 were significantly higher on live BCG-
stimulated CD8+ T-cells, compared to CD4+ T-cells (figure 2B; p = 0.02 and p = 0.03, 
respectively; Wilcoxon signed-rank test), whereas MFIs of heatkilled BCG-activated CD4+ 
T-cells did not differ from heatkilled BCG-activated CD8+ T-cells (data not shown). 
 
 
Co-expression of multiple Treg-cell markers enriches for CD8+, and not CD4+ T-cells   
Co-expression of multiple Treg-cell markers by live BCG-induced T-cells was analysed 
using Boolean gating (figure 3A). A significantly higher percentage of total CD8+ T-cells 
was CD25+Foxp3+, compared to CD4+ T-cells (p = 0.02; Wilcoxon signed-rank test). Also, 
the percentage of total CD8+ T-cells co-expressing CD25, Foxp3, CD39, LAG-3 and/or 
CCL4 in various combinations was significantly higher compared to CD4+ T-cells (p < 
0.01, Wilcoxon signed-rank test).  
To determine the relative distribution of CD4+ and CD8+ T-cells within the Treg-cell 
marker positive T-cells, we applied Boolean gating to the total CD3+ population (figure 3B, 
upper panel), and the CD8+ proportion was calculated for the CD3+ Boolean gates (figure 
3B, lower panel). Gating BCG-activated T-cells on expression of CD25 or Foxp3, enriched 
for CD8+ T-cells compared to the total CD3+ population (p = 0.03 and p = 0.06, 
respectively; Wilcoxon signed-rank test). Increasing selection of total BCG-activated T-
cells on regulatory T-cell markers further enriched for CD8+ T-cells significantly (p = 0.01 
for CD25+Foxp3+CD39+LAG-3+CCL4+ T-cells, Wilcoxon signed-rank test).     
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Figure 2. Treg-cell marker frequency and density are increased on live BCG-activated CD8+ vs. CD4+ T-
cells. A: BCG induces Treg-cell marker expression on CD4+ and CD8+ T-cells; after live BCG stimulation the 
percentage of total CD8+ T-cells expressing CD25, Foxp3, CD39, LAG-3 or CCL4 is significantly higher 
compared to CD4+ T-cells, depicted here as frequency of CD8+ or CD4+ population. Differences in Treg marker 
expression between heatkilled BCG-activated CD8+ vs. CD4+ T-cells were not significant, except for expression of 
CCL4; CCL4 expression was also significantly higher on CD8+ T-cells compared to CD4+ T-cells in samples not 
stimulated with BCG (Supplementary figure S1) (*p < 0.05, Wilcoxon signed-rank test). B: Mean fluorescence 
intensities (MFIs) of CD25 and CD39 are increased on live BCG-activated CD8+ T-cells as compared to CD4+ T-
cells. Gating was performed as demonstrated in figure 1A. To assess differences in intrinsic intensity of expression 
on CD4+ and CD8+ T-cells, respectively, MFIs of positive Treg marker populations in samples not stimulated with 
BCG were compared; this was similar on CD4+ and CD8+ T-cells for MFIs of CD25, Foxp3 and CD39. Data are 
representative of seven in vitro PPD-responders six days after heatkilled or live BCG stimulation (*p < 0.05; 
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Suppressive activity resides predominantly in live BCG-activated CD8+ T-cells 
T-cell lines were tested for their capacity to suppress proliferation of an unrelated CD4+ T 
helper-1 clone. This responder clone recognizes a cognate peptide presented in the context 
of HLA-DR3 in an assay which has been previously reported and validated [30-32;34]. 
Heatkilled BCG-activated T-cells did not suppress proliferation of the responder clone. In 
contrast, live BCG-stimulated T-cells exhibited suppressive activity towards the same 
responder clone (figure 4A). CD8+ / CD4+ ratios of heatkilled BCG-stimulated and live 
BCG-stimulated T-cell lines were 0.06 and 0.1, respectively (Supplementary figure S2), 
suggesting a potential association of T-cell subset distribution with  suppressive function. 
We next separated live BCG-activated T-cell lines into CD4+ or CD8+ expressing 
populations using magnetic beads (purity ≥ 97% as assessed by flowcytometry), and tested 
live BCG-activated CD4+ T-cells in parallel with live BCG-activated CD8+ T-cells for their 
suppressive capacity. Live BCG-activated CD8+ T-cells suppressed T helper-1 clone 
proliferation, whereas live BCG-activated CD4+ T-cells did not significantly inhibit 
proliferation. Thus, suppressive activity was dominant in live BCG-activated CD8+ T-cells, 







In this study, we present a comparative analysis of the suppressive phenotype and function 
of BCG-activated CD4+ vs. CD8+ T-cells. CD8+ T-cells consistently expressed higher 
levels of regulatory T-cell markers compared to CD4+ T-cells; also the cellular density of 
expression and co-expression of these markers were significantly higher. Selection of T-
cells based on CD25-positivity after live BCG-activation also enriched for CD8+ T-cells, 
and further selection on co-expression of combined regulatory markers further supported 
CD8+ enrichment. Suppressive Treg activity was dominantly present in live BCG- but not 
heatkilled BCG-activated T-cells; finally, the suppressive activity largely resided in the 
CD8+ T-cell- and not the CD4+ T-cell-population. 
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Figure 3. Co-expression of multiple Treg-cell markers enriches for CD8+, and not CD4+ T-cells. A: The 
percentage of total CD8+ T-cells co-expressing CD39, LAG-3, CCL4, CD25 and/or Foxp3 in different 
combinations is significantly increased, compared to CD4+ T-cells. Demonstrated is a combined analysis using 
Boolean gating of cells from ten donors six days after live BCG infection. Gating was performed as in figure 1A. 
Boxes: 25th to 75th percentiles; line at median; whiskers: minimum to maximum (*p<0.05, **p< 0.01; Wilcoxon 
signed-rank test). B: Combining Treg markers enriches for CD8+ T-cells as opposed to CD4+ T-cells. Boolean 
gating was performed on CD3+ T-cells of ten donors; CD8 vs. CD4 gating is demonstrated (top) and the CD8+ 
proportion of these gated populations is demonstrated (bottom) for a selection of CD3+ Boolean gates. The CD8+ 
proportion increased significantly using a combination of Treg markers as compared to the complete CD3+ 
population. Boxes: minimum to maximum, line at median (Wilcoxon signed-rank test). 
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Multiple CD4+ Treg-cell marker expressing subsets have been demonstrated in patients 
with tuberculosis [9;10] and after vaccination with MVA85A [18] and BCG [29]. We 
previously demonstrated the suppressive activity of CD8+LAG-3+CCL4+ and CD8+CD39+ 
Treg cells, isolated from live BCG-stimulated PBMCs; in those studies, we also observed 
upregulation of these markers in the CD4+ compartment [30;31]. However, also non-
suppressive, activated human CD4+ T-cells may transiently upregulate Foxp3-expression  
such that in vitro-induced Foxp3 expression by human CD4+ T-cells is not necessarily 
associated with suppressive function [37]. The co-expression of multiple Treg-cell markers 
can more reliably and specifically identify human Treg cells. In the current study we found 
that more stringent selection of total BCG-activated T-cells using multiple Treg cell 
markers further enriched for CD8+ T-cells significantly. In other work using allo-antigen 
induction of Treg cells by plasmacytoid dendritic cells, also discrepant activation of CD8+ 
vs. CD4+ Treg cells has been reported: suppressive activity was mediated by CD8+LAG-
3+Foxp3+CTLA-4+ T-cells, but not by plasmacytoid dendritic cell-induced CD4+ T-cells 
[38]. However, no systematic comparative studies have been performed so far comparing 
suppressive capacity of Mycobacterium-induced CD4+ vs. CD8+ T-cells.    
The type of antigen used for in vitro restimulation of specific responses may significantly 
influence the results, as stimulation with live mycobacteria could activate significantly 
different populations of T-cells as compared to killed mycobacteria or protein isolates like 
PPD. CD4+ Treg cells have been isolated from PBMCs of active TB patients through ex 
vivo selection on co-expression of CD4 and CD25 [9;16;39], and have been phenotyped 
after culturing PBMCs with TB-specific peptides [16] or mycobacterial PPD [9]. PPD-
stimulated PBMCs of TB patients revealed expansion of CD4+CD25+Foxp3+ T-cells in 
active TB patients, but low numbers of CD8+CD25+Foxp3+ T-cells [9]. In the current study, 
we compared live and heatkilled BCG, where heatkilled BCG was considered to be a 
primary stimulus for CD4+ T-cells, through the MHC-II antigen presentation pathway, 
resembling PPD. It is intriguing, as demonstrated here, that CD8+ Treg activity is 
specifically induced by live as opposed to heatkilled BCG, suggesting that the MHC-I 
antigen presentation pathway is involved in the activation of these cells, and also that cross-
presentation of killed bacteria to CD8+ T-cells is likely to be insufficient. We hypothesize 
that BCG, as a live intracellular bacterium, is able to modify antigen presentation/ 
stimulation, although the mechanisms and pathways involved remain unknown at this stage.  
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Figure 4. Suppressive activity resides predominantly in live BCG-activated CD8+ T-cells. 
Heatkilled BCG-activated and live BCG-activated T-cell lines were expanded, and live BCG T-cell lines were 
enriched for CD4 or CD8 expression using magnetic beads. Suppressive capacity was tested in a co-culture assay 
by titrating these T-cell lines onto a Th1 reporter clone that was stimulated with its cognate peptide [30;31]. 
Proliferation was measured by (3H)TdR incorporation after three days. Proliferation was divided by Th1 reporter 
clone proliferation in the absence of Treg cells to obtain relative proliferation as described previously [30-32]. 
Dotted lines represent background proliferation of T-cells, in the absence of reporter clone peptide, relative to Th1 
clone proliferation. A: Suppressive activity was confined to live BCG-activated T-cells, and could not be 
demonstrated for heatkilled BCG-specific T-cells. Data are depicted as mean ± SE of five different heatkilled 
BCG-activated T-cell lines, and six live BCG-activated T-cell lines. B: Suppressive activity resides predominantly 
in CD8+ T-cells, and not in CD4+ T-cells (mean ± SE of CD4+ and CD8+ T-cell lines of three donors, tested in at 
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The relatively long persistence of BCG as a live intracellular bacterium in the human body 
after vaccination, as opposed to other vaccines, may be responsible for inducing increased 
CD8+ (regulatory) T-cell responses over time, compared to CD4+ T-cells. Dendritic cells in 
the skin could optimally cross-present [40] extracellular fragments of BCG after 
vaccination, further adding to CD8+ T-cell priming by late cross-presentation. Additional 
research is needed to clarify the BCG-specific induction of Treg cells in vivo and to 
compare the magnitude and persistence of CD4+ and CD8+ T-cells prospectively, both early 
after BCG-vaccination as well as at later time points. 
Studies analysing immune responses induced by Mtb-infection, TB disease or BCG-
vaccination, may have largely overlooked the presence and role of CD8+ Treg cells, which 
may be surprising, considering the initial identification of suppressor cells as CD8+ T-cells 
[41], and the early cloning of CD8+ suppressor T-cells in mycobacterial disease [12;13]. 
Immune based diagnosis of TB infection, such as tuberculin skin tests and IFNγ-release 
assays (IGRAs), vaccine immunogenicity, and perhaps also vaccine induced protection 
could all be negatively impacted upon by Treg activity [15-17]. More research into the 
induction and activity of Treg cells, and comparative analyses of subsets, could be 
important to optimal vaccine design as well as a better understanding of correlates of 
protection. Our study highlights the important contribution of live BCG-activated CD8+ 
Treg cells to immune regulation, and emphasizes the possible negative impact of human 
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Supplementary information  
 
 
Supplementary figure S1. Treg-cell marker expression in samples not stimulated with BCG. Positive 
populations for Treg-cell markers were defined by comparison with not BCG-stimulated samples for each donor. 







Supplementary figure S2. CD8+ : CD4+ ratio after expansion of T-cell lines. Heatkilled and live BCG-activated 
T-cell-lines were expanded and CD4+ and CD8+ frequencies were assessed by flowcytometry. The median pre-
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Abstract 
Regulatory T (Treg) cells can balance normal tissue homeostasis by limiting inflammatory 
tissue damage, e.g. during pathogen infection, but on the other hand can also limit 
protective immunity induced during natural infection or following vaccination. Because 
most studies have focused on the role of CD4+ Treg cells, relatively little is known about 
the phenotype and function of CD8+ Treg cells, particularly in infectious diseases. Here, we 
describe for the first time the expression of CD39 (E-NTPDase1) on Mycobacterium- 
activated human CD8+ T-cells. These CD8+CD39+ T-cells significantly co-expressed the 
Treg markers CD25, Foxp3, lymphocyte activation gene-3 (LAG-3), and CC chemokine 
ligand 4 (CCL4), and suppressed the proliferative response of antigen-specific CD4+ T 
helper-1 (Th1) cells. Pharmacological or antibody mediated blocking of CD39 function 
resulted in partial reversal of suppression. These data identify CD39 as a novel marker of 
human regulatory CD8+ T-cells and indicate that CD39 is functionally involved in 
suppression by CD8+ Treg cells. 
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Introduction 
Mycobacterium tuberculosis was responsible for 1.4 million deaths in 2010 and is estimated 
to have infected one-third of the world population [1]. There is extensive evidence 
suggesting that M. tuberculosis strongly modulates the immune response, both innate and 
adaptive, to infection, with an important role for regulatory T (Treg) cells [2]. In mice, M. 
tuberculosis infection triggers antigen-specific CD4+ Treg cells that delay the priming of 
effector CD4+ and CD8+ T-cells in the pulmonary lymph nodes (LNs) [3], suppressing the 
development of CD4+ T helper-1 (Th1) responses that are essential for protective immunity 
[4]. Thus, these CD4+ Treg cells delay the adequate clearance of the pathogen [5] and 
promote persisting infection. 
M. tuberculosis - as well as Mycobacterium bovis bacillus Calmette-Guérin (BCG) - have 
been found to induce CD4+ and CD8+ Treg cells in humans [6-8]. CD4+ and CD8+ Treg 
cells are enriched in disseminating lepromatous leprosy lesions, and are capable of 
suppressing CD4+ Th1 responses [9;10]. Naive CD8+CD25- T-cells can differentiate into 
CD8+CD25+ Treg cells following antigen encounter [11]. In M. tuberculosis-infected 
macaques, IL-2-expanded CD8+CD25+Foxp3+ Treg cells were found to be present 
alongside CD4+ effector T- cells in vivo, both in the peripheral blood and in the lungs [12]. 
In human Mycobacterium-infected LNs and blood, a CD8+ Treg subset was found 
expressing lymphocyte activation gene-3 (LAG-3) and CC chemokine ligand 4 (CCL4, 
macrophage inflammatory protein-1β). These CD8+LAG-3+CCL4+ T-cells could be isolated 
from BCG-stimulated PBMCs, co-expressed classical Treg markers CD25 and Foxp3, and 
were able to inhibit Th1 effector cell responses. This could be attributed in part to the 
secretion of CCL4, which reduced Ca2+ flux early after T-cell receptor triggering [8]. 
Furthermore, a subset of these CD8+CD25+LAG-3+ T-cells may be restricted by the HLA 
class-Ib molecule HLA-E, a non-classical HLA class-I family member. These latter T-cells 
displayed cytotoxic as well as regulatory activity in vitro, lysing target cells only in the 
presence of specific peptide, whereas their regulatory function involved membrane-bound 
TGF-β [13]. Despite these recent findings, the current knowledge about CD8+ Treg cell 
phenotypes and functions is limited and fragmentary when compared with CD4+ Treg cells 
[6;14]. 
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CD39 (E-NTPDase1), the prototype of the mammalian ectonucleoside triphosphate 
diphosphohydrolase family, hydrolyzes pericellular adenosine triphosphate (ATP) to 
adenosine monophosphate [15]. CD4+ Treg cells can express CD39 and their suppressive 
function is confined to the CD39+CD25+Foxp3+ subset [16;17]. Increased in vitro 
expansion of CD39+ regulatory CD4+ T-cells was found after M. tuberculosis specific 
‘region of difference (RD)-1’ protein stimulation in patients with active tuberculosis (TB) 
compared with healthy donors. Moreover, depletion of CD25+CD39+ T-cells from PBMCs 
of TB-patients increased M. tuberculosis specific IFNγ production [18]. CD39 expression 
on CD8+CD25+Foxp3+ Treg cells has been described in simian immunodeficiency virus 
infection [19], but has not been studied in mycobacterial infections in humans. 
ATP and other nucleotides can induce an array of intercellular signals, depending on the 
receptor subtype and pathways involved [20]. In damaged tissues, ATP is released in high 
concentrations, and functions as chemoattractant, generating a broad spectrum of pro-
inflammatory responses [21]. ATP can also trigger mycobacterial killing in infected 
macrophages [22-24], can stimulate phagosome-lysosome fusion through P2X7 receptor 
activation [25], and can drive Th17 cell differentiation in the murine lamina propria [26]. In 
a study focusing on the novel M. tuberculosis vaccine MVA85A, a drop in extracellular 
ATP consumption by PBMCs from subjects 2 weeks after vaccination corresponded with a 
decrease in CD4+CD39+ Treg cells and a concomitant increase in the co-production of IL-
17 and IFNγ by CD4+ T-cells [27]. Further hydrolysis of adenosine monophosphate by 
ecto-5´-nucleotidase (CD73) generates extracellular adenosine [20], which modulates 
inflammatory tissue damage, among others by inhibiting T-cell activation and multiple T-
cell effector functions through A2A receptor-mediated signaling [28].  
BCG, the only currently available vaccine for TB, fails to protect adults adequately and 
consistently from pulmonary TB [29], and part of this deficiency may be explained by 
induction of Treg cells by the BCG-vaccine [7;30;31]. In this study, we have used live BCG 
to activate CD8+ Treg cells, and demonstrate that these CD8+ T-cells express CD39, and 
co-express the well-known Treg markers CD25, Foxp3, LAG-3, and CCL4. Finally, we 
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Materials and Methods 
 
Blood samples. Anonymous buffy coats were collected from healthy adult blood bank 
donors that had signed consent for scientific use of blood products. PBMCs were isolated 
by density centrifugation and cryopreserved in fetal calf serum supplemented medium. 
Cells were counted using the CASY cell counter (Roche, Woerden, the Netherlands). 
Recognition of mycobacterial PPD was tested by assessing IFNγ production in vitro. 
PBMCs were stimulated with 5 μg/mL PPD (Statens Serum Institute, Copenhagen, 
Denmark) for 6 days and supernatants were tested in IFNγ ELISA (U-CyTech, Utrecht, the 
Netherlands). Positivity was defined as IFNγ production ≥ 150 pg/mL. 
 
Cell cultures. PBMCs were cultured in Iscove’s modified Dulbecco’s medium (Life 
Technologies-Invitrogen, Bleiswijk, the Netherlands) supplemented with 10% pooled 
human serum. BCG (Pasteur) was grown in 7H9 plus ADC, frozen in 25% glycerol and 
stored at -800C. Before use, bacteria were thawed and washed in PBS/0.05% Tween 80 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). Infections were done at an MOI of 1.5. IL-
2 (25 U/mL; Proleukin; Novartis Pharmaceuticals UK Ltd., Horsham, UK) was added after 
6 days of culture. 
Restimulation of cell lines was done in 96-well round-bottom plates (1 x 105 cells/w) with 
αCD3/CD28 beads (Dynabeads Human T-activator, Life Technologies-Invitrogen), IL-2 
(50 U/mL), IL-7, and IL-15 (both 5 ng/mL, Peprotech, Rocky Hill, NJ, USA); pooled, 
irradiated (30 Gy) PBMCs were added as feeders. Cells were maintained in IL-2 (100 
U/mL). 
 
FACS analysis. T-cell lines were incubated overnight with αCD3/28 beads, for the last 16h 
Brefeldin A (3 μg/mL, Sigma-Aldrich) was added. Following the labeling with the violet 
live/dead stain (VIVID, Invitrogen), the following antibodies were used for surface 
staining: CD3-PE-Texas Red, CD14- and CD19-Pacific Blue (all Invitrogen), CD4-PeCy7, 
CD8-HorizonV500, CD73-PerCPCy5.5 (all BD Biosciences, Eerembodegem, Belgium), 
and CD39-PE (Biolegend, London, UK). 
For intracellular staining, we used Intrastain reagents (Dako-Cytomation, Heverlee, 
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Belgium) according to the instructions of the manufacturer and the following antibodies: 
CCL4-FITC (R&D Systems, Abingdon, UK), Foxp3-Alexa Fluor 700 (eBioscience, 
Hatfield, UK), LAG-3-atto 647N (ENZO Life Sciences, Antwerp, Belgium), CD25-
allophycocyanin-H7 (BD Biosciences), and IL-10-allophycocyanin (Miltenyi Biotec, 
Teterow, Germany). Samples were acquired on a BD LSRFortessa using FACSDiva 
software (version 6.2, BD Biosciences) and analyzed using FlowJo software (version 9.5.3, 
Treestar, Ashland, OR, USA). 
 
Cell sorting. CD8+ cells were enriched by positive selection using magnetic beads (MACS, 
Miltenyi Biotec). Cells were fluorescence-activated cell sorted (FACS) by BD FACSAriaIII 
cell sorter using CD39-PE (Biolegend). Purity of all cell sorts was ≥ 97% as assessed by 
flow cytometry. 
 
Suppression assays. Cell lines were tested for their capacity to inhibit proliferation of a 
Th1 responder clone (Rp15 1-1) and its cognate M. tuberculosis hsp65 p3–13 peptide, 
presented by HLA-DR3 positive, irradiated (20 Gy) PBMCs as APCs in a co-culture assay 
that has been previously reported [8;32]. Proliferation was measured after 3 days of co-
culture by addition of 0.5 μCi/well and (3H)thymidine incorporation was assessed after 18 
h. Values represent means from triplicate wells. 
For the CFSE-labeling assay, the Rp15 1-1 Th1-responder clone was labeled with 0.005 
μM of CFSE and the irrelevant, isogenic T-cell clone (R2F10), with different peptide 
specificity and HLA-DR2 restriction, with 0.5 μM of CFSE, similar in design to previously 
described [13]. After 16h of co-culture with 5x104 CD8+CD39+ T-cells, the p3-13 peptide 
(50 ng/mL) and HLA-DR3 positive APCs, cells were harvested and stained for CD3, CD4, 
and CD8. CFSE intensity was measured on a BD LSRFortessa using FACSDiva software 
and analyzed using FlowJo software. 
 
Blocking experiments. ARL 67156 trisodium salt hydrate (Sigma-Aldrich) was added to 
the well in 150 μM and daily during the 3 days of co-culture. Anti-CD39 monoclonal 
antibody BY40/OREG-103 (Orega Biotech, Ecully, France) was added to the well at the 
first day of co-culture at a final concentration of 10 μg/mL, as was the IgG1 isotype control 
(R&D Systems). Values represent mean ± SE from triplicate wells. 
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Suppressive capacity of CD8+CD39+ T-cells was independent of original proliferation of 
the Th1 clone, as tested by reducing the cognate peptide concentration in the co-culture 
assays. Reversal of suppression was calculated in proportion to original clone proliferation 
in the absence of Treg cells, since ARL and anti-CD39 monoclonal antibody interfered 
directly with Th1 clone proliferation signals in the CD39 pathway, as demonstrated by 
reduced (3H)thymidine incorporation after 3 days. Percentage blocking was calculated after 
natural logarithmic transformation, and inhibition of proliferation in the presence and 
absence of blocking agents was calculated and expressed as percentage [8]. Raw data can 
be provided per request. 
 
Statistical analyses. Mann-Whitney tests and Wilcoxon signed-rank tests were performed 
using GraphPad Prism (version 5, GraphPad Software, San Diego, CA, USA) and SPSS 







Live BCG activates CD39 expression on CD4+ and CD8+ T-cells 
We isolated PBMCs from healthy human donors and stimulated these PBMCs with live 
BCG [8]. Flow cytometric analysis was performed after 6 days (the full gating strategy is 
shown in Supplementary figure S1, in compliance with the most recent MIATA guidelines 
[33]). CD39 was expressed on T-cells of donors that responded to purified protein 
derivative (PPD) in vitro, but not on T-cells from PPD non-responsive donors or on 
unstimulated cell lines (figure 1). CD39 and CD25 were co-expressed on both CD4+ and 
CD8+ T-cells from PPD-responsive donors after stimulation with live BCG (figure 1). 
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Figure 1. Live Mycobacterium bovis BCG activates CD4+CD39+ and CD8+CD39+ T-cells. Flow cytometric 
analysis of CD39 and CD25 expression on CD8+ and CD4+ T-cells of in vitro PPD-responders and non-responders 
6 days after live M. bovis BCG stimulation. Gating was performed as shown in Supplementary figure S1. Data are 
representative of five PPD-responders and five non-responders. 
 
 
CD8+CD39+ T-cells specifically co-express Treg-cell markers 
CD8+CD39+ T-cells co-expressed the Treg-cell markers CD25, LAG-3, CCL4, and Foxp3 
(figure 2A). There was no co-expression of CD39 with CD73, consistent with other studies 
on human Treg cells [34] (data not shown). Gating CD8+ T-cells on Foxp3 and LAG-3 [8] 
demonstrated that the majority of these cells also expressed CD39 as well as CD25 (figure 
2B). Boolean gating was used to analyze expression of multiple markers on single cells 
(figure 2C). A significantly higher percentage of CD3+CD8+CD4- T-cells from PPD-
responders expressed CD39 as compared with non-responders (p = 0.03; Mann-Whitney 
test). The CD8+CD39+ T-cells from responders significantly co-expressed CD25, LAG-3, 
CCL4, and/or Foxp3 as compared with non-responders and this difference was highly 
significant for the CD8+ T-cells that were CD39+CD25+LAG-3+CCL4+Foxp3+ (p = 0.02 - 
0.03 and p = 0.0079, respectively; Mann-Whitney test). The majority of the 
CD3+CD8+CD4- T-cells co-expressed CD25, LAG-3, CCL4, and/or Foxp3 in combination 
with CD39, such that CD39 appears to be a preferential marker of CD8+ Treg cells 
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Figure 2 (A and B). CD39 expression is associated with Treg-cell markers on CD8+ T-cells. A: Flow 
cytometric analysis of CD8+ T-cells for a selection of Treg markers in a PPD-responder 6 days after live 
Mycobacterium bovis BCG infection. Gating was performed as shown in Supplementary figure S1. CD8+CD4- 
gate consisted of at least 10 000 cells. Data are representative of five donors and four experiments performed. B: 
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Figure 2 (continued). CD39 expression is associated with Treg-cell markers on CD8+ T-cells. C: Combined 
analysis of individual Treg markers. Expression of individual markers was combined using Boolean gating and 
data are expressed as the percentage of CD3+CD8+CD4- T-cells that express these markers. Data are shown of five 
PPD-responders in gray boxes versus five non-responders in open boxes, 6 days after live M. bovis BCG infection 
and are representative of four experiments. Boxes: 25th-75th percentiles; line at median; whiskers: minimum to 
maximum (*p < 0.05; **p < 0.01; Mann-Whitney test). 
 
 
CD8+CD39+ T-cells suppress CD4+ Th1 responses 
To determine the possible suppressive function of CD39+ T-cells, CD39-positive and 
negative T-cell populations were FACS-sorted and tested for their capacity to inhibit the 
activity of an unrelated CD4+ Th1 responder clone, recognizing a cognate peptide presented 
in the context of HLA-DR3 [8;32]. CD8+CD39+ T-cells, purified to ≥ 97% purity, indeed 
suppressed the proliferative response of (cloned) CD4+ Th1 cells in response to peptide in 
the context of HLA-class II. This suppressive activity was strongly enriched in the 
CD8+CD39+ T-cell population as compared with CD8+CD39- T-cells and unsorted CD8+ T-
cells (figure 3A). Flow cytometric analysis of sorted T-cell lines demonstrated enrichment 
for LAG-3, CD25, Foxp3, and CCL4 in the CD8+CD39+ compared with the CD8+CD39- T-
cells (figure 3B). 
CD39 + + − + − + − + − + −
CD25 + + + + + + + +
LAG-3 + + + + + +
CCL4 + + + +
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Figure 3. Mycobacterium bovis BCG-induced CD8+CD39+ T-cells suppress antigen-specific proliferation of 
(cloned) CD4+ Th1 cells. A: CD8+ T-cells of PPD-responders were enriched after BCG stimulation by positive 
selection using magnetic beads and FACS-sorted on CD39 expression. Their potential suppressive capacity was 
tested in a co-culture assay by titrating CD8+CD39+ T-cell lines, CD8+CD39- T-cell lines, or unsorted bulk CD8+ 
T-cell lines (containing on average 75% CD8+CD39+ T-cells) onto a Th1 reporter clone that was stimulated with 
its cognate peptide. Proliferation was measured by (3H)TdR (where TdR is thymidine) incorporation after 3 days. 
Proliferation was divided by Th1 reporter clone proliferation in the absence of Treg cells to obtain relative 
proliferation (Wilcoxon signed-rank test, p < 0.001). Dashed lines represent background proliferation of the 
different CD8+ T-cell subsets (at the indicated CD8+ T-cell concentrations) relative to Th1 reporter clone 
proliferation. Data are depicted as mean ± SE of three cell lines. B: Flow cytometric analysis demonstrating 
enrichment for Treg-cell markers in CD39-sorted CD8+ T-cell lines, compared with CD39-CD8+ T-cell lines. (A, 
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Blocking CD39 results in partial reversal of suppression by M. bovis BCG-stimulated 
CD8+CD39+ T-cells 
CD8+CD39+ T-cells preserved their expression of CD39 ( ≥ 99%), as well as of other Treg-
cell markers, including CD25, Foxp3, and CCL4 (Supplementary figure S2) following 
further in vitro expansion. We next tested the ability of ARL 67156 trisodium salt hydrate 
(ARL) and the anti-CD39 monoclonal antibody BY40/OREG-103 to reverse the 
suppressive activity of CD8+CD39+ T-cells. ARL is an ATP analog that can bind to, but is 
not hydrolysable by, CD39 [35], and has been used to inhibit the suppressive activity of 
CD4+CD25+CD39+ cells [27]. Here, ARL partially reversed the capacity of CD8+CD39+ T- 
 
 
Figure 4. Blocking CD39 by the chemical CD39 antagonist ARL 67156 trisodium salt hydrate (ARL) results 
in partial reversal of suppression by Mycobacterium bovis BCG-stimulated CD8+CD39+ T-cells. CD8+CD39+ 
T-cells, with previously demonstrated T-cell inhibitory capacity, were expanded using αCD3/CD28 beads, and 
suppression assays were performed by titrating these CD8+CD39+ T-cell lines onto a Th1 reporter clone stimulated 
with its cognate peptide as described in the legend of figure 3A. ARL was added daily in 150 μM and proliferation 
was measured as (3H)TdR (where TdR is thymidine) incorporation after three days. The response was calculated 
by dividing cognate-peptide-induced proliferation with unstimulated values after natural logarithmic 
transformation. To obtain a relative response, the response for each Treg concentration was normalized for 
proliferation in the absence of Treg cells (100%). Reversal of suppression was calculated by dividing relative 
responses in the presence or absence of ARL (14 - 47% reversal of suppression; p = 0.023; Wilcoxon signed-rank 
test) as previously described [8]. Data represent mean ± SE for three independent CD8+CD39+ T-cell lines tested 
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cells to suppress the proliferative responses of the Th1 responder clone (14 - 47% reversal 
of suppression; in three cell lines; p = 0.023; Wilcoxon signed-rank test) (figure 4). 
Suppression by the CD8+CD39+ T-cells was also (partially) reversed by the anti-CD39 
blocking monoclonal antibody BY40/OREG-103 [36;37] (0 - 35% reversal of suppression; 
in four experiments; p = 0.005; Wilcoxon signed-rank test) (figure 5); further supporting 






Figure 5. Suppression mediated by CD8+CD39+ T-cell lines is partly reversed by an anti-CD39 monoclonal 
antibody BY40/OREG-103. CD8+CD39+ T-cells were expanded using αCD3/CD28 beads and suppression assays 
were performed by titrating these CD8+CD39+ T-cell lines onto a Th1 reporter clone stimulated with its cognate 
peptide. Proliferation values were divided, after natural logarithmic transformation, by Th1 reporter clone 
proliferation values obtained in the absence of Treg cells, in order to obtain relative proliferation. Inhibition of 
proliferation in the presence and absence of anti-CD39 monoclonal antibody was calculated and expressed as 
percentage (0 - 35% reversal of suppression; p = 0.005; Wilcoxon signed-rank test). Data represent mean ± SE for 
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To exclude that suppressive activity by CD8+CD39+ T-cell lines was due to lysis rather than 
active suppression of the CD4+ Th1 responder clone, the Th1 responder clone and an equal 
number of cells of an irrelevant T-cell clone were labeled with low and high doses CFSE, 
respectively, and were added in equal numbers to the co-culture assay, identical to 
previously described [13]. After 16h, before division of the Th1 responder clone occurs, the 
percentages of responder and irrelevant T-cell clone without CD8+CD39+ T-cells were 
similar to the percentages of responder and irrelevant T-cell clone with the addition of 
CD8+CD39+ T-cells (Supplementary figure S3), indicating that in these co-culture assays, 






In this study, we describe for the first time the expression of, and a functional role for, 
CD39 on human pathogen activated CD8+ Treg cells. CD8+CD39+ T-cells from PPD-
responsive individuals specifically co-expressed the known classical Treg-cell markers 
CD25, Foxp3, LAG-3, and CCL4. To assess if CD39 expression was merely a marker of 
CD8+ Treg cells or was directly involved in the CD8+CD39+ T-cells’ suppressive activity, 
we purified CD8+CD39+ T-cells, and showed that they were strongly enriched for 
suppressive activity and the expression of Treg markers, and that both the chemical CD39 
antagonist, ARL, as well as a blocking anti-CD39 antibody were able to partly inhibit the 
suppressive activity of CD8+CD39+ T-cells. Altogether these data indicate that CD39 is a 
marker for regulatory CD8+ T-cells and that CD39 contributes functionally to the 
suppression mediated by human CD8+CD39+ T-cells. 
Both ARL as well as the blocking anti-CD39 antibody only partly inhibited suppressive 
activity, indicating that also other mechanisms may contribute to suppression. We 
previously demonstrated the expression of LAG-3 and the functional involvement of CCL4 
in immune regulation by BCG-activated CD8+ Treg cells. In the current study, ≥ 43% of 
CD8+CD39+ T-cells also expressed CCL4, while we did not find any expression of IL-10 
on these T-cells. 
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CD8+ Treg cells have been described in human Mycobacterium-infected LNs [8] and 
lepromatous lesions [9;10], demonstrating that CD8+ Treg cells are present at the site of 
disease and suggesting a potential role for these cells in disease pathogenesis. In line with 
our previous studies showing that BCG activated CD8+ Treg cells in PPD-responsive 
individuals, but not in donors that did not recognize PPD in vitro [8], also in the current 
study CD8+CD39+ Treg cells were confined to PPD-responders, suggesting that these cells 
originated from preexistent antigen-specific memory T-cells. We have previously 
hypothesized that Treg cells could contribute to the relative failure of BCG-vaccination in 
conferring protection against pulmonary TB in adults [6]. 
In TB, recent results have suggested a role for Th17 cells both in protection and pathology. 
IL-17 producing CD4+ T-cells in the lung, induced by BCG-vaccination, were associated 
with protective immunity to TB in mice [2;38]; interestingly, in human tuberculous pleural 
effusions, the number of CD4+CD39+ Treg cells was inversely related to the number of 
Th17 cells, and CD39+ Treg cells suppressed the differentiation of naive CD4+ cells into 
Th17 cells [39]. Frequencies of CD4+CD39+ T-cells correlated negatively with IL17A 
responses in stimulated PBMCs after MVA85A vaccination [40]. Stimulation of PBMCs in 
the presence of the CD39 chemical antagonist ARL 67156 increased coproduction of IL-17 
and IFNγ by CD4+ T-cells, 1 and 2 weeks after MVA85A vaccination [27]. Whether 
CD8+CD39+ T-cells are associated with IL-17 responses and/or protection needs further 
investigation. 
In this article, we describe for the first time a functional role for CD39 on human BCG-
activated CD8+CD39+ Treg cells. We show that CD39 expression marks a CD8+ Treg-cell 
subset, which co-expresses LAG-3, CD25, Foxp3, and CCL4, and that CD39 may play a 
direct role in exerting CD8+ Treg-dependent suppression. CD8+CD39+ Treg cells represent 
a new player in balancing immunity and inflammation in host defense against 
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Supplementary figure S1. Gating strategy. Studies were conducted in a laboratory guided by exploratory 
research principles with established Standard Operating Procedures (SOP): cells were isolated and cryopreserved 
according to SOP1. Cells were thawed (78% median viable cell yield) and stimulated with live BCG for six days in 
medium supplemented with pooled human serum (pretested in standardized protocols; only sera were pooled that 
had no inhibitory activity in standard mixed allogeneic lymphocyte cultures). Demonstrated is the gating strategy 
used for flowcytometric analysis at day 6: cells were gated on single cells, violet-live/dead-CD14-CD19-negative, 
CD3+ and CD8+CD4- vs. CD4+CD8-.  
















Supplementary figure S2. Expression of regulatory T-cell markers in restimulated CD8+CD39+ T-cell lines. 
CD8+CD39+ T-cells were expanded using αCD3/CD28 beads and analyzed for expression of regulatory T-cell 
markers by flowcytometry. Gating was similar for both plots and performed as shown in Supplementary figure S1. 
97% Of the restimulated CD8+CD39+ T-cells expressed CD25 (left) and 43% of restimulated CD8+CD39+ T-cells 
co-expressed CCL4 and Foxp3 (right). These cells did not express IL-10. Data are representative for three 
CD8+CD39+ T-cell lines. 
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Supplementary figure S3. Inhibition of Th1-responder cell proliferation is not the result of lysis by CD8+ T-
cells. The Th1-responder clone Rp15 1-1 was labeled with 0.005 μM of CFSE, and another, isogenic T-cell clone, 
with a different peptide specificity and HLA-DR restriction, with 0.5 μM of CFSE [13]. Both cells were then co-
cultured in equal numbers with the CD8+CD39+ T-cell lines in the presence of the peptide (50 ng/ml) recognized 
by the responder clone Rp15 1-1 in the context of HLA-DR3+ APCs. After 16 hours CFSE intensity was measured 
by flowcytometry. The percentages of responder and irrelevant T-cells without CD8+CD39+ T-cells were similar to 
the percentages of responder and irrelevant T-cells with the addition of 5 x 104 CD8+CD39+ T-cells, the highest 
concentration used in our co-culture experiments; thus indicating that the responder clone is not lysed by the BCG-
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Abstract 
Mycobacterium bovis bacillus Calmette-Guérin (BCG), the only currently available vaccine 
against tuberculosis, induces variable protection in adults. Immune correlates of protection 
are lacking, and analyses on cytokine-producing T-cell subsets in protected vs. non-
protected cohorts have yielded inconsistent results. We studied the primary T-cell response, 
both pro-inflammatory and regulatory T-cell responses, induced by BCG-vaccination in 
adults. Twelve healthy adult volunteers, who were tuberculin skin test (TST)-negative, 
QuantiFERON test (QFT)-negative, and BCG-naive, were vaccinated with BCG and 
followed up prospectively. BCG-vaccination induced an unexpectedly dichotomous 
immune response in this small, BCG-naive young adult cohort: BCG-vaccination induced 
either gamma interferon-positive (IFN +) interleukin 2-positive (IL2+) tumor necrosis factor 
α-positive (TNFα+) polyfunctional CD4+ T-cells concurrent with CD4+IL17A+ and 
CD8+IFNγ+ T-cells, or, in contrast, virtually absent cytokine responses with induction of 
CD8+ regulatory T-cells. Significant induction of polyfunctional CD4+IFNγ+IL2+TNFα+ T-
cells and IFNγ production by peripheral blood mononuclear cells (PBMCs) was confined to 
individuals with strong immunization-induced local skin inflammation and increased serum 
C-reactive protein (CRP). Conversely, in individuals with mild inflammation, regulatory-
like CD8+ T-cells were uniquely induced. Thus, BCG-vaccination either induced a broad 
pro-inflammatory T-cell response with local inflammatory reactogenicity or, in contrast, a 
predominant CD8+ regulatory T-cell response with mild local inflammation, poor cytokine 
induction, and absent polyfunctional CD4+ T-cells. Further detailed fine mapping of the 
heterogeneous host response to BCG-vaccination using classical and non-classical immune 
markers will enhance our understanding of the mechanisms and determinants that underlie 
the induction of apparently opposite immune responses, and how these impact the ability of 
BCG to induce protective immunity to TB.  
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Introduction 
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the second greatest 
infectious cause of death worldwide after HIV, accounting for 1.3 million deaths in 2012 
[1]. The only available vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), 
protects infants from disseminated forms of TB, but has insufficient and inconsistent 
efficacy in protecting adults from pulmonary TB [1;2]. A vaccine preventing active 
pulmonary TB, the contagious form of the disease, would greatly impact the epidemic [3], 
and a better understanding of vaccine-induced mechanisms of protection is essential in 
developing new surrogate endpoints [4]. 
Both CD4+ Th1 (IFNγ+) cells and CD8+ T-cells are critical for protection against TB [5]. 
Specifically, CD4+ IFNγ+IL2+TNFα+ polyfunctional T-cells have been proposed as correlate 
of vaccine-induced protective immunity in murine infection models [6]. In infants, BCG-
vaccination induced specific cytokine expression in CD4+ and CD8+ T-cells [7-9], 
including IFNγ+IL2+TNFα+ polyfunctional CD4+ T-cells [10]. However, there was no 
relation between the presence of such cells and the development of TB during follow-up 
[11]. 
In adults, BCG-vaccination induced CD4+ IFNγ+ responses [12-14] as well as IFNγ- and 
TNFα-secreting CD8+ T-cells with cytotoxic activity [15]. However, data on induction of 
polyfunctional T-cells by BCG-vaccination in adults have been conflicting [16;17]. In one 
report, the induction of polyfunctional CD4+ T cells was similar in magnitude in BCG-
vaccinated infants and adults; however, when induction was analyzed as the proportion of 
polyfunctional versus single-cytokine-producing T-cells, the proportion of polyfunctional 
CD4+ T-cells was larger in children than in adults [16]. Further, studies on latent 
(controlled) versus active TB in adults yielded variable results on changes in mono- and 
triple-cytokine producing T-cell subsets [18;19], such that it was suggested that 
polyfunctional T-cells are also present in active TB disease and that these cells are not a 
surrogate marker of protection against TB in humans [19;20]. 
Another explanation for the inconsistent protection induced by BCG against TB in adults is 
induction of regulatory T-cells (Tregs) by mycobacteria, which can dampen pro-
inflammatory responses [21]. In that context, we reported that live BCG triggers the 
specific activation of CD8+ (but not CD4+) Tregs from peripheral blood mononuclear cells 
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(PBMCs) of mycobacterial purified protein derivative (PPD)-responsive adults [22], while 
others found that BCG-vaccination induced CD4+ Tregs in newborns [23] and adults [24]. 
Here, in a small, well-defined cohort of previously BCG-naive adults, we studied the 




Materials and Methods 
 
Participants. Dutch volunteers were recruited via posters in the university library. All 
volunteers were screened for tuberculosis by anamnesis (history of TB disease or 
treatment), by a tuberculin skin test (TST; negative <  5mm), and by the QuantiFERON-TB 
gold in-tube test, according to the manufacturer’s specifications. Included volunteers (n = 6 
males, n = 6 females; median age 24 years (interquartile range (IQR) 23-25 years); median 
weight 70 kg (IQR 67-80 kg); all Dutch, all Caucasian) had not been vaccinated with BCG 
at any time prior to entering the trial (anamnestic, presence of scar, or on a vaccination 
card), were never treated for TB disease and had negative TST and QuantiFERON test 
results. In addition, they did not receive any live vaccination at < 4 weeks prior to BCG-
vaccination. Volunteers were excluded who were pregnant or not generally healthy, who 
had fever or received antibiotic treatment < 2 weeks prior to enrollment, or who were 
treated with immune modulating drugs < 3 months prior to enrollment; all volunteers tested 
negative for HIV at screening.  
 
Procedures. Participants were vaccinated with the live-attenuated BCG Danish strain 1331 
(Statens Serum Institute, Denmark) by intradermal injection in the upper arm and were 
followed up prospectively: at 2 weeks prior to vaccination, at day of vaccination, at 1, 3 and 
7 days after vaccination, at 4, 8 and 12 weeks after vaccination and at 1 year after 
vaccination. During follow up the injection site was inspected and photographed, and 
adverse events were recorded using a standardized case report form. Venous blood samples 
were collected in heparin-containing vacutainers for whole-blood stimulation assays and for 
PBMC isolation and cryopreservation according to standard operating procedures. Serum 
was collected from serum tubes after blood coagulation and stored at -80ºC.  
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Calculation of skin inflammation score. Signs of inflammation by visual inspection of the 
vaccination site and symptoms recorded in volunteer diaries were documented on 
standardized case report forms and photographed at 4, 8 and 12 weeks after vaccination. 
The local reaction was scored by two researchers (M.C.B. and C.P.) independently, with 
one point per sign of inflammation: redness of ≥ 1 cm, swelling of ≥ 1 cm, pus discharge 
and ulceration, pain, and regional lymph node enlargement (> 90% consensus; 
disagreements were solved by mutual reexamination of case report forms, photographs and 
volunteer diaries). The inflammation score was calculated as the cumulative scores of 
weeks 4, 8, and 12 after vaccination.  
 
C-reactive protein enzyme-linked immunosorbent assay. The serum samples of all pre-
vaccination and post-vaccination visits were thawed, and the C-reactive protein (CRP) 
concentration was measured using a standardized, highly sensitive, CRP human enzyme-
linked immunosorbent assay (ELISA) according to the instructions of the manufacturer 
(Abnova, Heidelberg, Germany). 
 
Whole-blood live BCG-stimulation. Bacillus Calmette-Guérin (Pasteur) was grown in 
7H9 plus ADC, frozen in 25% glycerol and stored at -800C. Before use, bacteria were 
thawed and washed in phosphate-buffered saline (PBS)/0.05% Tween 80 (Sigma-Aldrich). 
Then, 1 ml of heparinized blood was added within 1h of blood collection to Sarstedt 
microtubes (Sarstedt B.V., Etten-Leur, the Netherlands), containing 0.9 x 106 CFU 
(calculated multiplicity of infection (MOI) of 3), and anti-CD28 and anti-CD49d antibodies 
as co-stimulants (1 μg/ml, BD Biosciences, Eerembodegem, Belgium) [25] and 
immediately incubated at 370C. Staphylococcal enterotoxin B (SEB) (final concentration 5 
μg/ml; Toxin Technology, Sarasota, FL, USA) and unstimulated samples were used as 
controls. After 3 h, Brefeldin A (10 μg/ml; Sigma-Aldrich, Zwijndrecht, the Netherlands) 
and Monensin (1:1000; BD Biosciences) were added and samples were transferred to a 
water bath set at 37°C and programmed to switch off after 12h. Samples were harvested the 
next morning, using EDTA (2mM; Sigma-Aldrich), fixed and erythrocyte-lysed using a 
fluorescence-activated cell sorter (FACS)-lysing solution (BD Biosciences), and 
cryopreserved in fetal calf serum with 10% dimethyl sulfoxide (DMSO) [25]. 
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Cell cultures and BCG infection. PBMCs were thawed, and cells were counted using the 
CASY cell counter (Roche, Woerden, the Netherlands). Infections were done at an MOI of 
1.5. SEB (final concentration 2 μg/ml; Toxin Technology) and unstimulated samples were 
used as controls. PBMCs were cultured in 24-well plates (2 x 106/w) for 6 days in Iscove's 
modified Dulbecco's medium (Life Technologies-Invitrogen, Bleiswijk, the Netherlands) 
with 10% pooled human serum. For flow cytometric analysis PBMCs were incubated for 
the last 16h with αCD3/28 beads (Invitrogen) and Brefeldin A (3 μg/ml; Sigma-Aldrich).  
Lymphocyte stimulation assays were performed using PBMCs (0.5 x 106/w in 48-well 
plates) and stimulation with 5 μg/ml PPD (Statens Serum Institute, Copenhagen, Denmark) 
at 370C, 5% CO2. Phytohemagglutinin (PHA) (final concentration 2 μg/ml; Remel Europe) 
and unstimulated samples were used as controls. After 7 days, supernatants were collected 
and an IFNγ-ELISA (U-CyTech, Utrecht, the Netherlands) was performed.  
Direct IFNγ-enzyme-linked immunosorbent spot (ELISpot) assays were performed at 1 
year post-vaccination: 250,000 freshly isolated PBMCs were added in AIMV (synthetic 
non-human serum supplemented) medium (Invitrogen) to 96-well ELISpot plates 
(Millipore, Bedford, MA, USA), that were pre-coated with anti-IFNγ-antibody (1-D1K; 5 
μg/ml; Mabtech, Stockholm, Sweden) and blocked with AIMV. PBMCs were stimulated 
overnight with PHA (2 μg/ml), PPD (5 μg/ml) or an antigen 85B (Ag85B) peptide pool (1 
μg/ml) in triplicate [26]. For detection, biotinylated anti-IFNγ-antibody (0.5 μg/ml; 
Mabtech), streptavidin-alkalic phospatase conjugate (1:1000 dilution in 1% bovine serum 
albumin (BSA)-PBS; Mabtech IFNγ-ELISpot kit reagent) and a SigmaFast NBT/BCIP 
substrate (Sigma-Aldrich) were used. Positivity for vaccine take [27] was defined as an 
increase of > 100% of the average count in PPD-stimulated wells compared to unstimulated 
controls and at least 5 spots more than in unstimulated controls [28].   
 
Flow cytometry. Fixed whole-blood samples were thawed and stained in batches. Surface 
staining included CD3-Brilliant Violet 570 (clone UCHT1), CD19-Pacific Blue (clone 
HIB19), CD56-Brilliant Violet 421 (clone HCD56) (all Biolegend, London, U.K.), CD14-
Pacific Blue (clone TüK4) and CD4-PE-Texas Red (clone S3.5) (both Life Technologies-
Invitrogen); and CD8-HorizonV500 (clone RPA-T8), CD45RA-allo-phycocyanin (APC)-
H7 (clone HI100) and CD62L-Brilliant Violet 605 (clone DREG-56) (all BD Biosciences). 
For intracellular staining IL17A-FITC (clone eBio64DEC17; eBioscience, Hatfield, UK), 
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IFNγ-Alexa Fluor 700 (clone B27), TNFα-APC (clone 6401.1111), IL4-PE (clone 
3010.211), and CD69-PeCy5 (clone FN50) (all BD Biosciences); and IL2-Brilliant Violet 
650 (clone MQ1-17H12), IL10-Pe-Cy7 (clone JES3-9D7) and IL13-PE (clone JES10-5A2) 
(all Biolegend) were used in permeabilization solution (Fix&Perm cell permeabilization kit, 
An Der Grub BioResearch GMBH, Susteren, the Netherlands).   
The stimulated PBMCs were labelled with violet LIVE/DEAD stain (Vivid, Invitrogen) and 
surface stained with CD3-Brilliant Violet 570 (clone UCHT1), CD19-Pacific Blue (clone 
HIB19), CD56-Brilliant Violet 421 (clone HCD56), and CD39-PE (clone A1) (all 
Biolegend, London, U.K.); CD14-Pacific Blue (clone TüK4) and CD4-PE-Texas Red 
(clone S3.5) (both Life Technologies-Invitrogen); and CD8-HorizonV500 (clone RPA-T8; 
BD Biosciences). Cells were fixed and permeabilized using the Fix&Perm cell 
permeabilization kit. For intracellular staining the following antibodies were used: CC 
chemokine ligand 4 (CCL4)-fluorescein isothiocyanate (clone 24006; R&D Systems, 
Abingdon, UK), Foxp3-Alexa Fluor 700 (clone PCH101; eBioscience), lymphocyte 
activation gene (LAG)-3-atto 647N (clone 17B4; ENZO Life Sciences, Antwerp, Belgium), 
and CD25-allophycocyanin-H7 (clone M-A251; BD Biosciences).  
Samples were acquired on a BD LSRFortessa using FACSDiva software (version 6.2, BD 
Biosciences) with compensated parameters. Analysis was performed using FlowJo software 
(version 9.5.3, Treestar, Ashland, OR, USA) and gates were synchronized per donor for all 
visits and for both CD4+ and CD8+ T-cell subsets, using the comparison with unstimulated 
samples and SEB as controls.  
 
Statistical analyses. GraphPad Prism (version 6, GraphPad Software, La Jolla, CA, USA) 
and SPSS statistical software (version 20, SPSS IBM, Armonk, NY, USA) were used for 
Wilcoxon signed-rank tests and Mann-Whitney tests. To correct for paired resp. unpaired 
multiple testing, Friedman tests followed by Dunn’s multiple comparisons tests, and 
Kruskal-Wallis tests followed by Dunn’s multiple comparisons tests, respectively, were 
used. Only values significant after multiple testing correction are demonstrated. 
 
Study approval. Approval was obtained from the Medical Ethical Committee (registration 
number P 12.87) of the Leiden University Medical Center, the Netherlands. Each 
participant signed written informed consent prior to inclusion.   
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Twelve healthy adults (TST-negative, QuantiFERON-negative) were vaccinated with BCG 
(n = 6 males, n = 6 females; median age 24 years (IQR 23 - 25 years); all Caucasian). Ex 
vivo IFNγ-ELISpot assays were performed 1 year post-vaccination to determine the 
Mycobacterium-specific immunity [29]: all recipients tested positive except for one, who 
nevertheless demonstrated high BCG-induced IFNγ-responses in flow cytometric analysis 
(Supplementary figure S1).  
 
Local reactogenicity is variable and corresponds with serum CRP and PPD-induced 
IFNγ production   
T-cell responses as well as BCG-vaccine induced local skin reactions varied strongly 
between individuals. At 4, 8 and 12 weeks post-vaccination, inflammatory symptoms were 
scored for redness, swelling, ulceration and pus discharge, pain and regional lymph node 
enlargement. A cumulative skin inflammation score was then calculated (further described 
in the Materials and Methods). Representative photographs of low- and high-inflammation 
skin lesions are shown in figure 1A. Participants were subdivided into a low (n = 6) and a 
high (n = 6) responder group (referred to as low and high skin inflammation responders, 
respectively) based on skin inflammation scores using the median cumulative skin 
inflammation score of 7 as a cut-off (figure 1B).  
Since serum CRP has been used previously to study vaccine-induced inflammation [30-32], 
we determined CRP concentrations by a highly sensitive ELISA. Serum CRP 
concentrations 3 and 7 days post-vaccination correlated with the cumulative skin 
inflammation score (R2 = 0.76 at both visits using nonlinear regression, day 7 results shown 
in figure 1C, left). In high skin inflammation responders, serum CRP was significantly 
higher 7 days post-vaccination, compared to low skin inflammation responders (p = 0.03; 
figure 1C, right). CRP concentrations at baseline were not different between high and low 
inflammation responders.  
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We assessed the in vitro IFNγ production by ELISA after PPD stimulation of PBMCs for 7 
days. The PBMCs of high skin inflammation responders produced more IFNγ than low skin 
inflammation responders 4 and 8 weeks post-vaccination (p = 0.026 and 0.002, resp.). IFNγ 
production was significantly induced at 8 and 12 weeks post-vaccination compared to pre-
vaccination in high skin inflammation responders (both p = 0.031), but not in low skin 
inflammation responders (figure 1D). Prior to BCG-vaccination, IFNγ production was not 





A                                                                                             B 
 
 
Figure 1. BCG-vaccination induces highly variable local inflammation that corresponds with serum CRP 
and IFN  production. A: Photographs of low versus high degrees of skin inflammation at the vaccination site 12 
weeks after BCG-vaccination (left photograph, cumulative inflammation score of 3; right photograph, cumulative 
inflammation score of 11). B: Signs of inflammation of the vaccination lesion were recorded, and a skin 
inflammation score was calculated as the cumulative scores of 4, 8, and 12 weeks after vaccination. This divided 
recipients into 6 low and 6 high responders around a median skin inflammation score of 7.  
12 weeks after BCG vaccination: Cumulative scores of skin lesions:
Vaccinee A: Vaccinee B:
B










low responders high responders
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Figure 1 (continued). BCG-vaccination induces highly variable local inflammation that corresponds with 
serum CRP and IFN  production. C: Serum samples of volunteers were collected at all visits for CRP ELISA. 
The serum CRP concentrations at day 7 after vaccination correlated with the cumulative skin inflammation scores 
(R2 = 0.76 using nonlinear regression; left); high skin inflammation responders had significantly higher CRP 
values than low responders 7 days after vaccination (6 individuals in each group, with line at median; p = 0.03, 
Mann-Whitney test; right). D: PBMCs were stimulated with PPD, supernatants were harvested after 7 days, and 
IFN  production was measured by ELISA. IFN  production by PBMCs of high, compared to low skin 
inflammation responders was significantly higher at 4 and 8 weeks post-vaccination, and IFN  production was 
significantly induced only in comparison to that at pre-vaccination in high skin inflammation responders (6 
recipients in each group, line at median; Mann-Whitney test for comparison between groups, Wilcoxon signed-
rank test for within-group testing). 
 
CD4+IFNγ+IL2+TNFα+ T-cells and CD8+IFNγ+ T-cells are induced in high 
inflammation responders 
Whole-blood samples from pre-vaccination and at 4, 8, 12 weeks and 1 year after 
vaccination were stimulated directly ex vivo with live BCG for 16h. The gating strategy is 
shown in Supplementary figure S2A, and the representative flow cytometric analyses of co-
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expression of cytokines in CD4+ T-cells with negative and positive controls are shown in 
Supplementary figure S2B, compliant with MIATA (minimal information about T-cell 
assays)-guidelines [33].  
BCG-vaccination induced significant IFNγ-expression in CD4+ T-cells, but only in high 
inflammation responders (p = 0.031, at 4 and 12 weeks post-vaccination) and not in low 
inflammation responders (figure 2A, left graphs).  Polyfunctional CD4+IFNγ+IL2+TNFα+ T-
cells were significantly induced in BCG-recipients, but a division of the high versus low 
inflammation responders revealed that the proportion of CD4+IFNγ+IL2+TNFα+ T-cells was 
significantly increased in the high versus low inflammation responders (p = 0.015, p = 
0.048, and p = 0.041 at 4, 8, and 12 weeks after vaccination, resp.), but it was almost absent 
in the latter group. Thus, significant induction of CD4+IFNγ+IL2+TNFα+ T-cells was 
confined to high inflammation responders (figure 2A, right graphs).  
The majority of IFNγ, TNFα and/or IL2-expressing CD4+ T-cell subsets of high 
inflammation responders peaked at 8 weeks post-vaccination (Supplementary figure S3A). 
Single-, double- and triple-cytokine-producing CD4+ T-cell subsets consisted 
predominantly of effector cells at 4, 8 and 12 weeks post-vaccination (Supplementary 
figure S3B). 
CD4+IL17A+ T-cells were induced significantly post-vaccination, but only in high 
inflammation responders (figure 2B). Similarly, significant induction of IFNγ-expression in 
CD8+ T-cells was confined to high inflammation responders (figure 2B). No polyfunctional 
CD8+ T-cell responses could be detected (data not shown). CD4+ T-cells did not co-express 
IL17A and IFNγ (representative graph in Supplementary figure S2B). IL17A-expression 
correlated with IFNγ-expression in CD4+ T-cells at 4, 8 and 12 weeks post-vaccination 
(figure 2C upper graphs; R2 0.86, 0.94, and 0.83, resp., using nonlinear regression). IFNγ-
expression in CD8+ T-cells highly correlated with IFNγ-expression in CD4+ T-cells (figure 
2C lower graphs; R2 0.98, 0.85, and 0.99 at 4, 8, and 12 weeks post-vaccination, resp., 
using nonlinear regression), thus revealing a broad pro-inflammatory response induced by 
BCG-vaccination in high inflammation responders. No induction of IL10- or IL4/IL13-
expression was observed in CD4+ T-cells in low or in high inflammation responders (figure 
2D).  
The association between skin inflammation score and induction of CD4+ cytokine co-
expression was further substantiated by segregating vaccinees based on induction versus no 
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 T-cells instead of local inflammation 
scores. This revealed an increased total skin inflammation score in vaccinees with induction 
of CD4
+
 polyfunctional T-cells, compared to vaccinees with no polyfunctional CD4
+
 T-cell 
induction (n = 7 cytokine-responders versus n = 5 non-responders, including in the latter 
group a low skin inflammation responder with a skin inflammation score of 6; p = 0.037, 
Mann-Whitney test; Supplementary figure S4A). The differences in the CRP concentration 
7 days after vaccination did not reach statistical significance in cytokine-responders vs. 






Figure 2. BCG-vaccination induces a pro-inflammatory cytokine response, predominantly in high skin 
inflammation responders. A: BCG-vaccination induces IFN+ and IFN+IL2+TNFα+ CD4+ T-cells (upper graphs) 
in whole blood following BCG-stimulation for 16h, but the frequency of polyfunctional CD4+ IFN+IL2+TNFα+ T- 
cells is significantly increased in high, compared to low, skin inflammation responders, and the induction of CD4+ 
IFN+ and polyfunctional CD4+ IFN+IL2+TNFα+ T-cells is only significant in high, not in low, skin inflammation 
responders (lower graphs); n = 6 recipients in each group. Horizontal lines indicate median; Mann-Whitney test 
for comparison between groups, Wilcoxon signed-rank test for within-group testing. 
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B 
                      
C                                                                                 D 
                    
Figure 2 (continued). BCG-vaccination induces a pro-inflammatory cytokine response, predominantly in 
high skin inflammation responders. B: CD4+IL17A+ T-cells and CD8+IFN + T-cells are significantly induced 
in high skin inflammation responders. C: Expression of the pro-inflammatory cytokines IL17A in CD4+ T-
cells and of IFN  in CD8+ T-cells both highly correlate with IFN -expression in CD4+ T-cells, as determined by 
nonlinear regression. (Data are shown for all recipients at 4, 8, and 12 weeks after vaccination; whole-blood 
BCG-stimulation for 16h). Values of 0 were not plotted. D: In CD4+ T-cells, neither IL4/IL13 nor IL10 was 
significantly induced in any responder group following whole-blood BCG stimulation for 16h. 
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Figure 3. Treg markers on CD8+ T-cells, but not on CD4+ T-cells, are activated by in vitro live BCG-
stimulation of PBMCs of vaccinees 8 weeks after vaccination. A: Flow cytometric analysis of (co-)expression 
of Treg markers CD25, CD39, and Foxp3 on CD4+ and CD8+ T-cells in unstimulated PBMCs and PBMCs 
stimulated for 6 days with live BCG. The gating strategy was similar as that described in Supplementary figure 
S2A, with the addition of a LIVE/DEAD vivid stain. B: Treg markers on CD8+ but not CD4+ T-cells were 
significantly activated 6 days after in vitro live BCG stimulation, compared to unstimulated PBMCs, at 8 weeks 
post-vaccination. On CD4+ T-cells, only expression of CD25 was significantly different from unstimulated 
samples (box-whiskers of all individuals, with line at median; whiskers minimum (min) to maximum (max)). C: 
Co-expression of Treg markers is significantly activated by live BCG on CD8+ but not CD4+ T-cells 8 weeks after 
BCG-vaccination (box-whiskers of all individuals, with line at median; whiskers min to max) (*p < 0.05; **p < 
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CD8+, but not CD4+ T-cells express regulatory markers after live BCG stimulation in 
vitro 
PBMCs were stimulated for 6 days with live BCG to assess the expression of the regulatory 
markers CD25, Foxp3, CD39, lymphocyte activation gene-3 (LAG-3) and CCL4 
(macrophage inflammatory protein-1β) by FACS-analysis [22;34;35] (gating strategy in 
Supplementary figure S2A). BCG-induced expression of Treg markers on CD4+ and CD8+ 
T-cells was then compared to that on unstimulated control samples at 8 weeks post-
vaccination, the peak response (figure 3A). Expression of the single Treg markers CD25, 
Foxp3, CD39, LAG-3 and CCL4 was significantly induced on CD8+ T-cells by in vitro live 
BCG stimulation 8 weeks post-vaccination (p < 0.01 for CD25, Foxp3 and CCL4; p < 
0.001 for CD39 and LAG-3). In contrast, on CD4+ T-cells only CD25 was significantly 
induced by BCG stimulation (p < 0.05) (figure 3B).  
We then analysed co-expression of Treg markers using Boolean gating with synchronized 
gates on a per-donor basis for both CD4+ and CD8+ T-cells [22]. Co-expression of Treg 
markers was significantly induced on CD8+ but not CD4+ T-cells by in vitro live BCG 
stimulation 8 weeks post-vaccination (figure 3C; p < 0.001). On CD4+ T-cells, no 
expression of CD25+Foxp3+CD39+ was induced in either high or low inflammation 
responders (Supplementary figure S5).   
 
 
CD8+CD25+CD39+Foxp3+ T-cells increase post-vaccination only in low inflammation 
responders 
We then compared Treg markers on CD8+ T-cells post- and pre-vaccination; figure 4A 
displays a representative flow cytometric analysis of induction of CD25+CD39+ co-
expression and expression of Foxp3 on CD25+CD39+ CD8+ T-cells from a low skin 
inflammation responder. Compared to pre-vaccination, BCG-vaccination significantly 
induced CD8+CD25+Foxp3+CD39+ T-cells as well as CD8+CD25+Foxp3+CD39+LAG-
3+CCL4+ T-cells, but only in low inflammation responders (figure 4B; p = 0.031 at 8 weeks 
post-vaccination; p = 0.031 at 4 and 8 weeks post-vaccination, resp.). In contrast, in high 
inflammation responders, the expression of CD25+Foxp3+CD39+ or CD25+Foxp3+ 
CD39+LAG-3+CCL4+ on CD8+ T-cells post-vaccination did not differ from the patterns 
pre-vaccination (figure 4B).  
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Figure 4. BCG-vaccination induces CD8+CD25+CD39+Foxp3+ T-cells in low inflammation responders.  
A: Representative flow cytometric analysis of co-expression of the Treg markers CD25 and CD39 on CD8+ T-cells 
of a recipient with a low degree of skin inflammation (upper graphs), and the percentage of CD8+CD25+CD39+ T-
cells expressing Foxp3 (lower graphs; black overlay of CD8+CD25+CD39+ T-cells over total CD8+ T-cells), 6 days 
after live BCG stimulation of PBMCs. B: Treg markers are significantly induced by BCG-vaccination on PBMCs 
stimulated with live BCG for 6 days, but only on CD8+ T-cells from low inflammation responders. The frequency 
of Treg markers remained constant pre- and post-vaccination on CD8+ T-cells from high inflammation responders. 
Depicted are CD25+Foxp3+CD39+ co-expression (upper graphs) and CD25+Foxp3+CD39+LAG-3+CCL4+ co-
expression (lower graphs) on CD8+ T-cells of low responders (left) versus high responders (right) (box-whiskers 
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Of interest, CD8+CD25+Foxp3+CD39+ T-cells and CD8+CD25+Foxp3+CD39+LAG-
3+CCL4+ T-cells were still significantly increased 1 year post-vaccination in low 
inflammation responders (for both p = 0.031), suggesting that BCG-vaccination can induce 
long-term imprinting of CD8+ Treg phenotypes in individuals with low inflammation 








In this study, we describe high inter-individual variability in T-cell cytokine and regulatory 
responses following BCG-vaccination of BCG-naive healthy young adults in a setting 
where TB is not endemic. The unexpectedly dichotomous T-cell response consisted of 
either concurrent induction of IL2-, TNFα- and IFNγ- co-expressing polyfunctional CD4+ 
T-cell subsets, CD4+IL17A+ T-cells, and CD8+IFNγ+ T-cells in high inflammation 
responders, or an almost absent cytokine response accompanied by the induction of CD8+ 
regulatory T-cells in low inflammation responders. We quantified local reactivity by 
classical clinical symptoms of inflammation and found that the total skin inflammation 
score correlated with serum CRP early post-vaccination. Significant induction of 
IFNγ+IL2+TNFα+-polyfunctional CD4+ T-cells was confined to high inflammation 
responders, while the induction of regulatory-phenotype CD8+CD25+CD39+Foxp3+ and 
CD8+CD25+Foxp3+CD39+LAG-3+CCL4+ T-cells was confined to low inflammation 
responders.  
In theory, this study could have been limited by the description of T-cell responses based 
on the skin inflammation score, since dividing high and low skin inflammation groups 
using the median as cut off dichotomizes the described response. However, the dichotomy 
was also based on the induction of polyfunctional CD4+IFNγ+IL2+TNFα+ T-cells, and this 
revealed a significantly increased total skin inflammation score in vaccinees with CD4+ 
polyfunctional T-cells, compared to vaccinees with no polyfunctional CD4+ T-cell 
induction. Thus, it is unlikely that the described variability in responses is caused by a 
dichotomized representation, and this further affirms the relation between skin reactivity 
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and cytokine responses. Further, the opposing immune responses and phenotypes were 
observed within a relatively small cohort. Variability in BCG-immunogenicity has been 
ascribed to differences in pre-existing anti-mycobacterial responses in endemic vs. non-
endemic settings [36;37], the presence of helminth infections [38], variations in the BCG-
vaccine strain [39;40], and host genetic factors [41]. In addition, timing of sampling and 
technical variability may influence detection of cytokines [42;43]. This cohort, though 
small, was uniform in terms of age, genetic background, BCG-vaccine strain (Danish strain 
1331), sampling and testing, in a setting not endemic for TB or helminth infections. This 
excludes the above-mentioned possible confounders, and points to an unexpectedly large 
variation in adult human primary BCG-vaccine induced immune responses.  
Importantly, we confirmed vaccine take at 1 year post-vaccination by IFNγ-ELISpot, which 
was positive for both high and low inflammation responders. IFNγ-ELISpot has been 
described as the most sensitive assay for detecting long-term vaccine responses [29] and is 
used in TB-vaccine trials to describe the magnitude of vaccine-induced immunity. 
However, a sole reliance on IFNγ-ELISpot would disregard variability in other assays, 
thereby not fully capturing possible correlations between variation of the human immune 
response and vaccine-induced protection. The etiology of this variation remains unknown, 
but its unravelling could contribute significantly to a better understanding of BCG and 
related TB-vaccine induced immunity.      
The height of the in vitro cytokine response in BCG-vaccinated infants was associated with 
scarring of the BCG-vaccination site, but only in response to mycobacterial antigens, not 
unrelated antigens [44]. Also, cell-mediated immunity, as assessed by a leukocyte 
migration inhibition test, correlated with infant local skin reactivity 8 weeks after BCG-
vaccination, but not with TST-conversion after vaccination [45]. The absence of an 
association between BCG-induced TST-conversion and immunity against TB has been 
confirmed in various populations [46]. Here, induction of cytokine responses was confined 
to recipients with high skin reactivity, suggesting that a simple phenotype like vaccine-
induced skin inflammation might be used as a marker of strong pro-inflammatory T-cell 
induction in adults. The skin inflammation score was associated with serum CRP 
concentration 7 days post-vaccination, thus the absence of an increase in CRP early post-
vaccination might be used as an indicator of absent pro-inflammatory T-cell responses at 
later time-points.    
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Interference of CD4+ Tregs with effector immunity has been described in active TB 
[47;48]. Following MVA-85A-vaccination circulating CD4+CD25+Foxp3+ T-cells were 
increased in recipients with low antigen 85A-specific IFNγ-responses compared to high 
IFNγ-responders [28], and MVA-85A-induced CD4+ Tregs inhibited IL17A-production in 
vitro [49]. Interestingly, IL10-producing CD8+ Tregs were described in TB-patients anergic 
to intradermally injected PPD [50]. Thus, Tregs can interfere with inflammatory and 
specific antigen-induced cytokine responses. We previously reported in vitro activation of 
CD8+ (but not CD4+) Tregs by live BCG, both phenotypically and functionally, in 
mycobacterially-sensitized but not PPD-unresponsive donors [22;34;35]. These BCG-
activated CD8+ Tregs expressed CD25 and LAG-3 and inhibited Th1-responses through 
secretion of CCL4 [35]; in addition, we reported CD8+CD39+ Tregs which utilized CD39 to 
suppress Th1 proliferation [34]. Here, we found that CD8+CD25+CD39+Foxp3+ and 
CD8+CD25+Foxp3+CD39+LAG-3+CCL4+ T-cells were induced following BCG-
vaccination. Interestingly, the frequency of CD8+ T-cells with these Treg phenotypes was 
significantly increased only in comparison to that at pre-vaccination in low inflammation 
responders with low to absent cytokine responses, suggesting an inverse relation between 
the induction of CD8+ Tregs and BCG-induced skin inflammation with T-cell cytokine 
production.  
In murine leishmaniasis, cytokine-producing polyfunctional T-cells were inversely 
correlated with lesion size after (dermal) challenge [6]. In dermal BCG-challenge models in 
humans, vaccination-induced IFNγ-ELISpot-responses were inversely correlated with PCR 
quantification of BCG-load in biopsy specimens of the challenge site [51]. The PCR 
quantification method was suggested as a measure of pathogen clearance, possibly 
reflecting some degree of protective immunity, which might be used in human TB-vaccine 
trials. Based on the current study, it will also be relevant to assess the presence of pro-
inflammatory vs. regulatory T-cells in skin vaccine or challenge lesions and to further 
validate the modulation of skin inflammation and/or pathogen clearance by CD8+ Tregs in 
relevant models. Of note, in low inflammation responders CD8+CD25+Foxp3+CD39+ T-
cells were still significantly increased at 1 year post-vaccination, suggesting that BCG-
vaccination can induce long-term imprinting of a CD8+ Treg phenotype with a significant 
memory component. Further work is needed to assess their precise longevity. 
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In conclusion, our results show an unexpectedly dichotomous host response to BCG-
vaccination in a cohort of BCG-naive adults. It will be important to assess these divergent 
outcomes in settings where TB is endemic in order to determine the impact of these highly 
variable outcomes on protective efficacy against TB. The use of classical inflammation 
markers as non-classical indicators of vaccine-induced pro-inflammatory responses might 
be a simple means to assist in assessing BCG-induced phenotypes, even in small cohorts. 
Further detailed fine mapping of the heterogeneous host response to BCG-vaccination using 
classical and non-classical immune markers will enhance our understanding of the 
mechanisms and determinants that underlie the induction of apparently opposite immune 
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Supplementary figure S1. IFNγ-ELISpot results at 1 year after vaccination. Ex vivo IFNγ-ELISpot assays 
using freshly isolated PBMCs were performed 1 year after vaccination to verify vaccine-induced immunity. The 
person that lacked positive response by ELISpot demonstrated high IFNγ-responses in flow cytometric analysis, 
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Supplementary figure S2. Gating strategy and cytokine expression. S2A, gating strategy: for flow cytometric 
analysis of fixed whole blood samples, cells were gated on single cells, lymphocytes, CD3+ vs. CD14-CD19-
CD56-negative, and CD8+CD4- vs. CD4+CD8-. For PBMCs six days after live BCG-stimulation, a violet-
live/dead-stain was added prior to extracellular staining and cells were gated on CD3+ vs. (live/)dead-CD14-
CD19-CD56-negative. S2B, expression of cytokines in CD4+ T-cells: cytokine production by CD4+ T-cells after 
overnight live BCG-stimulation of whole blood; also depicted are unstimulated and SEB controls. No co-
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Supplementary figure S3. CD4+ cytokine-producing subsets and memory compartment in high skin 
inflammation responders. Supplementary S3A, CD4+ cytokine-producing subsets; whole-blood samples 
stimulated with live BCG for 16 hours and subsequent intracellular cytokine staining: almost all BCG-induced 
CD4+ cytokine-producing subsets peaked at 8 weeks after vaccination. CD4+ cytokine-producing subsets of high 
skin inflammation responders at 4, 8 and 12 weeks after vaccination were compared with pre-vaccination (*p < 
0.05 in Friedman with Dunn’s multiple comparison test).  
  





















IFNγ + + + - + - -
IL2 + + - + - + -
TNFα + - + + - - +






Chapter 5    
 






Supplementary figure S3 (continued). CD4+ cytokine-producing subsets and memory compartment in high 
skin inflammation responders. Supplementary S3B, memory compartments of CD4+ cytokine-producing 
subsets: the majority of single-, double- and triple-cytokine producing T-cells are effector cells, in whole-blood 
samples stimulated with live BCG for 16 hours. Pie chart representation of the proportion of effector (CD69+), 
effector memory (CD69-CD45RA-CD62L-), central memory (CD69-CD45RA-CD62L+) and naïve (CD69-
CD45RA+CD62L+) CD4+ T-cells for different cytokine-producing subsets as derived by Boolean gate analysis. 
Only populations of > 50 cells were included for analysis with a minimum of 3 donors per visit. Effector cell 
proportions were not significantly different between cytokine-producing subsets or between visits (p < 0.05 
deemed significant, Kruskal-Wallis with Dunn’s multiple comparisons test). 
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S4A                                                                     S4 B 
 
Supplementary figure S4. Higher total skin inflammation score in vaccinees with CD4+ polyfunctional T-cell 
induction. Vaccinees were divided by IFNγ+IL2+TNFa+ CD4+ T-cell induction, and (cumulative) skin 
inflammation scores (A) and CRP concentration at day 7 (B) were compared. The skin inflammation score was 
significantly higher in vaccinees with induction of CD4+ polyfunctional T-cells, compared to vaccinees with no 
induction of CD4+ polyfunctional T-cells (threshold for CD4+ T-cell induction set at change from pre-vaccination 







Supplementary figure S5. CD25+CD39+Foxp3+ expression on CD4+ T-cells as ratio BCG-stimulated : non-
stimulated. Co-expression of CD25, Foxp3 and CD39 on CD4+ T-cells (on day 6 following PBMC stimulation 
with or without live BCG) was analyzed as the ratio BCG-stimulated : non-stimulated. BCG-vaccination did not 
induce significant induction compared to pre-vaccination of CD4+CD25+Foxp3+CD39+ T-cells (A); also, dividing 
recipients in high vs. low inflammation scores did not reveal any significant induction of Treg marker expression 
on CD4+ T-cells as compared to pre-vaccination (B) (dot plots with line at median for all recipients (A; n = 12) 
and recipients divided by skin inflammation score (B; 6 individuals in each group); significance considered as p < 
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Abstract 
In cancer and chronic infectious diseases, immune checkpoint-blockade of inhibitory 
receptors can enhance T-cell immunity. In tuberculosis (TB), a chronic infectious disease, 
prolonged antigen exposure can potentially drive terminal T-cell differentiation towards 
functional ‘exhaustion’: in human TB T-cells express PD-1 (programmed cell death 
protein-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). However, in murine 
TB not PD-1 but rather killer cell lectin-like receptor subfamily-G1 (KLRG1) was a 
superior indicator of terminal T-cell differentiation. We therefore compared expression of 
KLRG1, PD-1 and CTLA-4 on T-cells in different stages of human TB, and also analyzed 
their induction following BCG-vaccination. KLRG1, PD-1 and CTLA-4 expression were 
highest on in vitro BCG-stimulated CD4+ T-cells following recent TB-treatment; KLRG1 
and PD-1 expression on CD4+ T-cells in active - but not latent - TB were only slightly 
increased compared to healthy donors. BCG-vaccination induced KLRG1 expression on 
BCG-stimulated CD8+ but not CD4+ T-cells, while neither PD-1 nor CTLA-4 expression 
increased. KLRG1-expressing CD8+ T-cells exhibited markedly decreased proliferation, 
whereas PD-1+ T-cells proliferated after in vitro BCG stimulation. Thus, we demonstrate 
the presence of increased KLRG1-expressing T-cells in TB-treated individuals, and present 
KLRG1 as a marker of decreased human T-cell proliferation following BCG-vaccination. 
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Introduction 
Based on the tuberculin skin test (TST), it is estimated that one-third of the world 
population is latently infected with Mycobacterium tuberculosis (Mtb), the bacterium 
causing tuberculosis (TB) [1]. Among latently infected (HIV-negative) individuals 3 - 10% 
will develop active TB during their life-time [1;2], but it is not yet clear what determines 
the loss of immune control resulting in active disease versus latent, contained infection 
[3;4]. In chronic viral infections and cancers many studies have reported the existence of T-
cells expressing inhibitory receptors, also called terminally differentiated or ‘exhausted’ T-
cells, which are thought to be impaired in their proliferative capacity and/or function 
(referred to also as the chronic (infection) phenotype) [5]. Signaling through inhibitory 
receptors, such as PD-1 (programmed cell death protein 1; CD279) and CTLA-4 (cytotoxic 
T-lymphocyte-associated protein 4; CD152) diminishes the response of activated T-cells 
[6]; and blocking of ligand-receptor interactions through monoclonal antibodies to re-
activate and enhance the lymphocyte response has received great attention as 
immunotherapy in cancer [7]. The clinical impact of this immune checkpoint blockade, 
especially with αPD-1-, αCTLA-4-, αPDL1- and αPDL2- antibodies, or combinations 
thereof, has already been demonstrated in cancer patients, and to a lesser extent in patients 
with chronic infectious disease ([8;9], clinical trials of both are summarized in [5]).  
PD-1 has been extensively described as inhibitory marker on CD8+ as well as CD4+ T-cells 
in human chronic viral infections such as chronic HIV, hepatitis B (HBV) and hepatitis C 
(HCV) infection [10-13]. Also on CD4+ and CD8+ T-cells from patients with pulmonary 
TB, increased expression of PD-1 compared to healthy donors has been described [14;15]. 
In vitro blocking with antibodies against PD-1 or it’s ligands enhanced production of IFN , 
IL2 [14] and IL17 [15], inhibited apoptosis of IFN -producing T-cells [14] and enhanced 
Mtb-stimulated degranulation of CD8+ T-cells [16]. In addition, increased expression of 
CTLA-4 (on regulatory T-cells) has been reported in patients with active TB [17], as well 
as in latently infected individuals [18;19], compared to healthy donors.  
However, in murine TB infection not PD-1 but rather expression of KLRG1 (killer cell 
lectin-like receptor subfamily G member -1) marked terminally differentiated CD4+ T-cells, 
which had a short life span and high T-bet expression [20-22]. KLRG1 is expressed on 
murine and human NK-cells and antigen-experienced CD4+ and CD8+ T-cells [23]. 
Chapter 6    
 
- 140 - 
 
Ligation of KLRG1 with cadherins (ubiquitously expressed cell adhesion molecules [24]) 
triggers inhibitory signaling through decreased AKT (Ser473) phosphorylation [25], which 
is reversible through blocking KLRG1-ligand interaction [26]. In contrast to other chronic 
murine infection models, murine Mtb-specific PD-1+ T-cells were found to be proliferative, 
whereas KLRG1+ effector T-cells were reduced in their proliferative capacity; and 
following adoptive transfer in Mtb-infected mice, donor CD4+PD1+KLRG1LO T-cells 
downregulated PD-1 expression, but increased KLRG1 expression [20]. Moreover, 
decreased protective efficacy against TB-challenge by ESAT-6 specific KLRG1+ T-cells, 
compared to ESAT-6 specific PD-1+ T-cells, following murine adoptive transfer was 
recently demonstrated [21]. Only adoptive transfer into Mtb-infected but not uninfected 
mice steered differentiation of PD-1+ into KLRG1+ T-cells [20;21], indicating that exposure 
to mycobacterial antigen is essential in steering towards terminal differentiation.  
Thus, KLRG1 has been described as a key inhibitory marker of non-proliferating cells 
during murine Mtb infection; also after murine BCG-vaccination CD4+ and CD8+ T-cells 
upregulated KLRG1 expression [27]. In human mycobacterial infection, the existence of 
KLRG1+ T-cells has been suggested, but not compared to relevant control groups or 
complemented with functional data [28]. Here, we compared expression of KLRG1, PD-1 
and CTLA-4 on human T-cells in different stages of TB infection, and assessed 
mycobacterial induction of these cellular phenotypes in humans by comparing expression 
before and after BCG-vaccination of BCG-naive healthy adult volunteers. In addition, we 
compared the proliferative capacity of KLRG1-expressing and PD-1-expressing T-cells 
following BCG-vaccination. We found increased expression of KLRG1, PD-1 and CTLA-4 
in individuals that had recently been treated for TB, and minor increased expression in 
active TB patients. BCG-vaccination significantly induced CD8+KLRG1+ T-cells, which 
unlike CD8+PD-1+ T-cells, were markedly reduced in their proliferative capacity. Thus, we 
demonstrate for the first time KLRG1 as marker of non-proliferating T-cells following 
BCG-vaccination in humans. 
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Materials and Methods 
Patients and participants. This study was approved by the Ethical Committee of the L. 
Spallanzani National Institute of Infectious diseases ((INMI); approval number 10/2010) 
and the Medical Ethical Committee of the Leiden University Medical Center, the 
Netherlands (registration number P 12.87). Written informed consent was obtained from all 
participants in the study. All blood bank donors had signed consent for scientific use of 
blood products. 
In this study, active pulmonary TB was sputum culture confirmed and patients were 
enrolled within 7 days of starting treatment. Cured-TB subjects were patients who had 
completed 6 months of treatment for culture-positive pulmonary TB and who resulted 
sputum culture-negative during treatment. These patients were evaluated after therapy 
completion (median time post-treatment 8 ± IQR 2.5 - 13.5 months). Latent Mtb infection 
was defined based on a positive response to QuantiFERON-TB gold in-tube test (QFT-IT) 
(Qiagen, Hilden, Germany) in healthy subjects without radiological signs of active disease 
[29]. Demographic and epidemiological information was collected at enrolment (Table 1). 
QFT-IT-negative contacts and healthy volunteers, as well as healthy adult blood bank 
donors (Sanquin blood bank, Leiden) that tested negative for recognition of mycobacterial 
PPD in vitro, were used as controls. PPD-reactivity was tested by stimulation of PBMCs 
with 5 μg/ml PPD (Statens Serum Institute, Copenhagen, Denmark) for 6 days and 
supernatants were tested in IFNγ-ELISA (U-CyTech, Utrecht, the Netherlands). Negativity 
was defined as IFNγ-production ≤ 150 pg/ml.  
For the study on the BCG-vaccination of Dutch volunteers, the recruitment occurred via 
posters in the university library. Included volunteers (6 males, 6 females; median age 24 ± 
IQR 23 - 25 yrs) were healthy, and had not been vaccinated with BCG at any time prior to 
enrolment, or with any live vaccination four weeks or less prior to BCG-vaccination. 
Volunteers were screened for TB by anamnesis, by tuberculin skin test (negative < 5mm) 
and by QFT-IT test. All patients and participants tested negative for HIV at screening and 
were not treated with immune-modulating drugs prior to enrolment. 
 
Procedures. BCG-vaccination with the live-attenuated BCG Danish strain 1331 (Statens 
Serum Institute) was by intradermal injection in the upper arm. Volunteers were followed at 
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two weeks prior to vaccination, at four, eight and twelve weeks and at one year after 
vaccination. Venous blood samples of patients and participants were collected for PBMC 
isolation by ficoll density centrifugation. PBMCs were cryopreserved in 10% DMSO and 
20% fetal calf serum-supplemented medium.  
 
Cell cultures and BCG-infection. PBMCs were thawed, counted (CASY cell counter, 
Roche, Woerden, the Netherlands) and in vitro infected with BCG. PBMCs were infected at 
a multiplicity of infection (MOI) of 1.5 - 3 and cultured in 24 well plates (2 x 106/w) for six 
days in Iscove's modified Dulbecco's medium (Life Technologies-Invitrogen, Bleiswijk, the 
Netherlands) with 10% human serum (pooled serum from blood bank donors, pretested for 
inhibitory activity) in an incubator at 370C with 5% CO2 [30;31].  
 
Flow cytometry. Stimulated PBMCs from TB patients, individuals with latent TB, 
individuals treated for TB, and healthy donors were labelled with violet live/dead stain 
(VIVID, Invitrogen) and surface stained with CD3-Brilliant Violet 570 (clone UCHT1), 
CD19-Pacific Blue (clone HIB19), KLRG1-Pe-Cy7 (clone 2F1/KLRG1) (all Biolegend, 
London, U.K.); CD56-Alexa 700 (clone B159), CD8-HorizonV500 (clone RPA-T8), PD-1-
PerCp-Cy5.5 (clone EH12.1) (all BD Biosciences, Eerembodegem, Belgium); CD14-
Pacific Blue (clone TüK4) and CD4-PE-Texas Red (clone S3.5) (both Life Technologies-
Invitrogen). Cells were fixed and permeabilized using FIX&PERM® Cell Permeabilization 
Kit (An Der Grub BioResearch GMBH, Susteren, the Netherlands). For intracellular 
staining CTLA-4 (cytotoxic T-lymphocyte protein 4; CD152)-PeCy5 (clone BNI3; BD 
Biosciences) was used.  
Stimulated PBMCs from BCG-vaccinated participants were labelled with violet live/dead 
stain (VIVID) after incubation for the last 16 hours with αCD3/28 beads (Invitrogen) and 
Brefeldin A (3 μg/ml, Sigma-Aldrich, Zwijndrecht, the Netherlands). PBMCs were surface 
stained with CD3-Brilliant Violet 570 (clone UCHT1), CD19-Pacific Blue (clone HIB19), 
CD56-Brilliant Violet 421 (clone HCD56), KLRG1-Pe-Cy7 (clone 2F1/KLRG1) (all 
Biolegend, London, U.K.); CD14-Pacific Blue (clone TüK4), CD4-PE-Texas Red (clone 
S3.5) (both Life Technologies-Invitrogen); CD8-HorizonV500 (clone RPA-T8) and PD-1-
PerCp-Cy5.5 (clone EH12.1) (both BD Biosciences). Fixation, permeabilization and 
intracellular staining were performed as described above. Samples were acquired on a BD 
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LSRFortessa using FACSDiva software (version 6.2, BD Biosciences). Analyses were 
performed using FlowJo software (version 9.5.3, Treestar, Ashland, OR, USA). Gates were 
defined per donor for CD4+ and CD8+ T-cell subsets (and for all visits after vaccination) 
using unstimulated samples and SEB (Toxin Technology, Sarasota, FL, USA)-stimulated 
samples as controls. 
 
CFSE proliferation assays. Stimulated PBMCs from BCG-vaccinated participants were 
harvested, labelled with 5 μM of CFSE, and cultured in 96 well plates (1 x 105/w) in 
Iscove's modified Dulbecco's medium (Life Technologies-Invitrogen) with 10% pooled 
human serum. PHA (Remel Europe) was used as a positive control for proliferation of 
CFSE-labelled cells. After 6 days cultures were harvested and stained with KLRG1-Pe-Cy7 
(clone 2F1/KLRG1) and CD56-Brilliant Violet 650 (clone HCD56) (both Biolegend, 
London, U.K.); CD14-Pacific Blue (clone TüK4), CD4-PE-Texas Red (clone S3.5) (both 
Life Technologies-Invitrogen); CD8-HorizonV500 (clone RPA-T8), PD-1-Alexa 647 
(clone EH12.1) and CD3-PeCy5 (clone UCHT1) (all BD Biosciences). Samples were 
acquired on a BD LSRFortessa using FACSDiva software. Analyses were performed using 
FlowJo software (version 9.5.3, Treestar). 
 
Analyses. Using GraphPad Prism (version 6, GraphPad Software, La Jolla, CA, USA) 
Mann-Whitney tests were used for non-paired samples; Kruskal-Wallis with Dunn’s 
multiple test correction was used for non-parametric unpaired comparisons between more 
than 2 groups. Wilcoxon signed-rank tests were used for paired samples, after correction for 




Expression of the inhibitory markers KLRG1, PD-1 and CTLA-4 after in vitro 
stimulation of PBMCs 
PBMCs were isolated from patients with active TB (n = 11); individuals with latent TB 
infection (n = 13); successfully treated cured-TB subjects (n = 15; median time post-
treatment 8 ± IQR 2.5 - 13.5 months); and healthy donors (n = 16). All samples from active 
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TB patients were collected within the first week of treatment. Further demographic and 




 HD* LTBI Active TB Cured TB Total p-value 
Enrolled subjects 6* 13 11 15 45  












Female gender (%) 2 (33) 11 (85) 2 (18) 10 (67) 25 (65) 0.0062 
 
Origin N (%)      0.092 
Western Europe 4 (67) 8 (62) - 5 (33) 17 (38)  
Eastern Europe 1 (17) 3 (23) 8 (73) 5 (33) 17 (38)  
Asia - - 1 (9) - 1 (2)  
Africa - 1 (8) 1 (9) 3 (20) 5 (10)  
South America 1 (17) 1 (8) 1 (9) 2 (13) 5 (10)  
 
BCG N (%)      0.0152 
Vaccinated 3 (50) 5 11 (100) 10 (67) 29 (64)  
Unvaccinated 3 (50) 8 0 (0) 5 (33) 16 (36)  
 
 
Table 1. Demographic and clinical characteristics of the subjects enrolled in the study. 
Footnotes: TB: Tuberculosis; LTBI: Latent Tuberculosis Infection; IQR: Interquartile range; BCG: Bacillus 
Calmette-Guérin. *Additional healthy donors were included in the study: anonymous samples were obtained 
from the Dutch blood bank, therefore no information was available in terms of age, sex, origin and BCG 
status.1Kruskal-Wallis test; 2 Chi-square test. 
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PBMCs were stimulated with live M. bovis BCG (BCG) and analyzed for expression of 
KLRG1, PD-1 and CTLA-4 after six days. The gating strategy for flowcytometric analysis 
is shown in figure 1A and B, and is compliant with recent MIATA guidelines [32]. 
Activation of CD4+ and CD8+ T-cells was evaluated by calculating the CD4+ or CD8+ 
frequency of CD3+ parent as CD4+ : CD8+ ratio; this was similar between groups (data not 
shown). Positive populations of KLRG1, PD-1 and CTLA-4 expression by CD4+ and CD8+ 
T-cells were defined by comparison with unstimulated samples (figure 1B), and gates were 








Figure 1. Expression of KLRG1, PD-1 and CTLA-4 after in vitro stimulation of PBMCs. A: Gating strategy 
for flowcytometric analysis of PBMCs six days after in vitro stimulation with live BCG. Cells were gated on 
single cells, lymphocytes, violet-(live/)dead- CD14- CD19- CD56-negative, CD3+, and CD4+CD8- vs. CD8+CD4-. 
B: Positive populations for KLRG1, PD-1 and CTLA-4 expression were defined by comparison with unstimulated 
samples, as demonstrated for expression of KLRG1, PD-1 and CTLA-4 on CD4+ T-cells six days after BCG 
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Highest expression of KLRG1, PD-1 and CTLA-4 is found on CD4+ T-cells in TB-
treated individuals 
The expression of KLRG1 following six day in vitro BCG stimulation was significantly 
increased on CD4+ T-cells from cured-TB individuals (p = 0.030 between groups in 
Kruskal-Wallis test with Dunn’s multiple test correction; p = 0.018 for cured-TB 
individuals compared to healthy donors in Mann-Whitney test; figure 2A). The frequency 
in BCG-stimulated samples relative to the frequency in unstimulated samples (expressed as 
the ratio BCG : non-BCG) was compared between groups. This demonstrated a trend 
towards an increased ratio of KLRG1 expression on CD4+ T-cells and CD8+ T-cells from 
cured-TB subjects, compared to healthy donors (p = 0.019 and p = 0.024 resp., Mann-
Whitney test), but this was not significant after multiple test correction (figure 2A).  
There was an interesting trend towards an increased frequency of CD4+KLRG1+ T-cells in 
active TB patients - and not in individuals with latent TB infection - compared to healthy 
donors (p = 0.020, Mann-Whitney test, not significant following multiple test correction). 
On CD8+ T-cells KLRG1 expression was not significantly different in individuals with 
active or latent infection compared to healthy donors (figure 2A). 
A similar pattern was observed for PD-1: distinctly increased expression on CD4+ T-cells in 
cured-TB subjects (p = 0.039 between groups in Kruskal-Wallis test with Dunn’s multiple 
test correction; p = 0.017 for cured-TB individuals compared to healthy donors in Mann-
Whitney test); and a trend towards an increased ratio (BCG : non-BCG) of CD4+ T-cells 
and CD8+ T-cells expressing PD-1 in cured-TB subjects compared to healthy donors (p = 
0.015 and p = 0.010 resp., Mann-Whitney test; not significant following multiple test 
correction; figure 2B). Similarly, in patients with active TB disease CD4+ T-cells - but not 
CD8+ T-cells - exhibited a trend towards increased expression of PD-1 compared to healthy 
donors (p = 0.031, Mann-Whitney test; not significant following multiple test correction). 
In cured-TB subjects the frequency of CTLA-4-expressing CD4+ T-cells was highest also 
(p = 0.017 between groups in Kruskal-Wallis test with Dunn’s multiple test correction; p = 
0.002 for cured-TB individuals compared to healthy donors in Mann-Whitney test; figure 
2C). CD8+ T-cells in cured-TB individuals exhibited a trend towards an increased 
frequency and ratio of CTLA-4 expression compared to healthy donors (p = 0.014 and p = 
0.019 resp., Mann-Whitney test; not significant following multiple test correction; figure 
2C). In latently infected individuals but not in active TB patients, the frequency of CTLA-4 
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-expressing CD4+ T-cells was moderately increased (p = 0.025, Mann-Whitney test; not 







Figure 2. Increased expression of KLRG1, PD-1 and CTLA-4 on T-cells from cured-TB patients. Expression 
of KLRG1, PD-1 and CTLA-4 was highest on six day BCG-stimulated CD4+ T-cells from cured-TB subjects. 
There was a trend towards an increased BCG : non-BCG ratio (as frequency in BCG-stimulated samples relative 
to the frequency in unstimulated samples) of KLRG1 and PD-1 expression on CD4+ and CD8+ T-cells, and of 
CTLA-4 expression on CD8+ T-cells, in cured-TB subjects compared to healthy donors. Active TB patients 
exhibited slightly increased expression of KLRG1 and PD-1 on CD4+ T-cells. Data are shown as scatter plots with 
line at median for 11 patients with active TB, 13 individuals with latent TB infection, and 15 cured-TB subjects, 
compared with 16 healthy donors (Mann-Whitney tests; *indicates not significant following Kruskal-Wallis test 
with Dunn’s multiple test correction). 
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Four out of 13 latently infected individuals received preventive therapy with isoniazid, but 
no trend or significant association was observed between preventive therapy and expression 
of KLRG1, PD-1 or CTLA-4. In addition, in cured-TB subjects no association was 
observed between inhibitory marker expression and either time post-treatment (median 8 ± 
IQR 2.5 - 13.5 months) or age (median 33 ± IQR 25 - 49.5 yrs) (data not shown).  
 
BCG-vaccination induces expression of KLRG1 on CD8+ T-cells in BCG-naive 
healthy adults 
To assess the mycobacterial induction of inhibitory molecules on human T-cells, we 
compared the cellular expression of the above markers before and after BCG-vaccination of 
healthy adult volunteers. Only among CD8+ T-cells a significantly increased frequency of 
KLRG1-expressing cells was found, at 4, 8 and 12 weeks post-vaccination compared to 
pre-vaccination baseline (p = 0.006 in Friedman test with Dunn’s multiple test correction; p 
= 0.001, p = 0.002, p = 0.009 in Wilcoxon signed-rank tests resp. 4, 8 and 12 weeks post-
vaccination compared to pre-vaccination; figure 3A), following in vitro-stimulation with 
BCG. Also KLRG1 expression relative to unstimulated cells (ratio BCG-stimulated : 
unstimulated) was significantly induced on CD8+ but not CD4+ T-cells compared to pre-
vaccination (p = 0.050 in Friedman test with Dunn’s multiple test correction; p = 0.016 and 
p = 0.007, 4 resp. 8 weeks after vaccination in Wilcoxon signed-rank tests; figure 3A). One 
year after vaccination, the frequency and relative expression of CD8+KLRG1+ T-cells had 
returned to pre-vaccination values (figure 3A). 
Remarkably, BCG-vaccination did not induce expression of either PD-1 nor CTLA-4 on in 
vitro BCG-stimulated CD4+ or CD8+ T-cells compared to pre-vaccination in cells in vitro 
stimulated with BCG; also the expression of PD-1 and CTLA-4 on CD4+ and CD8+ T-cells 
relative to unstimulated cells (ratio BCG-stimulated : unstimulated) did not increase 
compared to pre-vaccination baseline (relative expression of PD-1 and CTLA-4 on CD4+ 
and CD8+ T-cells demonstrated in figure 3B and C).  
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Figure 3: BCG-vaccination induces KLRG1 expression on CD8+ T-cells in BCG-naïve healthy adults.  
A, upper panels: KLRG1 expression is significantly induced on CD8+ T-cells, but not on CD4+ T-cells, after BCG-
vaccination of healthy adults 4, 8 and 12 weeks after vaccination (stimulated samples compared to pre-vaccination 
in Friedman test with Dunn’s multiple test correction followed by Wilcoxon signed-rank test). A, lower panels: 
KLRG1 expression relative to unstimulated samples (ratio BCG-stimulated : unstimulated) is significantly 
increased on CD8+, but not on CD4+ T-cells, 4 and 8 weeks after vaccination (compared to pre-vaccination in 
Friedman test followed by Wilcoxon signed-rank test). Results from 12 vaccinees as box-whiskers (line at median, 
whiskers min. - max.), or as dot plot (line at median), resp., at pre-vaccination, at 4, 8 and 12 weeks, and 1 year 
after vaccination. B, C: Neither PD-1 nor CTLA-4 expression is significantly induced on CD4+ or CD8+ T-cells 
after BCG-vaccination, neither as frequency nor as relative to unstimulated samples (ratio BCG-stimulated : 
unstimulated), compared to pre-vaccination. Results are shown as  ratios for BCG-stimulated : unstimulated for 
PD-1 (B) and CTLA-4 (C) expression on CD4+ and CD8+ T-cells for 12 vaccinees (dot plots, line at median).   
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KLRG1 expression marks CD8+ T-cells with reduced proliferation 
To evaluate possible functional consequences of KLRG1 induction on CD8+ T-cells 
following BCG-vaccination, we studied the proliferative capacity of CD8+ T-cells, 
CD8+KLRG1+ T-cells, and CD8+PD-1+ T-cells after vaccination. Following 6 day in vitro 
BCG stimulation, cells were CFSE-labelled and after another six days stained and analyzed 
by flowcytometry. BCG-activated CD8+KLRG1+ T-cells displayed markedly reduced 
proliferation compared to the total CD8+ population and compared to PHA-stimulation 
induced CD8+ T-cell proliferation (representative overlay histograms of cell proliferation 
12 weeks after vaccination displayed in figure 4A and B). In contrast, the PD-1+ fraction of 
CD8+ T-cells displayed enhanced proliferative capacity compared to the total CD8+ 
population (figure 4B displays proliferation of total CD8+ T-cells, CD8+PD-1+ T-cells and 







Figure 4. BCG-stimulated CD8+KLRG1+ T-cells show reduced proliferation compared to CD8+PD-1+ T-
cells. A: In vitro BCG-stimulated cells of BCG-vaccinated donors were CFSE-labelled after 6 days, and after 
another 6 days stained for flowcytometric analysis (gated on single cells, lymphocytes, CD14-CD56-negative, 
CD3+, and CD4+CD8- vs. CD8+CD4-). Figure 4A displays representative overlay histograms of cell proliferation of 
CD8+ T-cells (shaded light grey) and the PHA-stimulated control cell line (also gated on CD8+; shaded dark grey) 
of a BCG-vaccinated donor 12 weeks after BCG-vaccination. B: KLRG1 expression on BCG-activated CD8+ T-
cells denotes cells with reduced proliferative capacity in a CFSE proliferation assay: overlay histogram with CD8+ 
T-cells (shaded light grey) as in (A); also cell proliferation of CD8+KLRG1+ T-cells (black line) and of CD8+PD-
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Relative cellular proliferation was then obtained by dividing total CD8+ CFSE intensity by 
CD8+KLRG1+ and CD8+PD-1+ CFSE intensity. At 4, 8 and 12 weeks after BCG-
vaccination the relative cell proliferation of CD8+KLRG1+ T-cells was significantly 
decreased, while CD8+PD-1+ relative T-cell proliferation was significantly increased, 
compared to the total CD8+ population. Thus, these data indicate that KLRG1 expression 
identifies non-proliferating CD8+ T-cells after BCG-vaccination, whereas CD8+PD-1+ T-
cells are proliferating (figure 4C; p < 0.001 for CD8+KLRG1+ and CD8+PD-1+ T-cells at all 






FIGURE 4 (continued). BCG-stimulated CD8+KLRG1+ T-cells show reduced proliferation compared to 
CD8+PD-1+ T-cells. C: The relative cell proliferation of CD8+KLRG1+ T-cells is decreased, whereas the relative 
cell proliferation of BCG-activated CD8+PD-1+ T-cells is increased after BCG-vaccination compared to pre-
vaccination baseline; scatter plots with line at median 4, 8 and 12 weeks post-vaccination (resp. 6, 6 and 5 BCG-
vaccinated donors) are shown. To obtain cell proliferation relative to total CD8+ T-cell proliferation, the geometric 
mean of CFSE intensity of CD8+ T-cells was divided by the geometric mean of CD8+KLRG1+, or CD8+PD-1+ T-
cells; and the relative cell proliferation of CD8+KLRG1+ and CD8+PD-1+ T-cells was tested against the theoretical 
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Discussion 
In this study, we studied and compared expression of KLRG1, PD-1 and CTLA-4 on 
human T-cells in different stages of TB-infection/disease and assessed mycobacterial 
induction of these markers in humans. Expression of KLRG1, PD-1 and CTLA-4 was 
increased most on in vitro BCG-stimulated T-cells of cured-TB subjects, and expression of 
KLRG1 and PD-1 was mildly increased on CD4+ T-cells in active TB patients, compared to 
healthy donors. BCG-vaccination of BCG-naïve adults induced KLRG1 expression on 
CD8+ T-cells, and CD8+KLRG1+ T-cells had - in contrast to CD8+PD-1+ T-cells - a 
markedly reduced proliferative capacity.  
We found the highest expression of KLRG1, PD-1 and CTLA-4 on T-cells from cured-TB  
individuals. In contrast, others have reported a decrease of PD-1 expression during TB-
therapy in humans and mice, and of KLRG1 expression in mice [15;33]. Also in contrast to 
our observation of a mild increase in KLRG1 and PD-1 expression in active disease, others 
have reported no modulation of PD-1 expression during active TB [34]. However, in South-
African active TB patients the proliferative capacity of CD4+ and CD8+ T-cells was 
impaired compared to latently infected individuals [35], which may suggest that continued 
antigen exposure could drive a progressive loss of T-cell functionality associated with 
progression to active disease. Interestingly, in these South-African TB patients the 
impairment in the proliferative capacity of Mtb-induced T-cells was not restored during or 
months after treatment [36].  
In murine Listeria and vaccinia infection models, CD8+KLRG1+ T-cells exhibited reduced 
proliferative capacity but optimal cytolysis and infection control compared to KLRG1- T-
cells [37]. However, in murine Mtb-infection KLRG1-, IL-2-secreting central memory T-
cells exhibited optimal infection control [38]. We did not assess the cytokine-secreting 
capacity of KLRG1+ T-cells, but in murine Mtb-infection KLRG1 expression was generally 
inhibitory, and KLRG1-/- mice had both increased pulmonary CD4+ T-cell IFN  production 
and survived longer following Mtb infection [39]. Indeed, murine PD-1+KLRG1- T-cells 
exhibited increased polyfunctionality compared to PD-1-KLRG1+ T-cells [20-22]. 
The high expression of inhibitory markers in recently cured-TB individuals could be 
explained as a consequence of antigen presence following antibiotic treatment. In murine 
LCMV, demethylation of the promotor region of the PD1-encoding gene (Pdcd1) was 
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stable after viral titers had fallen below detection levels [40]; also in HIV-elite controllers 
or long-term treated individuals such demethylation was persistent [41]. After HCV 
infection, PD-1 was equally expressed on HCV-specific T-cells from individuals that had 
cleared infection and from chronic HCV patients [42], suggesting a stable phenotype 
independent of the pathogen load (reviewed in [5]). Also in our study, the expression of 
PD-1 on T-cells from TB-treated individuals may be thus explained as an epigenetically 
conserved and stable phenotype independent of antigen exposure. Longitudinal studies with 
prolonged follow up times will be needed to establish the kinetics of these possibly 
epigenetically regulated phenotypes.  
Importantly, it was recently demonstrated that in murine TB, PD-1-expressing T-cells have 
stable memory-like properties: these cells sustain a T-cell pool in the absence of antigen 
and expand after re-exposure; then they partly differentiate into KLRG1+ T-cells [21]. PD-1 
(as well as CTLA-4) is ubiquitously expressed on immune cells [7;13], and PD-1+ T-cells 
probably represent a highly heterogeneous T-cell pool in TB [43]. PD-1 serves as an 
important brake on immune cells [7], illustrated by the reported lethal immunopathology 
following Mtb infection of PD-1-/- mice [44;45]. In the light of their polyfunctionality and 
protective capacity [21], PD-1+ T-cells - at least in murine TB - could thus be proliferating 
precursors that maintain long-term responses against TB, differently from the role of PD-1+ 
T-cells in other infection models [43]. In these murine TB-models KLRG1 is a powerful 
marker of terminal differentiation and functional exhaustion compared to PD-1. 
Furthermore, it was suggested that after TB-treatment the presence of pro-apoptotic T-cells 
indicated a deregulated memory component, enhancing host susceptibility towards 
recurrent disease [30]. Future research should delineate whether in human TB the 
expression of KLRG1 (or PD-1) is a risk factor towards disease progression, and whether 
KLRG1 rather than PD-1 indicates functional exhaustion. Due to the cross sectional design 
of our study, it remains unclear whether in Mtb-infected humans PD-1+ T-cells differentiate 
into KLRG1+ T-cells and whether antigen re-exposure is involved.  
We found that BCG-vaccination induced KLRG1, but not PD-1 or CTLA-4 expression on 
T-cells. Also in murine BCG-vaccination expansion of KLRG1+ but not PD-1+ T-cells was 
observed [27], and T-cells from BCG-vaccinated individuals did not express PD-1 [46], in 
contrast with latently infected individuals [14;46;47]. Importantly, in Mtb-infected mice 
intravascular effector T-cells exhibited high KLRG1 expression, and only KLRG1- T-cells 
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were capable of entering the lung parenchyma to mediate protective immunity [48]. Lung 
tissue-resident KLRG1- Th1 cells expressed high levels of PD-1 compared to intravascular 
effector T-cells, as well as CTLA-4 [48;49]. We thus cannot exclude that following 
vaccination PD-1+ and CTLA-4+ T-cells could have expanded at the inflamed skin 
vaccination site, while BCG-induced KLRG1+ T-cells would be sequestered in the 
circulation. It is conceivable that KLRG1 expression following BCG-vaccination could 
represent impaired protective efficacy in terms of decreased migratory potential.  
We found increased KLRG1 expression on CD4+ T-cells, and a slight enhancement in the 
ratio of KLRG1-expressing CD4+ T-cells and CD8+ T-cells, in cured-TB subjects compared 
to healthy donors. Interestingly, after BCG-vaccination we only found specific induction of 
KLRG1 expression on CD8+, but not CD4+ T-cells. Rapid early clonal proliferation of 
CD8+ T-cells has been demonstrated after antigen encounter [50], whereas clonal CD4+ T-
cell expansion occurs in response to repeated antigen stimulation, as during the course of 
infection and perhaps not sufficiently following a single vaccine dose, or due to specific 
immunomodulating properties of live BCG  [50]. In contrast, high antigen exposure during 
active TB disease and antigen release induced by chemotherapy could trigger clonal 
expansion of KLRG1-expressing CD4+ T-cells in TB-treated individuals. M. bovis BCG 
lacks the RD1-region that is present in Mtb, however it is unlikely that differences in the 
cytosolic processing of mycobacterial antigens account for the differences in CD4+KLRG1+ 
and CD8+KLRG1+ T-cell frequencies between the TB and BCG-vaccinated cohorts in this 
study: RD1-deficient bacteria generally induce lower, and not higher CD8+ T-cell activation 
[51]. Moreover, TB8.4-specific CD8+ T-cell clones were as activated by Mtb-infected DCs 
as by DCs infected with RD1-mutant Mtb strains [52].  
We demonstrated proliferating CD8+PD-1+ T-cells vs. non-proliferating CD8+KLRG1+ T-
cells following human BCG-vaccination, analogous to murine TB-vaccine models [22;53]. 
In murine BCG-vaccination KLRG1 expression on CD4+ and CD8+ T-cells increased 
during contraction of the immune response, which inversely correlated with proliferation, 
cytokine production, and immunity against TB-challenge [27;38]. In human HCV-
infection, increased KLRG1 expression and decreased IL2-production by CD4+ T-cells was 
found in HBV-vaccine non-responders, compared to HBV-vaccine responders, and in vitro 
KLRG1 blocking increased Akt (Ser473) phosphorylation, cell proliferation and IL-2 
production [54]. In our study the frequencies of circulating CD8+KLRG1+ T-cells returned 
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to baseline one year post BCG-vaccination. Future studies should determine whether the 
observed KLRG1+ T-cell expansion impacts a (neo)antigen vaccine response, whether 
blocking the KLRG1 signaling would enhance the vaccine response, and whether 
expression of KLRG1 (in any phase of the response) leads to a deregulation in the vaccine-
induced (central) memory formation.  
In conclusion, we demonstrate increased expression of KLRG1, PD-1 and CTLA-4 in 
individuals that had recently been treated for TB, and we describe for the first time - to the 
best of our knowledge - the induction of non-proliferating KLRG1+ CD8+ T-cells following 
BCG-vaccination in humans. Future research should delineate whether inhibitory marker 
expression leads to an increased susceptibility towards developing disease or a lack of 
vaccine-induced protective efficacy. Immune checkpoint inhibition studies will hopefully 
answer the question whether KLRG1-blockade is clinically feasible, safe and effective in 
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General conclusions 
There is no effective vaccine against pulmonary TB in adults. The only currently available 
TB-vaccine, M. bovis BCG, reduces the risk of severe TB in infants, but protection against 
pulmonary TB in adults is highly variable and only limited. This thesis aimed to identify 
cellular responses that may account for the variable efficacy of BCG-vaccination, by 
assessing the induction of regulatory, pro-inflammatory and inhibitory marker-expressing 
T-cell subsets by M. bovis BCG in adults.  
Many pathogens induce, recruit and expand regulatory T-cells that act at the interface of 
human host and pathogen in immunity against diseases and following vaccination (Chapter 
2). Besides ‘specific’ suppression, also heterologous suppression can impact on (vaccine-
induced) immunity. M. tuberculosis induces Tregs, and CD4+ Tregs were also 
demonstrated in M. bovis BCG-vaccinated infants and adults. CD8+ Tregs are less studied - 
and often even overlooked - compared to CD4+ Tregs, especially in infectious diseases and 
vaccination. BCG-induced CD4+ Tregs had been reported, but no comparative analysis of 
BCG-activated CD4+ vs. CD8+ Tregs existed. 
We studied the induction of CD4+ and CD8+ Tregs following in vitro M. bovis BCG-
stimulation of PBMCs isolated from PPD-reactive healthy human donors. Next, we 
compared suppressive activity of live vs. heatkilled BCG-stimulated T-cells, and compared 
suppressive activity of live BCG-stimulated T-cell subsets (Chapter 3). We found that live 
BCG-stimulation induced a regulatory T-cell phenotype that consisted predominantly of 
CD8+, and not CD4+ T-cells. Expression, co-expression, and expression level of regulatory 
markers was higher on BCG-activated CD8+ T-cells compared to CD4+ T-cells, and 
selection of T-cells on co-expression of regulatory markers indeed enriched for CD8+ T-
cells. Heatkilled BCG-activated T-cells were not suppressive, while in contrast live BCG-
activated T-cells suppressed proliferation of Th1-cells. The suppressive activity of live 
BCG-activated T-cells was mediated predominantly by CD8+ Tregs, and not by CD4+ T-
cells.   
CD39 (E-NTPDase1) has previously been described as a functionally active marker of 
mycobacteria-induced CD4+ Tregs, but has not been studied on mycobacteria-activated 
CD8+ Tregs. Chapter 4 demonstrates specific CD39-expression on CD8+ T-cells following 
live BCG-activation of PBMCs from PPD-responsive donors. CD8+ T-cell lines sorted on 
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CD39-expression were highly enriched in expression of (other) regulatory markers. Only 
CD8+CD39+ T-cells, but not CD8+CD39- T-cells suppressed proliferation of Th1 cells, and 
blocking of CD39 resulted in partial reversal of suppression by CD8+CD39+ T-cells. This 
demonstrates the functional involvement of CD39 in mediating suppression by in vitro live 
BCG-activated CD8+ Tregs.  
We then assessed - prospectively - the induction of primary pro-inflammatory and 
regulatory T-cell responses by BCG-vaccination of TST-negative, QuantiFERON test-
negative, and BCG-naive healthy adults (Chapter 5). The primary immune response 
following BCG-vaccination was unexpectedly dichotomous: we found either induction of 
IFNγ+IL2+TNFα+ polyfunctional CD4+ T-cells concurrent with CD4+IL17A+ and 
CD8+IFNγ+ T-cells, or virtually absent cytokine responses. Vaccine-induced skin 
inflammation correlated well with serum CRP early after vaccination, and induction of 
polyfunctional CD4+ T-cells and IFNγ production by PBMCs was confined to high skin 
inflammation responders. Treg induction by BCG-vaccination was also assessed. 
Analogous to the predominant activation of CD8+ Tregs following in vitro BCG activation 
of PBMCs from PPD-responders in Chapter 3, we found induction of the regulatory 
phenotype only within the CD8+ T-cell compartment, and did not find any significant 
induction of CD4+ Tregs following live BCG-stimulation. In notable contrast to 
polyfunctional CD4+ T-cell induction, the induction of CD8+ Tregs compared to pre-
vaccination was confined to low skin inflammation responders. Thus, following BCG-
vaccination highly variable and opposing immune responses were found already within a 
small adult cohort, in a non-TB endemic region.  
Recent studies in murine TB-vaccine models discovered a relation between expression of 
PD-1 or KLRG1 and vaccine-induced protective efficacy against TB. In these murine TB-
models KLRG1 was a more powerful marker of terminal differentiation and functional 
exhaustion compared to PD-1, however the induction of KLRG1 expression on human T-
cells in response to mycobacteria had not been investigated yet. We found that following 
BCG-vaccination of BCG-naive adults, KLRG1 expression on CD8+, but not CD4+ T-cells, 
significantly increased compared to pre-vaccination (Chapter 6). Neither PD-1 nor CTLA-
4 expression increased on CD4+ or CD8+ T-cells. KLRG1-expressing CD8+ T-cells 
exhibited markedly decreased proliferation, whereas PD-1+ T-cells proliferated after in 
vitro BCG-stimulation, analogous to murine TB-vaccine models. In patients with active TB 
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disease, we observed a mild increase of KLRG1 and PD-1 expression on CD4+ T-cells. 
However, KLRG1, PD-1 and CTLA-4 exhibited highest expression on CD4+ T-cells of 
individuals recently treated for TB, which may be a consequence of persistent antigen 
release during antibiotic treatment. Thus, we have demonstrated induction of non-
proliferating KLRG1+ CD8+ T-cells following BCG-vaccination in humans; future research 
should delineate whether inhibitory marker expression indicates a lack of vaccine-induced 
protective efficacy.  
This thesis addressed BCG vaccine-induced immunity against mycobacteria, and has 
characterized three important cellular immune responses that are induced by M. bovis BCG 
in human adults. Firstly, M. bovis BCG induces CD8+, but not CD4+ regulatory T-cells, in 
human adults. We additionally demonstrated that CD39 is functionally involved in 
mediating suppression by these BCG-activated CD8+ Tregs. Secondly, the pro-
inflammatory response induced by BCG-vaccination was unexpectedly dichotomous: either 
the induction of polyfunctional CD4+ T-cells, that was confined to vaccinees with high 
inflammation of the skin vaccine lesion, or virtually no induction of cytokines with a 
concomitant induction of CD8+ Tregs. Thirdly, non-proliferating KLRG1+ CD8+ T-cells 
were induced following BCG-vaccination in humans, and expression of this inhibitory T-
cell marker may possibly be associated with a lack of vaccine-induced protective efficacy.  
Thus, BCG-vaccination induced highly variable and opposing T-cell responses. 
 
M. bovis BCG modulates immunity against M. tuberculosis 
This thesis demonstrates that BCG, a live bacterial vaccine against TB, induces highly 
variable pro-inflammatory responses, as well as CD8+ regulatory T-cell responses 
(Chapter 3, 4 and 5). Mycobacteria are master manipulators of the immune system and 
employ a myriad of mechanisms to induce immune regulation (Chapter 2). Major 
virulence factors were lost by in vitro passaging of M. bovis to obtain M. bovis BCG, but M. 
bovis BCG clearly shares regulatory-inducing capacities with Mtb. Mycobacteria activate 
tolerizing DCs and anti-inflammatory macrophages [1], that produce IL-10 and induce 
Tregs [2;3]. In return, Tregs could further limit the pro-inflammatory response by 
suppressing APC activation [4]. It is however unknown which exact mechanisms are 
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employed by M. bovis or M. bovis BCG to induce Tregs; and the evaluation in this thesis 
did not extent to assessment of these mechanisms. 
BCG-induced innate signaling pathways could lead to Treg induction, however another 
highly interesting aspect of innate immunity, for which evidence of the effect of BCG-
vaccination is increasing, is the induction of trained immunity by M. bovis BCG. Trained 
immunity is a state of long-term and increased responsiveness of monocytes to secondary 
infections, associated with epigenetic alterations that affect both intracellular signaling and 
cell metabolism [5;6]. It can be induced by pathogens or vaccination with live microbes 
such as M. bovis BCG, measles or yellow fever [5]. This is important, since BCG-induced 
trained immunity could be partly responsible for the protection against TB mediated by 
BCG-vaccination in infants, and could further account for the heterologous, ‘non-specific 
effect’ of BCG-vaccination in protecting infants against unrelated infectious diseases, as 
well as the protective effect of intravesical BCG-therapy in bladder cancer [7-9].  
What constitutes vaccine-induced (T-cell mediated) protective immunity against TB is not 
clear; and so far no specific TB biomarker or correlate of protection has been found in 
either infants or in the adult population. CD4+ polyfunctional T-cells have been proposed as 
correlate of vaccine-induced protective immunity [10], and in infants these cells are 
induced by BCG-vaccination [11]. However, during follow up the presence of such cells 
was not associated with the development of or protection against TB [12]. The impact of 
the BCG-induced regulatory T-cell response, as demonstrated in this thesis, on vaccine-
induced immunity against TB remains unknown. Future research should delineate the 
impact of the regulatory response, as well as the mechanisms that are causing it. 
 
BCG-vaccination induces predominantly CD8+ Tregs, and not CD4+ 
Tregs 
CD4+ and CD8+ Tregs have been demonstrated in murine and human infection with M. 
tuberculosis and M. leprae (Chapter 2). Here we found in comparative analyses that 
following live M. bovis BCG-stimulation CD8+ but not CD4+ Tregs were activated in 
human adults (Chapter 3 and 5). M. tuberculosis actively modulates phagosome-lysosome 
fusion, autophagy and antigen presentation in the macrophage [13], yet Mtb and M. bovis 
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BCG could differ in their intracellular lifestyle and antigen presenting pathways. Induction 
of CD8+ T-cell responses requires access to the MHC-I antigen processing pathway; 
translocation of mycobacteria from the phagosome into the cytosol, cross-priming by DCs, 
or alternative antigen presenting pathways would provide this access. In one study 
translocation of Mtb into the cytosol was dependent on secretion of ESAT-6 and CFP-10, 
as part of the ESX-1 secretion system which is encoded in region of difference 1 (RD1) 
[14]. The same study demonstrated that BCG did not translocate into the cytosol [14]. Since 
the genomes from all BCG strains lack RD1, this questions how BCG could induce CD8+ 
T-cell responses, which it does, as described in this thesis.  
It was noted previously [15] that cytosolic Mtb could be due to atypical cell death instead 
of translocation from the phagosome, and that in vivo murine and human studies - though 
limited in number - so far only observed Mtb in membrane-bound organelles. Furthermore, 
various cytosolic and vacuolar pathways enable mycobacterial antigen to enter MHC-I 
presentation pathways without a requirement for escape from the phagosome [15]. At least, 
escape of bacilli into the cytosol is not essential in inducing CD8+ T-cell responses. 
Following intradermal vaccination, BCG is present relatively long as a live (intracellular) 
bacterium in the human body. Live BCG bacilli are transported into the draining lymph 
node by dendritic cells, macrophages and neutrophils [16]. Prolonged antigen availability 
could increase CD8+ T-cell responses through optimal cross-presentation by dendritic cells 
(Chapter 3 and 5). In addition, extracellular fragments of BCG could be cross-presented 
and CD8+ T-cells could be induced [17].  
Interestingly, in vitro stimulation of PPD-responsive PBMCs with heatkilled BCG did not 
induce either CD4+ or CD8+ Tregs (Chapter 3). BCG may need to be present as a live 
bacterium to modulate - through so far unknown mechanisms - towards tolerance. 
Interestingly, the phagosome membrane containing live BCG was found to have pores 
permissive of molecules up to 70 kDa; but only viable and not formalin-killed BCG was 
associated with permeability of these membranes [18]. Therefore, live BCG may actively 
employ mechanisms to enter antigen into MHC-I presentation pathways. Also in our cell 
cultures, the ratio of CD4+ : CD8+ T-cell expansion was increased following heatkilled 
BCG-stimulation (Chapter 3).  
So far, CD4+CD25+ Tregs have been identified - in TB disease and after BCG-vaccination - 
by in vitro PBMC stimulation with mycobacterial PPD, TB-specific peptides or freeze-
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dried BCG in culture with antibiotics [19-21]. This may have overlooked the induction of 
CD8+ Tregs by live BCG bacilli. Since BCG is administered as a (partly) live vaccine, the 
possible negative impact of CD8+ Tregs on BCG-vaccine mediated immunity may be larger 
than previously thought.    
 
Host factors in the heterogeneous pro-inflammatory response following 
BCG-vaccination 
The primary immune response following BCG-vaccination in TST-negative, 
QuantiFERON test-negative, BCG-naive healthy adults, was unexpectedly found to be 
highly heterogeneous. Previous reports on induction of polyfunctional CD4+ T-cells by 
BCG-vaccination had also yielded variable results; but here, we demonstrate high 
variability of BCG-vaccination-induced pro-inflammatory cytokines, and an inverse 
relation with a CD8+ regulatory response, within one cohort (Chapter 5). To detect BCG-
induced immune responses, we used short-term live BCG-stimulation of whole blood, 
followed by fixation, cryopreservation, and intracellular cytokine staining. This whole 
blood assay (WBA) has previously been optimized for assessment of immunogenicity in 
TB-vaccine trials [22]. It has been qualified as precise, robust and operator-independent, 
furthermore the detection of cytokines is independent of the duration of cryopreservation 
[23]. Importantly, we confirmed vaccine ‘take’ one year after vaccination by IFNγ-
ELISpot: a standardized and sensitive assay to detect long-term mycobacterium-specific 
immune responses [24]. The variation in immunogenicity assessed by live BCG-whole 
blood stimulation was furthermore reflected in the heterogeneous IFNγ production of PPD-
stimulated PBMCs of vaccinees at 4, 8 and 12 weeks after vaccination. Cytokine 
responders and non-responders were evenly distributed among vaccination days and 
gender; furthermore all participants were Caucasian, and ranges of age and weight were 
small. We therefore concluded that the observed heterogeneous response reflected true 
inter-individual variation.  
What causes a pro-inflammatory response in some individuals, and a predominantly 
regulatory response in others, is probably partly attributable to M. bovis BCG-vaccine 
immunomodulation, and partly intrinsic to the individual that is vaccinated; the relative 
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contribution of these factors and their mechanism of interaction is yet unclear. Our cohort 
was too small for meaningful genetic analyses, but in larger cohorts it would be highly 
informative to correlate heterogeneity of immune responses with host specific allelic 
variations, homo- vs. heterozygosity for specific HLA loci, and to single nucleotide 
polymorphisms (SNPs) in HLA genes, immune receptors and signaling molecules. It is 
likely that polymorphisms also exist for regulatory cytokines and regulatory receptors / 
surface markers. Thus, in larger cohorts an assessment of genetic variation in regulatory 
molecules should be included.   
In infectious diseases, lessons on immune pathways can be drawn from major immune 
deficiency syndromes such as the extreme susceptibility to mycobacteria caused by 
mutations in e.g. genes encoding IFNγ- and IL12-receptors [25]. However, genetic variants 
in the general population may also regulate susceptibility towards infectious diseases 
including TB, HIV and malaria [26;27]. A striking example that also genetic variation in 
regulatory responses can be involved in susceptibility towards infectious disease, comes 
from two ethnic groups living in one area in Burkina Faso: the Fulani people are relatively 
resistant to P. falciparum-caused malaria compared to the Mossi people; this is associated 
with reduced CTLA4 and FOXP3 expression compared to Mossi [28]. In addition, the risk 
of developing malaria in Kenyan adults is related to Treg frequencies [29]. Antibody serum 
levels induced by measles-vaccination were associated with HLA-I and -II variation [30], 
and antibody levels induced by both measles- and rubella-vaccination correlated with 
cytokine- and cytokine receptor SNPs (including IL12B, IL12RB1, IL2, and IL10) [30;31]. 
In infant BCG-vaccination, Toll-like receptor (TLR) polymorphisms correlated with the 
amplitude of the IFNγ response in BCG-stimulated whole blood 10 weeks after vaccination 
[32].  
Major lessons can be drawn from the TB-vaccine candidate MVA85A in infants and adults. 
Even though no enhanced protection against TB was observed following MVA85A-
booster- compared to placebo-vaccination of previously BCG-vaccinated children, analysis 
of the variation within this large cohort provides valuable insights into host and vaccine 
immune mechanisms. In South-African infants, positive responses to antigen 85A (Ag85A) 
in IFNγ ELISpot 28 days after MVA85A-vaccination were associated with expression of 
genes enriched in innate cells [33]. This was in contrast with the MVA85A-induced 
immune response in British adults: there, not pre-vaccination inflammatory pathways, but 
Chapter 7    
 
- 170 - 
 
pre-vaccination expression and early (day 2) induction of regulatory pathways were 
inversely related with the IFNγ ELISpot response [34]. In another study, high pre-
vaccination TGF-β1 serum levels correlated with low Ag85A-specific IFNγ ELISpot 
responses for up to 4 months after MVA85A-vaccination [35]. The authors concluded that 
different pathways are involved following vaccination of infants vs. adults, or African vs. 
British individuals. 
Immunogenetics can reveal important vaccine-induced immune pathways, and possibly in 
the future predict vaccine outcomes. High- and low cytokine responders of the BCG-
vaccinated cohort in this thesis (Chapter 5) did not significantly differ in either cytokine- 
or regulatory marker expression before vaccination. It is however possible that minor 
genetic variations in inflammatory or regulatory-related genes were decisive in expansion 
of pro-inflammatory vs. regulatory cells. This may have been in interplay with intrinsic 
immunomodulatory capacities of the M. bovis BCG-vaccine.  
 
Classical, regulatory and clinical markers of immunity 
There is no ultimate TB biomarker or correlate of protection; also CD4+ polyfunctional T-
cells were found to be not associated with immunity against TB. However, new surrogate 
endpoints of protection may be found by deciphering vaccine-induced cellular profiles and 
mechanisms of (in vitro) protection [36]. This would both accelerate vaccine trial 
evaluation, as well as enhance the statistical power of small(er) cohorts [37]. As described 
in the previous section, the induction of a regulatory response, inversely related to a pro-
inflammatory response, was also reported following MVA85A-vaccination of British adults 
[34]. Furthermore, vaccination of South African adults with the candidate TB-vaccine 
M72/AS01 induced pro-inflammatory, but also regulatory responses [38]. This suggests 
that assessment of regulatory responses in relation to deep immune phenotyping could 
assist in the search for protective correlates in future TB-vaccine trials.  
In Chapter 4 we reported for the first time expression of CD39 on human BCG-activated 
CD8+ Tregs. A murine cancer model has yielded mechanistic insights into the pivotal role 
of the ectonucleotidases CD39 and CD73 in differentiation of suppressive vs. non-
suppressive Th17 cells: differentiation in the context of IL-6 and TGF-β activated Stat3 and 
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Gfi-1, which bound to promotor regions of CD39 and CD73 and activated their expression. 
These Th17 cells were suppressive through production of adenosine and promoted tumour 
growth following adoptive transfer, whereas Th17 cells generated with IL-1β, IL-6, and IL-
23 did not express ectonucleotidases and were not suppressive [39]. In human TB pleurisy, 
CD39+ Tregs isolated from pleural effusion inhibited in vitro differentiation of naïve T-
cells into Th17 cells through TGF-β [40]. Also - as reviewed in Chapter 2 - combined 
action of Mtb and CD39+ Tregs within the granuloma can induce a macrophage type 1 
towards type 2 switch. CD39-expressing Tregs may thus be a pivotal player in hampering 
protective immunity against TB through several mechanisms.  
Following murine BCG-vaccination, production of IL-17 by pulmonary CD4+ T-cells 
correlated with protection against TB challenge [41]. In humans, the MVA85A-vaccination 
induced CD39-expression on CD4+ T-cells correlated negatively with IL17A-responses in 
stimulated PBMCs [42;43]. In Chapter 4 we demonstrated functional involvement of 
CD39 on CD8+ T-cells in mediating suppression of CD4+ (IFNγ+) Th1 cells. We did not 
assess the relation of CD39-expression with Th17 differentiation or IL17 production. 
Future studies should determine whether CD8+CD39+ Tregs impair BCG-induced 
protection against TB, and whether (CD8+)CD39+ Treg frequency or activity could be used 
as a correlate of (impaired) protection. Yet, it is unknown if vaccination-induced cellular 
subsets are stable or may transdifferentiate into other subsets. 
Markers of inflammation that are ‘classical’ in clinical medicine, could be used as ‘non-
classical’ indicators of  vaccine-induced immunity. The skin inflammation score (and CRP 
assay) described in Chapter 5 do not represent specific correlates, however the vaccine-
induced skin reactogenicity likely represents inflammation as a result of multiple 
underlying immune mechanisms. The in vitro pro-inflammatory cytokine response in BCG-
vaccinated infants and in BCG-revaccinated British adults also correlated with scar 
formation of the BCG-vaccine lesion [44;45]. It is highly interesting that scar formation in 
infants has also been associated with the non-specific protective effects of BCG-vaccination 
[46]. BCG-induced TST-conversion was not associated with protection against TB [47]. In 
Chapter 5 we identified two types of primary opposing immune responses following BCG-
vaccination in BCG-naive individuals: a pro-inflammatory response or a regulatory T-cell 
response, which correlated with the skin inflammation score. Follow-up of skin reactivity 
and/or scar formation may possibly provide insight into protective immunity, and may 
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assist in identification of various responses and mechanisms, including innate immunity.  
Any potential correlate of vaccine-induced protection will need to be validated in 
sufficiently powered clinical vaccine trials [36]. Yet, in the absence of any protective TB-
vaccine, potentially valuable information of protective activity could be obtained from in 
vitro functional estimates of mycobacterial control such as growth inhibition, and the 
recently developed human BCG-challenge model with intradermal injection of BCG bacilli 
followed by skin biopsy [45;48].  
 
Expression of inhibitory receptors by T-cells 
Continued effector T-cell function and proliferation of T-cells are essential to maintain 
control of Mtb [49]. However, studies on chronic viral infections such as HIV, hepatitis B 
and hepatitis C, as well as on tumours, have shown how continued antigen exposure 
exhausts T-cell function [50]. This is marked by expression of inhibitory receptors and 
impaired proliferative capacity, and is associated with diminished T-cell mediated control 
of infection [50]. Persistent Mtb infection could potentially exhaust the T-cell response in a 
similar way, impairing T-cell mediated immunity. There is currently no evidence that 
mycobacteria actively manipulate towards terminal T-cell differentiation (as is the case for 
induction of Tregs). Since BCG persists relatively long  in the human body following 
vaccination, we have hypothesized (Chapter 6) that BCG - besides actively inducing CD8+ 
Tregs - by its prolonged presence may also steer T-cells towards terminal differentiation.  
In Chapter 6 we described the induction of CD8+KLRG1+ T-cells following BCG-
vaccination of human adults, which exhibited markedly impaired proliferative capacity. 
Interestingly, in Mtb-infected mice only KLRG1- T-cells were able to enter the lung 
parenchyma, while KLRG1+ T-cells were contained intravascularly [51]. Thus, the 
upregulation of terminal differentiation markers following vaccination may be associated 
with impaired vaccine-induced protection, deregulated memory, or decreased migratory 
potential. Considering the specific association of KLRG1 expression with loss of T-cell 
mediated immune control in murine TB [52;53], this has potential impact on the study of 
vaccine-induced immune correlates of protection in humans.  
KLRG1 expression was significantly induced on CD8+, but not CD4+ T-cells. Given the 
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predominant CD8+ regulatory response induced by M. bovis BCG (Chapter 3 and 5), it is 
important to note that BCG-induced CD8+KLRG1+ T-cells were not enriched for regulatory 
markers compared to the total CD8+ T-cell population. Also no relation was observed 
between expression of KLRG1 on CD8+ T-cells and the skin inflammatory response or the 
induction of polyfunctional CD4+ T-cells, such that these seem to be independent 
phenomena following BCG-vaccination. Interestingly, also CD8+PD-1+ T-cells were not 
enriched for the regulatory phenotype. PD-1 is ubiquitously expressed on various immune 
cells, including Tregs, yet PD-1 ligation of Tregs causes their expansion and activation, 
while PD-1 ligation on other cells serves as a brake in the immune response [54]. PD-1 
ligation is actively exploited by Mtb to inhibit effector immunity and to expand Tregs ([55]; 
Chapter 2). In addition, and not mutually exclusive, PD-1 expressing cells may have a dual 
role in that they could also maintain long-term immune responses during persistent Mtb 
infection [49]. 
Only CD8+CTLA-4+ T-cells were enriched for the regulatory markers Foxp3, CD25 and 
CD39 following BCG-vaccination (Chapter 6); indeed, these cells partially mimicked the 
pattern observed for the CD8+CD25+Foxp3+CD39+ phenotype as described in Chapter 5. 
The mean fluorescence intensity of CTLA-4 expression on CD8+ T-cells was slightly 
increased eight weeks post-vaccination, and this was confined to low inflammation 
responders. CTLA-4 is expressed on a variety of cells, including Treg cells, and CTLA4 is 
a Foxp3 target gene in mice [54]. Tregs modulate APCs by CTLA-4-mediated trans-
endocytosis of CD80 and CD86, which depletes co-stimulatory receptor expression on 
APCs [56]. Tregs have multiple and highly adaptable other modes of suppression [57]; vice 
versa not all CTLA-4 expressing T-cells are Tregs [58]. In any case, its active involvement 
in APC modulation, and the numerous associations with the Treg phenotype and function 
that have been reported in infectious diseases (Chapter 2), provide a rationale for the 
enrichment in regulatory markers that we observed.  
It is interesting that immune checkpoint blockade of ligand-receptor interaction thus can not 
only enhance pro-inflammatory effector immunity, but can simultaneously also decrease 
Treg function and proliferation [54]. In addition, intriguing interactions between Tregs and 
terminally differentiated (exhausted) T-cells have been described: in murine LCMV 
infection models CTLA-4+ Tregs preserved the exhausted state of antigen-specific CD8+ T-
cells through B-7 modulation, depleting the APC of costimulatory molecules in the face of 
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continued antigen presence [59]. Depletion of Tregs reactivated T-cell function, but 
additional PD-L1 blockade was needed to control viral load [59]. In murine retroviral 
infection, both Treg depletion and blocking inhibitory receptors (PD-1 and TIM-3) 
decreased viral load, however combination therapy was superior in achieving sustained 
reduction [60]. Trials of combination checkpoint blockade in individuals with metastasized 
melanomas demonstrated synergy and improved control of tumour progression compared to 
monotherapy [61]. This provides new rationale for combined immunotherapy: modulation 
of two different pathways, regulatory and exhausted, could be optimal to resurrect immune 
control of chronic infection. Also (vaccine-induced) immunity against TB may be enhanced 
by combined immunotherapy; future studies will hopefully answer the question whether 
this would indeed result in improved protective immunity and whether this is clinically 
feasible and safe.   
 
Concluding remarks  
The (1) induction of CD8+CD39+ regulatory T-cells, that partly suppress via CD39, the (2) 
variability of the primary pro-inflammatory response with either induction of CD4+ 
polyfunctional Th1 cells or CD8+ Tregs, and (3) the induction of CD8+KLRG1+ T-cells 
with impaired proliferative capacity by BCG-vaccination in humans, represent a novel 
network of inter-related immune responses, that may all impact on vaccine-induced 
protective immunity against TB. Though the induction of CD4+ Tregs has been 
demonstrated in TB, following vaccination with BCG or candidate TB-vaccines, M. bovis 
BCG-induced CD8+ Tregs have been overlooked as significant modulators of immunity in 
TB and TB-vaccine studies. In addition, alternative indicators such as skin reactivity and 
CRP were found that could assist in future analysis of vaccine-induced immune responses. 
Basic research into vaccine-induced pro-inflammatory, regulatory and terminally 
differentiated cellular responses thus provides novel immune markers and uncovers new 
mechanisms regulating vaccine-induced immunity, with significant repercussions for 
protection. This could guide vaccine design and provide a basis for immunotherapy options 
- as are now emerging in cancer medicine - to optimize immune control of tuberculosis.             
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Op dit moment bestaan geen effectieve vaccins tegen de drie grootste - en dodelijkste - 
infectieziekten op aarde: HIV/AIDS, tuberculose (TB; TBC) en malaria. TB, in mensen en 
dieren, wordt veroorzaakt door bacteriën van het ‘Mycobacterium tuberculosis complex’, 
een groep nauw-verwante bacteriën met een gedeelde voorouder van naar schatting drie 
miljoen jaar oud. Tot deze groep behoren o.a. Mycobacterium tuberculosis (M. 
tuberculosis; Mtb), Mycobacterium africanum en Mycobacterium bovis (M. bovis). De 
meest voorkomende veroorzaker van TB in mensen, M. tuberculosis, is ongeveer 70.000 
jaar geleden ontstaan in vroege menselijke populaties in Afrika. In het Europa van de 
Middeleeuwen steeg de incidentie van TB – ook bekend als ‘de tering’, ‘the white plague’ 
of ‘consumption’ - tot epidemische proporties; en er is geen ander pathogeen dat in de 
wereldgeschiedenis zoveel slachtoffers heeft geëist. Pas laat 19e eeuw werd Mtb 
geïdentificeerd door Robert Koch als het pathogeen dat TB veroorzaakt; vanaf 1944 werden 
antibiotica ontdekt tegen TB. Naar schatting is op dit moment een-derde van de 
wereldbevolking latent geïnfecteerd met Mtb. Bij latente infectie zijn levende, niet- of 
nauwelijks delende bacteriën aanwezig in het menselijk lichaam, maar deze worden onder 
controle gehouden door het immuunsysteem. Latent geïnfecteerde mensen vertonen dan 
ook geen klinische tekenen van infectie, maar hebben een risico op reactivering van 3-10% 
gedurende het leven. In mensen met HIV is dit risico 5-10% per jaar; en TB is de 
belangrijkste doodsoorzaak onder HIV-patiënten. Hoewel in de Westerse wereld de TB-
incidentie dramatisch is afgenomen, is, door de HIV-epidemie en de toenemende 
antibiotica-resistentie, TB nog altijd een zeer groot probleem in ontwikkelingslanden, 
oostelijk Azië en de voormalige Sovjet Unie. Per jaar sterven ten minste 1,5 miljoen 
mensen aan TB, waarvan 95% in ontwikkelingslanden.       
Mycobacterium bovis bacillus Calmette-Guérin (M. bovis BCG) is het enige beschikbare 
vaccin tegen TB. M. bovis BCG is aan het begin van de 20e eeuw  geïsoleerd door het 
kweken van M. bovis, de verwekker van TB in koeien, op een mengsel van glycerine, gal 
en aardappel-extract, door Albert Calmette en Camille Guérin. Sinds de eerste vaccinatie in 
1921 is BCG ten minste drie miljard maal toegediend, meer dan enig ander vaccin. BCG 
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wordt, als onderdeel van het Expanded Programme on Immunization van de World Health 
Organization, in vrijwel alle ontwikkelingslanden met hoge TB-prevalentie binnen 24 uur 
na de geboorte toegediend. BCG-vaccinatie beschermt pasgeborenen en jonge kinderen 
tegen gedissemineerde vormen van TB, maar biedt onvoldoende en zeer wisselende 
bescherming tegen open (actieve) long TB op volwassen leeftijd. Een effectief TB-vaccin 
zou juist bescherming moeten bieden tegen open long TB, de besmettelijke vorm van de 
ziekte, en dit zou grote impact hebben op de TB-epidemie. Hoewel nieuwe vaccins worden 
ontwikkeld en getest, zijn op dit moment nog geen nieuwe vaccins beschikbaar. 
Een van de grootste uitdagingen is te definiëren wat beschermende immuniteit tegen TB 
precies inhoudt en hoe dit door vaccinatie moet worden geïnduceerd. Succesvolle vaccins 
tegen infectieziekten induceren ‘normaliter’ een antilichamen titer, echter door de 
voornamelijk intracellulaire levensstijl van Mtb moet een succesvol TB-vaccin - evenals 
succesvolle HIV- of malaria-vaccins - ook effectieve T-cel immuniteit induceren. Er bestaat 
echter nog geen gouden standaard voor wat een beschermende T-cel respons op vaccinatie 
tegen deze drie dodelijke infectieziekten precies inhoudt. Een effectieve, door een TB-
vaccin geïnduceerde immuunrespons zal minimaal de inductie van CD4+ T-helper (Th)-1 
cellen omvatten; daarnaast zijn in muizenstudies vaccin-geïnduceerde polyfunctionele 
(simultaan IFNγ-, IL2- en TNFα-producerende) CD4+ T-cellen aangetoond die correleerden 
met bescherming tegen TB. Echter, in jonge kinderen correleerde de frequentie van deze 
polyfunctionele CD4+ T-cellen na BCG-vaccinatie niet met het risico op het ontwikkelen 
van TB. Meer basaal onderzoek naar de vaccin-geïnduceerde T-cel respons is essentieel om 
de immuun respons en beschermende immuniteit te definiëren, als rationele onderbouwing 
voor de ontwikkeling van een nieuw TB-vaccin. Daarnaast kunnen door het onderzoeken 
van vaccin-geïnduceerde cellulaire profielen mogelijk nieuwe correlaten van bescherming 
tegen TB worden gevonden, en beschikbaarheid van zulke correlaten zou de evaluatie van 
nieuwe TB-vaccins uitermate faciliteren en versnellen. 
Mycobacteriën hebben zich door co-evolutie met de menselijke soort ontwikkeld tot 
meester manipulators van het immuunsysteem. Regulatoire T-cellen (Tregs) zijn T-cellen 
die de pro-inflammatoire respons onderdrukken en essentieel zijn voor immuun 
homeostase, het voorkomen van auto-immuniteit en bescherming van weefsels tegen 
destructie door geprolongeerde immuun responsen, zoals bij chronische infectie. Deze 
regulatoire T-cellen worden echter ook door Mtb actief geïnduceerd en geëxpandeerd, 
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waarmee Mtb het immuunsysteem in essentie manipuleert om in het lichaam te kunnen 
blijven voortbestaan. Er bestaan verscheidene hypotheses rondom de matige effectiviteit 
van het M. bovis BCG-vaccin, waaronder inductie van Tregs door BCG zelf. CD4+ Tregs 
zijn eerder aangetoond in kinderen na BCG-vaccinatie; echter, CD8+ Tregs worden veel 
minder bestudeerd – of zelfs over het hoofd gezien – in vergelijking met CD4+ Tregs, 
vooral in het kader van infectieziekten en vaccinatie. Er zijn dan ook geen vergelijkende 
analyses van de impact van CD4+ vs. CD8+ Tregs op de immuun respons of effectiviteit van 
het BCG-vaccin. Ook is weinig bekend over het suppressieve arsenaal waarmee CD8+ 
Tregs de activiteit van andere cellen kunnen onderdrukken.  
Daarnaast komt toenemend het belang naar voren van de expressie van inhiberende markers 
door functioneel ‘uitgeputte’ T-cellen in immuniteit; zo wordt in recente immuun-
therapeutische doorbraken in de oncologie, blokkade van deze inhiberende markers 
(receptoren) al ingezet om uitgeputte T-cellen weer opnieuw te activeren zodat ze de tumor 
effectief kunnen opruimen. Naar aanleiding van deze successen wordt ook toenemend de 
betekenis onderzocht van expressie van inhiberende markers, zoals KLRG1 en PD-1, door 
T-cellen in de immuun respons tegen TB. In TB-vaccin studies in muizen vertonen T-cellen 
die KLRG1 tot expressie brengen een significant lagere activiteit, in de vorm van verlaagde 
cel proliferatie en productie van pro-inflammatoire cytokines. Dit werd niet gevonden voor 
T-cellen die PD-1 tot expressie brachten. De expressie van KLRG1, maar niet PD-1, door 
T-cellen is in deze studies dus geassocieerd met een verminderde vaccin-geïnduceerde 
bescherming tegen TB. De expressie van KLRG1 op humane cellen na BCG-vaccinatie is 
voorheen echter niet onderzocht.  
Er bestaan derhalve meerdere, mogelijke verklaringen voor de zeer matige effectiviteit van 
BCG-vaccinatie op de volwassen leeftijd. Onderzoek naar de BCG-geïnduceerde cellulaire 
respons in volwassenen is dan ook essentieel om deze mechanismen op te helderen. 
 
Dit proefschrift 
In dit proefschrift zijn verschillende cellulaire responsen geïdentificeerd die een verklaring 
zouden kunnen bieden voor de matige en inconsistente effectiviteit van BCG-vaccinatie in 
bescherming tegen TB. Ten eerste door de inductie van CD4+ en CD8+ regulatoire T-cellen 
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door BCG te onderzoeken, ten tweede door de primaire T-cel respons op BCG-vaccinatie, 
zowel pro-inflammatoir als regulatoir, te onderzoeken en ten derde door specifieke 
expressie van inhiberende markers, met name KLRG1, door humane T-cellen na BCG-
vaccinatie te onderzoeken.  
Hoofdstuk 2 begint met een literatuur overzicht van de inductie en expansie van Tregs 
door bacteriën, virussen en parasieten en het effect van Tregs op de effector immuniteit 
tegen pathogenen. Tregs functioneren op het grensvlak tussen mens en pathogeen in 
immuniteit tegen infectie en ziekte, en na vaccinatie: zij beschermen de weefsels tegen 
buitensporige inflammatie, maar verhogen het risico op persistentie van het pathogeen en 
daarmee de ontwikkeling van een chronische infectie. Tregs mediëren niet alleen specifieke 
suppressie, maar kunnen ook de immuunrespons tegen niet-gerelateerde pathogenen, of de 
respons op niet-gerelateerde vaccinaties (heteroloog) onderdrukken. Mycobacteriën, 
waaronder M. tuberculosis en M. leprae (de veroorzaker van lepra), behoren tot de oudste 
pathogene bacteriën ter wereld en hebben zich ontwikkeld tot meesterlijke modulators van 
de immuunrespons om in het menselijk lichaam te kunnen voortbestaan. Het merendeel van 
de mycobacteriële infecties komt voor in gebieden die ook endemisch zijn voor andere 
virale, parasitaire of bacteriële infecties; het is dus belangrijk de effecten van Tregs niet 
slechts homoloog, maar ook in heterologe (modellen van) infecties en vaccinaties te 
bestuderen.  
Door anderen is de inductie na M. bovis BCG-vaccinatie van CD4+ Tregs aangetoond; 
echter er bestond geen vergelijkende analyse van inductie van CD4+ vs. CD8+ Tregs door 
M. bovis BCG. In hoofdstuk 3 is de inductie van CD4+ vs. CD8+ Tregs vergeleken door 
cellen, afkomstig van gezonde bloeddonoren die in vitro immuunreactief waren tegen 
mycobacteriën, te stimuleren met levend M. bovis BCG. Het was verrassend dat levend 
BCG-stimulatie met name CD8+ Tregs, in tegenstelling tot CD4+ Tregs induceerde. De 
expressie, co-expressie, en de mate van expressie van regulatoire cel markers was 
consistent hoger op CD8+ T-cellen in vergelijking met CD4+ T-cellen; vice versa verrijkte 
het selecteren van T-cellen op regulatoire markers voor CD8+, en niet CD4+ T-cellen. 
Vervolgens vergeleken we de capaciteit van T-cellen, na stimulatie met levend BCG vs. 
geïnactiveerd BCG, voor het mediëren van suppressie. Alleen T-cellen, die gestimuleerd 
waren met levend BCG, onderdrukten de proliferatie van andere cellen. Dit is belangrijk 
omdat BCG als (partieel) levend vaccin wordt toegediend; door in vitro te testen met 
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geïnactiveerd BCG worden dus belangrijke suppressieve eigenschappen van (levend) BCG-
gestimuleerde T-cellen gemist. Suppressie na levend BCG-stimulatie werd inderdaad 
gemedieerd door CD8+ Tregs, en niet door CD4+ T-cellen.  
Er is weinig bekend over de manier waarop deze CD8+ Tregs suppressie uitoefenen op 
andere cellen. CD39 (E-NTPDase1) is een enzym aan de oppervlakte van de cel, dat door 
omzetting van nucleotides cellen in de omgeving kan remmen. CD39 is dan ook eerder 
bestudeerd op CD4+ Tregs, maar niet op CD8+ Tregs na BCG-stimulatie. In hoofdstuk 4 
wordt aangetoond dat CD39 tot expressie komt op CD8+ Tregs na stimulatie met levend 
BCG. Het sorteren van CD8+ T-cellen op CD39-positiviteit verrijkte significant voor 
andere regulatoire T-cel markers; bovendien oefenden alleen CD8+CD39+ T-cellen, en niet 
CD8+CD39- T-cellen, suppressie uit op T-helper 1 cellen. Het toevoegen van een CD39-
antagonist, alsmede toevoegen van een CD39-blokkerend antilichaam, maakte deze 
suppressie deels ongedaan. CD39 komt dus niet alleen tot expressie op BCG-geactiveerde 
CD8+ Tregs, maar is ook functioneel betrokken bij het mediëren van suppressie door 
CD8+CD39+ Tregs.   
In hoofdstuk 5 is prospectief de primaire inductie van pro-inflammatoire en regulatoire T-
cellen door BCG-vaccinatie in gezonde volwassenen onderzocht. Deze volwassenen waren 
niet eerder gevaccineerd met BCG en testten negatief voor TB (anamnestisch, in Mantoux- 
en in QuantiFERON-testen). Hoewel het cohort bijzonder homogeen was in demografische 
kenmerken, was de primaire immuunrespons op BCG-vaccinatie verrassend heterogeen: 
deze bestond uit ofwel een brede inductie van pro-inflammatoire CD4+ en CD8+ T-cellen, 
waaronder IFNγ+IL2+TNFα+ polyfunctionele CD4+ T-cellen, ofwel uit een vrijwel afwezige 
cytokine respons. Aangezien ook de mate van ontsteking van de vaccinatielaesie op de huid 
zeer variabel was, werd deze gekwantificeerd in een ‘skin inflammation score’, gebaseerd 
op klassieke klinische kenmerken van ontsteking. Deze skin inflammation score correleerde 
met de CRP (C-Reactive Protein) concentratie, een bepaling in het serum die onderdeel is 
van een klinische routine om ontsteking in het lichaam vast te stellen. Tot dusver werden 
echter ontstekingsparameters van de vaccinatielaesie, of bepalingen van het serum CRP, 
vrijwel niet ingezet om cellulaire responsen op vaccinatie te onderzoeken. De studie in 
hoofdstuk 5 toont aan dat de inductie van een pro-inflammatoire cytokine response door 
BCG-vaccinatie alleen plaatsvindt in personen met een hoge mate van BCG-geïnduceerde 
huidontsteking.  
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Daarnaast is in hoofdstuk 5 de inductie van Tregs door BCG-vaccinatie onderzocht. 
Analoog aan de activatie van CD8+, maar niet CD4+ Tregs na in vitro BCG-activatie van 
humane cellen beschreven in hoofdstuk 3, vonden we ook na BCG-vaccinatie in dit cohort 
alleen inductie van CD8+ maar niet CD4+ Tregs. In contrast met de inductie van pro-
inflammatoire responsen in personen met een hoge mate van huidontsteking, was de 
inductie van een CD8+ regulatoire respons beperkt tot personen met geen tot lage 
huidontsteking. Concluderend leidt BCG-vaccinatie tot een zeer variabele, en zelfs 
dichotome primaire cellulaire respons binnen één cohort; daarbij functioneren de mate van 
huidontsteking door vaccinatie en de CRP-concentratie in serum als indicatoren van de 
cellulaire vaccin-respons.     
Het belang van expressie van inhiberende markers, zoals KLRG1 en PD-1, door T-cellen 
voor vaccin-geïnduceerde immuniteit tegen TB werd, zoals besproken, aangetoond in 
recente studies in muizen. Hoofdstuk 6 toont voor het eerst expressie van KLRG1 op 
humane CD8+ T-cellen na BCG-vaccinatie. Deze CD8+KLRG1+ T-cellen vertoonden na in 
vitro BCG-restimulatie een lage proliferatieve activiteit, in tegenstelling tot proliferatie van 
PD-1+ T-cellen. Om het belang van deze markers in immuniteit tegen TB verder te 
onderzoeken, werd de expressie van KLRG1, PD-1, alsmede CTLA-4, vergeleken tussen 
patiënten met actieve TB, individuen met latente TB, patiënten na afloop van hun 
behandeling tegen TB en gezonde controles. Hoewel in actieve TB-patiënten expressie van 
deze inhiberende markers op CD4+ T-cellen mild verhoogd was in vergelijking met 
gezonde mensen, was de expressie nog hoger op CD4+ T-cellen na behandeling tegen TB. 
Dit is mogelijk een gevolg van de grote hoeveelheid eiwitten, peptides en andere immuun-
stimulerende stoffen die uit geïnfecteerde weefsels vrijkomen tijdens en na antibiotische 
behandeling. Meer onderzoek is nodig om de betekenis van met name KLRG1-expressie, in 
vergelijking met PD-1-expressie, door T-cellen vast te stellen voor immuniteit tegen TB. 
 
Concluderend en toekomst perspectief 
In dit proefschrift is de cellulaire immuun respons van volwassen mensen op BCG 
onderzocht, waarbij drie belangrijke cellulaire responsen zijn geïdentificeerd. Dit betreft ten 
eerste de inductie van CD8+ en niet CD4+ Tregs, door levend M. bovis BCG. Deze CD8+ 
Nederlandse samenvatting 
 
- 189 - 
 
Tregs bleken CD39 te expresseren op het cel oppervlak; bovendien werd de functionele 
betrokkenheid van CD39 in het uitoefenen van suppressie door BCG-geactiveerde CD8+ 
Tregs aangetoond. Ten tweede demonstreerden we een onverwacht dichotome respons op 
BCG-vaccinatie: er was ofwel inductie van een pro-inflammatoire respons met 
polyfunctionele CD4+ T-cellen in personen met een hoge mate van huidontsteking van de 
BCG-vaccinatielaesie en circulerend CRP, ofwel een virtueel afwezige cytokine respons 
met daarbij inductie van CD8+ Tregs en een lage tot afwezige huidontsteking  en CRP. Ten 
derde toonden we aan dat BCG-vaccinatie CD8+KLRG1+ T-cellen induceert met een lage 
proliferatieve activiteit. Expressie van deze inhiberende T-cel marker zou, zoals aangetoond 
in recente studies in muizen, geassocieerd kunnen zijn met een gebrek aan immuniteit tegen 
TB.  
De inductie van CD8+ Tregs, de variabiliteit van de pro-inflammatoire respons die 
tegengesteld is aan de inductie van CD8+ Tregs, en de inductie van KLRG1+ T-cellen met 
beperkte proliferatie-activiteit, door BCG-vaccinatie in mensen, duidt op een netwerk van 
gerelateerde immuun responsen die mogelijk impact hebben op de beschermende 
effectiviteit van BCG-vaccinatie tegen TB. Dit is belangrijk gezien de beperkte effectiviteit 
van BCG als TB-vaccin, en een beter begrip van deze immuun mechanismen is essentieel 
om betere TB-vaccins te kunnen ontwerpen in de nabije toekomst, alsmede om vaccins te 
kunnen selecteren en prioriteren voor (verdere) klinische ontwikkeling. Ontsteking van de 
BCG-vaccinatielaesie en CRP-concentraties in serum na vaccinatie kunnen hierbij dienen 
als alternatieve indicatoren van de cellulaire respons op vaccinatie. Dit basale onderzoek 
naar vaccin-geïnduceerde regulatoire, pro-inflammatoire en inhiberende responsen onthult 
dus nieuwe factoren en mechanismen van vaccin-geïnduceerde immuniteit en immuun 
regulatie, met potentieel belangrijke implicaties voor het ontwerpen van effectieve vaccins 
tegen TB, en mogelijk andere belangrijke infecties zoals HIV en malaria. Dit kan rationeel 
vaccin-ontwerp en -evaluatie ondersteunen in de strijd tegen tuberculose. 
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